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five symptom categories, which can be roughly divided into positive and 
negative symptoms, plus disorganization (impaired cognition), excite-
ment, and emotional distress [11-15]. 
Pathophysiology and etiology 
Very little is known about the pathophysiology and etiology of schizophre-
nia. The situation is complicated by the clinical variability of schizophre-
nia. It is increasingly suggested that schizophrenia is not a single disease, 
but a clinical syndrome, perhaps comprising several disease entities [16], 
and certainly associated with different syndromes like depression and 
anxiety, in addition to positive, nega-tive and cognitive symptoms. Many 
hypotheses have been generated in an attempt to explain the pathogenesis 
and phenomenology of schizophrenia. These can be roughly divided into a 
neurodevelopmen-tal and neuropharmacological hypothesis [17]. As the 
neuropharma co logi cal hypothesis will be more relevant for this thesis, this 
will be discussed in more detail than the neurodevelopmental hypothesis. 
Neurodevelopmental hypothesis of schizophrenia 
The neurodevelopmental hypothesis of schizophrenia postulates that an 
environmental insult (e.g. obstetric complications, maternal viral infec-
tion, nutritional deficits, psychological experiences) disrupts normal brain 
maturation, resulting in the emergence of psychosis at puberty or young 
adulthood [18]. However, a purely environmental origin of schizophrenia  
is refuted by the strong genetic predisposition, which accounts for 24-80% 
of the risk of developing the disease (depending on the diagnostic criteria 
or the use of endophenotypes [17]). The neurodevelopmental hypothesis 
was therefore later extended to the ‘two hit hypothesis’, which postulates 
that an interaction between an early life insult and multiple susceptibility 
genes is required to cause schizophrenia [19,20]. This hypothesis could be 
broadened, as Henquet et al showed that an environmental factor in a later 
stage in life (cannabis use), synergistically with genetic predisposition,  
can also increase the risk of developing psychosis [21-23]. 
Background schizophrenia 
Schizophrenia, which is in the top ten of most debilitating psychiatric 
disorders [1], affects up to 1-1.5% of the world population. Usually the 
symptoms of schizophrenia occur in young adulthood and persist for 
the entire lifetime [2]. Schizophrenia means a shorter life expectancy, 
an almost life-long loss of economic productivity and higher health care 
costs for many patients [3-5]. There is no schizophrenia therapy available 
today that addresses these issues. 
This thesis describes a number of studies related to early drug develop-
ment for schizophrenia and related disorders. The reader will note the 
pharmacological diversity of drugs and systems that are dealt with in this 
thesis. In a way, this reflects the clinical complexity of schizophrenia. 
According to the Disease State Manual dsm-iv of the American Psychiat-
ric Association [6], the diagnosis of schizophrenia requires the presence 
for a significant part of one month of at least two of the following diverse 
symptoms: delusions, hallucinations, disorganized speech, grossly dis-
organized or catatonic behaviour and negative symptoms. People diag-
nosed with schizophrenia usually experience a combination of positive 
symptoms (i.e. hallucinations, delusions, incoherent thoughts), nega-
tive symptoms (i.e. apathy, lack of emotion, poor or nonexistent social 
functioning) and cognitive dysfunction (memory problems, disorganized 
behaviour, and difficulties planning, concentrating, following instruc-
tions or completing tasks) [7-9]. Many researchers include the cognitive 
deficits with the negative symptoms in the articles they write. Further-
more, many patients suffer from comorbid disorders like depression  
and anxiety [7]. The most frequently used instrument to measure the 
signs and symptoms of schizophrenia has been the Positive and Negative  
Syndrome Scale (panss), which in its common form addresses three fac-
tors: positive and negative symptoms and general psychopathology [10]. 
Due to growing knowledge of neurobiology and neuropharmacology of 
schizophrenia and the increasing recognition of comorbid symptomatol-
ogy, new ways have been proposed to assess signs and symptoms associ-
ated with schizophrenia more accurately. Many publications now identify 
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dopamine	
Many different pharmacological systems have been suggested to be 
implemented in schizophrenia, but the most widely accepted theory 
regarding the origin of psychotic symptoms is the dopamine hypo thesis 
[35,36]. This hypothesis is based on two observations. First, substances 
that increase dopamine neurotransmission, such as amphetamine and 
cocaine, have psychomimetic properties in non-schizophrenics and 
enhance symptoms in schizophrenia patients [37-39]. And second,  
the central mechanism of antipsychotic action of even the newer anti-
psycho tics is directed at dopamine d2 receptors. The first publication  
of what was later called ‘the dopamine receptor hypothesis’, reported  
on the anti psychotic actions of chlorpromazine (introduced in the 50s  
as the first antipsychotic drug) in a trial with 38 schizophrenic patients 
[40]. Carlsson and Lindqvist introduced the mechanism of action of 
antipsychotics by showing that they increased the turnover of mono-
amines as reflected by increased levels of their metabolites in animals 
[41]. The dopamine receptor was only identified and firmly linked to 
antipsychotic response in the 70s [42-45]. It was not until the mid-1990s 
that imaging studies provided supporting evidence [46-48]. A systematic 
literature review by De Visser et al showed a relationship between d2 
affinity and therapeutic starting dose across a large number of classic  
and atypical antipsychotic drugs [49]. 
Changes in dopamine regulation play a major role in both the 
symptoms and treatment of schizophrenia. In this theory several 
dopamine tracts are involved (figure 1), which account for the majority  
of clinical symptoms of schizophrenia and adverse effects of antipsy - 
chotic drugs. 
Emotional tracts: 
1. Mesolimbic pathway (dopamine 2 receptors): begins in the ventral 
tegmental area (vta) and connects to the limbic system via the nucleus 
accumbens (na), the amygdala, and the hippocampus as well as to the 
medial prefrontal cortex. Dopamine in the hippocampus is thought to 
A neurodevelopmental pathogenesis is compatible with the numerous 
molecular and structural changes that have been found in the brains of 
schizophrenic patients [24]. Many of the observed changes in gray matter 
would seem to result from reduced neuropil density (network of dendrites, 
dendritic spines, axons, and pre- and postsynaptic terminals) and support 
the suggestion that schizophrenia is a disorder of synaptic connectivity 
[25,26]. These changes are part of widespread neuroanatomical 
derangements, which are also reflected by the progressive cerebral 
(temporal) volume reductions that have repeatedly been found with 
neuroimaging [27]. Several compounds that target brain growth factors 
are in early stages of development [28-30]. The currently used drugs are 
not able to reduce or reverse the structural and neurodegenerative aspects 
of schizophrenia. However, in some studies indications for secondary 
structural effects of symptomatic antipsychotics have been found [31,32]. 
For example, Brennand et al showed that loxapine (a registered atypical 
antipsychotic in the us, structurally related to clozapine) resulted in a 
statistically significant improvement in neuronal connectivity [26]. If 
corroborated, these findings illustrate the intricate and reciprocate - 
though still poorly understood - relationships between psychological, 
social and biological development of the nervous system in childhood  
and adolescence.  
Neuropharmacological hypotheses of schizophrenia 
The pathogenesis of schizophrenia and the pathophysiology of its clinical 
manifestations have also been related to abnormalities of neurotransmit-
ter systems, which are thought to be the consequences of the underlying 
neurodevelopmental derangements [33,34]. The most important neuro-
pharmacological hypotheses are based on observations that key symp-
toms of schizophrenia such as psychotic-like or disorganized states could 
be either suppressed with or caused by certain drug classes that affect the 
actions of for example dopamine, serotonine, glutamate, endocannabi-
noids, gaba (gamma-aminobutyric acid) and acetylcholine.  
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mesolimbic	dopamine	tracts	At first, it was hypothesized that the 
mesolimbic dopamine tracts would be hyperactive causing excessive 
stimulation of d2 receptors, resulting in positive symptoms. While there 
is general acceptance of a role for a dopaminergic abnormality in psycho-
sis, what the exact underlying mechanism is, is still a matter of debate.  
It has been postulated that the mesolimbic dopamine abnormality may be 
a secondary consequence of another deficit, for example hypo-functional-
ity of the frontal cortex (associated with a reduced glucose utilization and 
blood flow in the prefrontal cortex, also called cerebral hypofrontality) 
[53,54], a glutamate deficit [55,56], or a primary neurodevelopmental 
disorder [34,57]. All these models include a final mesolimbic dopamine 
dysregulation, but do not specify how this leads to symptoms. The so 
called aberrant salience hypothesis of Kapur may provide a link between 
the biological dysfunction of the dopamine system and the symptomatic 
expression of psychosis [58]. To understand this hypothesis, it is neces-
sary to know one of the roles of dopamine on the mesolimbic pathway 
(earlier described as ‘initiative and motivation’ as functions of the meso-
limbic tract), called the motivational salience hypothesis [51,59-61]. 
According to this hypothesis, dopamine mediates the conversion of the 
neural representation of an external stimulus from a neutral bit of infor-
mation into an attractive or aversive entity [51]. Thus, dopamine, which 
under normal conditions is a mediator of contextually relevant saliences, 
in the psychotic state becomes a creator of aberrant saliences. Accord-
ing to the idea of salience attenuation, antipsychotics do not primarily 
change thoughts or ideas; instead, they provide a neurochemical milieu 
in which new aberrant saliences are less likely to form and previously 
aberrant saliences are more likely to extinguish [62]. They do not remove 
the core content of the symptom, but rather the degree to which the symp-
toms occupy the mind, distress the patient, and drive action [63]. In neu-
rochemical terms this means that antipsychotics are seen as blocking the 
expression of abnormal dopaminergic transmission, but they do not fun-
damentally alter the dopaminergic dysregulation [64,65]. This explains 
why delusions and hallucinations do not immediately resolve when treat-
ment is introduced, but do lose their emotional significance and pervasive 
play a role in new episodic memories and in spatial coding (orientation  
in space) [50]. Dopamine in the vta - na pathway plays a role in the 
reward system and eating behaviour [51]. The exact role of the meso - 
limbic dopamine system in the reward system is widely discussed [52]. 
Three hypotheses have been proposed as explanations for dopamine’s 
function in the reward system: hedonic, learning and motivational 
salience hypothesis [52]. This hypothesis is discussed in more detail  
in the next chapter of this introduction. 
2. Bulbus olfactorius (not depicted in figure 1 as it is not thought to  
play an important role in schizophrenia or antipsychotic drug action): 
involved in olfaction, the perception of odours. 
Cognitive tracts: 
3. Mesocortical pathway (dopamine 1 receptors): begins in the vta  
and connects to the prefrontal cortex. It is thought to be involved in 
working memory, time orientation, analysis and arguing, planning  
and mental organisation, and initiative and motivation. 
Motor tracts: 
4. Nigrostriatal pathway (dopamine 1 receptors): begins in the 
substantia nigra and projects to the basal ganglia. It is part of a system 
called the basal ganglia motor loop, and involved in psychomotor and 
supportive locomotion and facial expression. 
Neuroendocrine tracts: 
5. Tuberoinfundibular pathway (both dopamine 1 and 2 receptor): 
begins in the hypothalamus and projects to the posterior pituitary.  
It is involved in regulation of prolactin secretion from the anterior 
pituitary gland and metabolic activity. 
6. Area postrema (not depicted in figure 1 as it is not thought to play  
an important role in schizophrenia): controls vomiting through dopa-
mine 2 receptors. Its privileged location in the brain also allows the area 
postrema to play a vital role in the control of autonomic functions by the 
central nervous system 
16	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia 17	 1	–	introduction
Neuroimaging studies have contributed to a better understanding of 
the pathophysiology of schizophrenia and give strong evidence for the 
‘combined mesolimbic and mesocortical dopamine hypothesis’ of 
[76,81,81-83]. Davis et al postulates that a deficit of dopamine in the 
prefrontal cortex results in hypostimulation of d1 receptors (leading 
to cognitive deficit symptoms [84,85]), the predominant dopamine 
receptor subtype in this area [53]. In addition, these alterations feed into 
each other as it has been shown that cortical dopamine has an inhibitory 
effect on subcortical dopamine. This deficit in cortical dopamine may 
itself contribute to excess in subcortical dopamine activity in mesolimbic 
dopamine neurons (inducing positive symptoms) [86]. The hypothesis  
of Abi-Dargham is similar to that of Davis et al, but slightly more detailed. 
It makes use of an excitatory (glutamatergic) and inhibitory (gabaergic) 
system, which both control the dopamine neurons in the vta to explain  
a simultaneously-induced imbalance of the two systems [76]. 
genetic	vulnerability	and	dopamine	Although susceptibility to 
schizophrenia is largely explained by genetic variation, demonstrated 
by family, twin and adoption studies [87], schizophrenia is a complex 
disorder, not simply defined by several major genes, but rather evolving 
from addition or potentiation of a specific cluster of genes, which 
subsequently determines the genetic vulnerability of an individual. 
Linkage and association studies suggest that genetic factors increase 
the vulnerability to the disease, but that penetration is modulated by 
different triggering factors and environmental influences. Over the past 
years, a large number of genes or polymorphisms have been evaluated, 
which could in some way be related to pharmacological systems involved 
in schizophrenia. Several studies and meta-analyses point at the potential 
involvement of the gene for dopamine d2 receptors (drd2) [88,89]. 
However, the relationship between polymorphisms and schizophrenia 
is complex and makes it impossible to draw strong, direct conclusions 
as dopamine availability and brain functioning are not linearly related 
[90]. Catechol-O-methyl transferase (comt), a catabolic enzyme involved 
in the degradation of particularly dopamine [91,92], has been shown 
character. It is only after some weeks of treatment that the fundamental 
content of the delusions and hallucinations is deconstructed and recedes 
(entirely for some) from awareness[66,67]. The detailed mechanism 
behind this concept is unknown, but it fits well for the phenomenon of 
relapse, exacerbation and recurrence of psychosis in schizophrenia[68]. 
mesocortical	dopamine	tracts	The classical dopamine hypothesis  
of schizophrenia thus postulates that an excess of dopamine subcorti- 
cally (as a consequence of hyperactivity of the mesolimbic pathway) is 
associated with positive symptoms of schizophrenia. About 20 years 
ago, it was proposed that the negative symptoms and cognitive impair-
ment, commonly found in schizophrenia, could be associated with a lack 
of dopamine in the prefrontal cortex [69]. This idea was raised, because 
dopamine depletion in the prefrontal cortex produced cognitive impair-
ment in animals [70]. Functional imaging studies [71,72] and postmor-
tem studies of the brains of schizophrenic patients [73-75] demonstrated 
a range of abnormalities in cortical areas within the working memory 
network, including (most consistently) the dorsolateral prefrontal cor-
tex, cingulate, and temporal cortices. The overall function of a cortical 
network presumably relies on the competence of both local information 
processing within specific local circuits and axonal connections between 
local circuits and distant cortical areas. Therefore, a deficit of a single 
region (for example in the dorsolateral prefrontal cortex) could conceiv-
ably have functional consequences in the working memory network [72]. 
mesolimbic	and	mesocortical	imbalance	Combining the meso-
limbic and mesocortical theories, the current dopamine hypothesis 
suggests an imbalance between mesocortical and mesolimbic dopa-
minergic systems [53,76]. Several hypotheses have been published 
on how the overactivity and underactivity in these different regions 
can co-exist at the same time and whether these are linked. There 
is an ongoing debate whether subcortical dopamine dysregulation 
(mesolimbic) is a primary phenomenon, or is rather associated with 
prefrontal cortical dysfunction (mesocortical) [77-80]. 
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However, this hypothesis has frequently been criticized as ‘pure’ 5-ht2a 
antagonists have never shown antipsychotic properties. 
Although the interest in the 5-ht2a antagonists has decreased, there 
is increasing evidence that 5-ht6 receptors are involved in cognition 
and learning, and that they might play a role in convulsive disorders and 
appetite control [98]. It has been hypothesized that clozapine’s relatively 
high affinity for 5-ht6 receptors might explain some of its beneficial 
cognitive effects in schizophrenia [104,105]. In animals 5-ht6 receptor 
antagonists showed improvements in several cognition models [106- 
109], although contradictive results were reported as well [110,111]. 
Several reports suggest a potential therapeutic role of 5-ht6 receptor 
antagonists in the treatment of cognitive dysfunction. Interestingly,  
these agents seem to be effective in syndromes associated with 
cholinergic hypofunction [112]. 
Summarizing, 5-ht2a antagonism by itself has never been persuasi-
vely shown to have antipsychotic properties, despite clear evidence for 
psychomimetic effects of 5-ht2a activation. However, 5-ht6 antagonism 
might be promising in the treatment of cognitive impairment in 
schizophrenia. 
glutamate	
In the late 50s it was hypothesized that hypofunction of the glutamatergic 
system, and specifically of the N-methyl-D-aspartate (nmda) receptor, 
contributed to the pathophysiology of schizophrenia [113,114]. This was 
based on effects of non-competitive antagonists of the N-methyl-D-
aspartate (nmda) glutamate receptor (e.g. ketamine and phencyclidine), 
which exacerbated symptoms in schizophrenic patients and induce 
psychotic symptoms in healthy men [115]. The effects were considered 
to better resemble schizophrenia than those induced by dopamine 
activation or partial 5-ht2 agonism: not only positive, but also negative 
symptoms and cognitive deficits were shown after administering these 
compounds [115,116]. Furthermore, reciprocal synaptic relationships 
between forebrain dopaminergic projections and glutamatergic systems 
have been described and therefore dysfunction of glutamatergic neuronal 
to be critical for prefrontal dopamine flux as well as prefrontal cortex-
dependent cognition and activation [93]. Several comt polymorphisms 
substantially influence the activity of the enzyme [90,93]. Except for comt, 
studies looking for links between polymorphisms and schizophrenia  
have mostly been negative or ambiguous [81,94-97]. 
In summary, the dopamine hypothesis has been and still is the 
currently most widely accepted theory of schizophrenia. Even though 
it has been accepted that changes in dopamine are playing a role in 
schizophrenia, it still remains a matter of debate whether dopamine  
is the primary or only cause of these derangements. 
serotonin	
Serotonin was discovered in the late 1940s, and the first serotonin 
(5-ht) receptors were identified shortly thereafter [98]. In the 1950’ 
and 60’s, the partial 5-ht2a agonist lysergic acid diethylamide (lsd) 
was extensively used and even registered for some time (as Delysid¨), 
for its hallucinatory effects and as a tool to investigate or experience 
psychotic-like states. Interest in the role of serotonin for the treatment 
of schizophrenia was further enhanced by the discovery of the efficacy 
of clozapine in treatment resistant schizophrenia [99]. The use of this 
drug is thwarted by the occurrence of rare but serious adverse events like 
bone marrow suppression, but it is an effective antipsychotic medication 
that causes fewer extrapyramidal and cognitive side effects than other 
antipsychotics [100]. Clozapine has a relatively low affinity for the d2 
receptor, but it affects a range of other targets, including 5-ht2 receptors 
[101]. Clozapine’s specific properties have contributed to the serotonin-
dopamine hypothesis, which states that a certain ratio of serotonin 
5-ht2 to dopamine d2 affinity is the most critical mechanism behind 
the atypical antipsychotic action. For a long period, this has been the 
most widely accepted basis for atypicality [102,103]. The thought behind 
this hypothesis is that by blocking the presynaptic 5-ht2a receptors in 
the nigrostriatal and mesocortical tracts, the net effect of a decrease in 
dopamine neurotransmission (and therefore the associated side effects 
seen with chronic antipsychotic therapy in these tracts) would be reduced. 
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of two endogenous cannabinoids were increased in the cerebrospinal 
fluid of schizophrenic patients seems consistent with this hypothesis. 
However, the direct contribution of endocannabinoid systems in the 
pathophysiology of the psychotic symptoms of schizophrenia are still 
unclear [121]. 
The evidence for pharmacological relationships between endocan-
nabinoid and dopamine systems is increasing [122,123] and psychotic 
symptoms have consistently been related to increased dopamine function 
in the striatum [43]. In a study of Fernandez-Ruiz, the literature address-
ing the cannabinoid-dopamine interactions was reviewed [124]. The cb1 
receptor in particular functions as a retrograde signalling system in many 
synapses within the cns, particularly in gabaergic and glutamatergic syn-
apses. They also play a modulatory function on dopamine (da) transmis-
sion, although cb1 receptors do not appear to be located in dopaminergic 
terminals in the major brain regions receiving dopaminergic innervations 
(e.g. the caudate-putamen and the nucleus accumbens or prefrontal 
cortex). Therefore, the effects of cannabinoids on da transmission and 
da-related behaviours seem generally indirect and exerted through the 
modulation of gaba and glutamate inputs received by dopaminergic 
neurons. Recent evidence however suggests a direct interaction between 
cannabinoid and dopaminergic pathways [125,126]. Cannabinoids have 
an important influence on various da-related neurobiological processes 
(e.g. control of movement, motivation/reward) and pathologies (schizo-
phrenia, basal ganglia disorders, and drug addiction) [124]. Bossong et al 
have shown that striatal dopamine release is increased by an acute dose 
of ∆9-tetrahydrobannabinol (thc), the most important cb1/2-partial ago-
nist from marijuana, which may explain how cannabis contributes to the 
development and pathophysiology of schizophrenia [127]. In chapter 8 a 
study is presented which supports the notion that psychotic-like effects 
induced by thc are mediated by dopaminergic systems, but that other 
systems also seem to be involved in the ‘feeling high’ effects. Additionally, 
the clear reductions of psychotic-like symptoms by a clinically relevant 
dose of haloperidol suggest that thc administration may be a useful 
pharmacological cannabinoid model for psychotic effects in healthy 
systems would not be inconsistent with the dopamine hypothesis of 
schizophrenia [113]. Olney and Farber conjectured that dopamine 
receptors inhibit glutamate release [117,118]. A primary defect in the 
dopamine system that causes dopamine hyperactivity could result in 
excessive suppression of glutamate release at nmda receptors, with 
consequent hypofunction of the nmda receptor system, which could be 
the basis for schizophrenic symptoms [113]. It was stated that this theory 
would fill some of the gaps of the dopamine hypothesis. 
Receptors for glutamate are divided into two broad families:  
1) ionotropic receptors, which are differentiated based upon sensitivity 
to the synthetic glutamate derivatives nmda, ampa and kainate and 
2) metabotropic receptors, which are G protein coupled and mediate 
longer-term neuromodulatory effects of glutamate [119]. In addition to 
the recognition site for glutamate, nmda receptors contain allosteric 
modulatory sites for glycine, which affects channel open time and 
desensitization rate in the presence of glutamate. ampa and kainate 
receptors mediate the majority of glutamate in the brain. ampa receptors 
work heavily in concert with nmda receptors. Metabotropic receptors, 
which regulate glutamatergic neurotransmission both pre- and post-
synaptically, may serve as an alternative pharmacological target for the 
treatment of schizophrenia [119]. 
Summarizing, hypofunction of the glutamatergic system is thought  
to contribute to the development of schizophrenia. Furthermore, it would 
not be inconsistent with the dopamine hypothesis. 
endocannabinoids	
Many articles have been published about the relationship between the  
use of marijuana and schizophrenia and there is little doubt that cannabis 
can lead to clinical psychosis, particularly in susceptible individuals and/
or after heavy use [21,22]. It is believed that many of the pharmacological 
effects of marijuana are mediated through the specific endogenous 
receptors cb1 and cb2, and it has been proposed that dysfunction of the 
endogenous cannabinoid system may play a role in the production of at 
least some of the symptoms of schizophrenia [120].The finding that levels 
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co-morbid anxiety and disordered sleep, which can have profound effects 
on the intensity of hallucinations, delusions, and on cognitive organiza-
tion. Benzodiazepines and other gaba(a) agonists are well-known for 
their anxiolytic and sleep inducing effects, which during short term treat-
ment may secondarily improve sleep and decrease paranoia. At the same 
time however, gaba(a) agonists are equally well-known for their detri-
mental effects on memory and attention, particularly at higher doses and 
in cognitively vulnerable subjects, and there is no reason to suspect that 
this would be different in schizophrenia. These two aspects of generalized 
gaba(a)-activation thwart the non-discriminant use of benzodiazepines 
in schizophrenia, although these treatments can be quite useful in case 
of pronounced anxiety, restlessness or insomnia. Non-selective gaba(a) 
receptor inverse agonists (with a negative efficacy at all a subunits) have 
been shown to improve alertness and memory in experimental animals, 
but such drugs can also cause anxiety and seizures, and have therefore not 
been studied extensively in humans [130]. Secondly, gaba(a)-receptors 
are composed of different subunits, which have increasingly been associ-
ated with different cns-functions. gaba(a) agonists containing alpha1 
subunits are associated with alertness and sedation. gaba(a) agonists  
with a high affinity for these subtypes have been developed as potent 
hypnotics. Particularly these so-called z-hypnotics (including zolpidem, 
mentioned earlier) can sometimes cause hallucinations, which has been 
attributed to a dissociated wake-sleep transition [132]. gaba(a) recep-
tors containing alpha2 and alpha3 subunits are linked to anxiety and 
anxiolysis. Subtype selective alpha2,3 agonists are in development for 
anxiety disorders with an improved side effect profile. These drugs have 
not been studied in schizophrenia [128] but could be useful as add-on 
treatments for hallucinations or paranoid delusions or other co-morbid 
anxieties. Alpha4 containing gaba(a) receptors are located extrasynapti-
cally throughout the brain. Their physiological role is uncertain. gaba(a) 
receptors containing alpha5 subunits have been associated with memory. 
Consequently, alpha5-selective inverse agonists have been in develop-
ment as memory-enhancers for various cognitive disorders, but they have 
not been examined in schizophrenia.  
volunteers. A similar study was recently performed by Kleinloog et al using 
olanzapine instead of haloperidol. They found similar results, confirming 
the use of this practical psychosis model for the currently used antipsy-
chotics. It would be interesting to investigate whether this model can also 
be used for compounds with other mechanisms investigated for the treat-
ment of schizophrenia. 
In summary, relationships between cannabis and psychosis are 
increasingly clear. There is increasing evidence for a pharmacological 
relation between (endo)cannabinoid and dopamine systems. However,  
it is uncertain whether endocannabinoids contribute to the patho physio-
logy of schizophrenia. 
gamma-aminobutyric	acid	(gaba)	
The gaba(a)ergic (gamma-aminobutyric acid) system has been impli-
cated in the pathophysiology of schizophrenia, both for positive, nega-
tive [128,129] and cognitive symptoms [130]. gaba(a)ergic interneurons 
are a core component of the corticolimbic circuitry and modulate the 
mesolimbic and mesocortical dopaminergic system in a complex way. 
A growing body of evidence suggests that a malfunction in cortical 
gabaergic transmission resulting in a disturbance in cortical network 
activity is a critical factor underlying schizophrenia [131]. The exact role  
of gabaergic systems in the pathophysiology of schizophrenia is still 
unclear and in part controversial. 
gaba(a) agonists have shown beneficial effects on positive, and to a 
lesser degree, negative symptoms in some schizophrenic patients [129]. 
On the other hand, some gaba(a) agonists like zolpidem can induce  
florid hallucinogenic effects [132,133]. Moreover, gaba(a) agonists such 
as benzodiazepines, although widely used as sleep aids in schizophrenia, 
can impair, rather than correct, sleep architecture and cognition [134]. 
gaba(b) agonists, may be a better option for sleep problems in schizo-
phrenia [134]. Whether gaba(b) agonists have a good or deleterious  
effect on the positive and negative symptoms has not been sorted out yet. 
These apparently contradictory reports are at least partly due to two 
important factors. Firstly, many schizophrenic patients suffer from 
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neuropharmacological	combination	theory	
The different neuropharmacological theories are not mutually exclusive 
and can be combined to a ‘neuropharmacological combination model’  
(partially adapted from Stahl [11]). The relationship between dopaminer-
gic, serotonergic, glutamatergic and gabaergic tracts in people without 
schizophrenia could be simplified as shown in figure 2. The endocan-
nabinoid system has not been included in the picture, since the position 
of endocannabinoid systems is still unclear and could in fact overlap with 
several of the other neurotransmitter pathways, by direct or indirect inter-
actions with dopamine and gaba or glutamate [124]. This is also the case 
for acetylcholine. 
In the vta the cortical brainstem glutamate projection is linked to the 
mesolimbic dopamine pathway through a gaba interneuron. Stimula-
tion of interneuron nmda receptors by glutamate induces gaba release. 
This inhibits dopamine release from the mesolimbic dopamine pathway, 
which communicates with the parahippocampal gyrus, linked with the 
sensory associative cortex in both ways, resulting in ‘recognition’ of sen-
sory information. The mesolimbic pathway also communicates with the 
amygdala, which also links to the sensory associative cortex, resulting 
in the realization whether something is ‘safe’ or whether it is a ‘threat’. 
This can be explained by the motivational salience hypothesis. According 
to this hypothesis, dopamine can be a mediator of contextually aberrant 
saliences as was explained before in this introduction [51]. 
In this relatively simple integrated neuropharmacological model  
of schizophrenia, nmda receptors in the cortical brainstem glutamate 
projection would be hypoactive, resulting in disinhibition of the meso-
limbic dopamine pathway, leading to hyperactivity of this pathway and 
eventually to positive symptoms (figure 3). 
The cortical brainstem glutamate projection also communicates 
directly with the mesocortical dopamine pathway in the vta, normally 
causing tonic excitation. In schizophrenia, hypoactivity of nmda receptors 
in cortical brainstem glutamate projections leads to a loss of tonic excita-
tion, and mesocortical dopamine pathways become hypoactive, which 
could contribute to cognitive, negative and affective symptoms (figure 3). 
In conclusion, specific gaba(a)ergic systems (or specific receptor 
subtypes of the gaba system) may be relevant for various functional 
abnormalities in schizophrenia, which opens possibilities for potential 
novel treatments for specific clinical features of this disease. However, 
schizophrenia is a complex disorder with a multitude of pharmacological 
derangements, and the role of gabaergic systems is still largely unclear. 
At present, the development of gaba-ergic drugs is mainly directed at 
more restricted clinical syndromes, with better established links to the 
different gaba-systems and their functional characteristics, such as 
anxiety and memory impairment. 
acetylcholine	
The cholinergic system (and acetylcholine) is thought to play a role in 
the symptoms of cognitive dysfunction in schizophrenia [129,135,136]. 
Cognitive impairments observed in schizophrenia in many aspects 
resemble those that occur in healthy subjects following administration 
of scopolamine [137,138]. Scopolamine has been applied as a disease 
model for dementia [139] and for memory impairment in schizophrenia 
[137]. Although the scopolamine model does not capture the complexity 
of cognitive decline in schizophrenia (or Alzheimer’s disease for that 
matter), it has become the most frequently used model for studies of 
cognitive impairment in experimental animals and healthy volunteers 
[139-142]. Scopolamine-induced memory impairments in animals 
show similarities to those in humans [143,144]. It is thought that there 
is an interaction between cholinergic and glutamatergic systems on 
cognitive function although the exact mechanism behind this interaction 
has not been resolved [145-147]. In chapter 5 and 6 of this thesis, the 
scopolamine model was used in healthy volunteers to study the effects of 
two new glycine reuptake inhibitors. In chapter 7 the pharmacokinetic-
pharmacodynamic relationships were investigated. 
The evidence that abnormalities in the cholinergic system may play  
a role in other symptoms of schizophrenia is still marginal and will 
therefore not be discussed further in this introduction. 
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catie (Clinical Antipsychotic Trials of Intervention Effectiveness) trial, in 
which discontinuation of treatment was the main endpoint, a difference 
between the studied sgas and fga was found [150]. Olanzapine was the 
most effective in terms of lower rates of discontinuation, but the efficacy 
of the fga perphenazine appeared similar to that of the other sgas 
(quetiapine, risperidone, and ziprasidone). However, olanzapine was 
associated with greater weight gain and increases in measures of  
glucose and lipid metabolism. Several other meta-analyses did not  
lead to a definitive answer to the question whether fgas and sgas  
differ in efficacy [150-158]. 
The only exception seems to be clozapine, which has repeatedly 
been effective for treating both positive and negative symptoms in 
treatment resistant schizophrenia [100], but may cause severe side 
effects such as agranulocytosis that limit its use [159-161]. The beneficial 
pharmacological properties of clozapine are unknown [162], and many 
different hypotheses for the superior effectiveness in treatment resistant 
schizophrenia have been published. 
Many have claimed that the sgas are more efficacious than fgas 
in reducing negative symptoms (e.g., lack of emotion, interest, and 
expression), possibly due to the absence of extrapyramidal symptoms 
[163] or other secondary causes of negative symptoms (e.g. depression) 
rather than to direct therapeutic effects [164]. However, it should be 
noted that this is difficult to assess, because it is hard to distinguish 
secondary negative symptoms (due to some features of epss caused by 
antipsychotics [163] or exacerbation of mesocortical hypodopaminergic 
function by d2 antagonists) from primary negative symptoms of the 
disease. Lehman et al conclude in the second edition of the American 
Psychiatric Association (apa) Practice Guideline for the treatment of 
patients with schizophrenia that at this moment there is no effective 
treatment for primary negative symptoms [165]. 
Comparable to negative symptoms, it is unknown whether there is 
a difference in effects on cognitive impairment and mood disturbance 
[166,167]. The ability of atypical agents to prevent relapse and their 
effects on social and vocational functioning, quality of life, long-term 
Pharmacological treatment 
Currently used antipsychotics 
Almost all currently available antipsychotic drugs are based on the 
dopamine hypothesis, and although many drugs have been designed 
to affect or avoid certain other specific pharmacological targets, all 
registered antipsychotics antagonize the dopamine d2 receptor [49]. 
Several publications have clearly reviewed these drugs (see for example 
[148,149]) and therefore only a brief summary will be given. 
The current pharmacological treatments can be divided in two groups: 
1) first-generation antipsychotics (fgas), also called classic or conven-
tional antipsychotics or neuroleptics; and 2) second-generation antipsy-
chotics (sgas), also called atypical or nonconventional antipsychotics. 
The fgas (phenothiazines, butyrophenones, thioxanthines) have been the 
main therapy until the introduction of sgas in the early 1990s. Although it 
is not completely clear what differentiates fgas from sgas (as discussed in 
the next chapter of this introduction), the term ‘atypicality’ refers to drugs 
that have at least equal antipsychotic efficacy compared to conventional 
drugs, with less extrapyramidal side effects (eps) (acute dystonic reac-
tions, akathisia, parkinsonism, tardive dyskinesia) and/or prolactin eleva-
tion [148]. The extrapyramidal syndromes such as medication-induced 
parkinsonism and dystonias are caused by dopamine antagonism in the 
nigrostriatal tract. Low dopamine in the tuberoinfundibular tract leads  
to prolactin release, which in some patients leads to gynecomastia. 
The high risk of the possibly irreversible movement disorder tardive 
dyskinesia, and the high rates of acute eps were the major reason for 
psychiatrists to switch patients to sgas when these became available. 
Many studies have been performed that compare fgas to sgas or sgas 
to each other. These studies, however, were often performed in patients 
with acute exacerbation, did not include treatment-resistant patients, 
were relatively short and did not take into account sufficient efficacy 
and safety parameters. Moreover, these studies were usually sponsored 
by the manufacturer of the new antipsychotic and often included a 
higher than necessary dose of the comparator fga [149,149]. In the 
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Another known adverse effect of antipsychotics is cognitive dysfunction.  
A growing body of evidence from such animal studies indicates that sev-
eral antipsychotics, including both sgas and fgas (if administered for 
sufficient periods of time), can be associated with impairments in mem-
ory-related task performance, as well as alterations in central cholinergic 
function [182]. It is not completely clarified how this can be explained 
pharmacologically, but the importance of cholinergic receptor to infor-
mation processing and cognitive function is thought to play a role [182]. 
Pharmacological theories for differences between 
FGAs and SGAs 
Many hypotheses have been generated for the pharmacological  
difference between fgas and sgas. According to Kapur and Seeman  
all efforts to produce antipsychotic action without d2 blockade have 
been unsuccessful [183]. Kapur and Seeman proposed that a low affinity 
at the d2 receptor in and of itself, is sufficient for producing atypical 
antipsychotic activity. Affinity (Kd) is defined as the ratio of koff/kon  
(the rate at which the drug moves off and binds to the receptor). It has 
been found that koff is the most important determinant of how drugs  
and dopamine compete [183]. The faster koff, the more quickly the  
drug will release from the receptor after an endogenous dopamine surge. 
The slower koff, the slower the drug responds to changes in endogenous 
dopamine. Antipsychotics with a fast koff under clinical conditions give 
rise to a fast-on, fast-turnover and fast-off blockade of d2 receptors.  
The fast dissociation hypothesis suggests that the combination of a  
fast koff at the molecular level and transient d2 occupancy at the system 
level is sufficient to provide an atypical antipsychotic effect. Kapur and 
Seeman propose that drugs with fast dissociation when used in doses 
that lead to appropriately high d2 blockade modulate the dopamine 
system in a manner that allows for a better accommodation to changes in 
physiological dopamine transmission, permitting an antipsychotic effect 
without motor side effects, prolactin elevation, or anhedonia and other 
outcome, and the caregivers’ burden have been incompletely explored 
[156,163,168]. Similar to negative symptoms, cognitive dysfunction may 
be secondary to other factors such as eps, anticholinergic effects and 
sedation or the underlying disease. 
The superior tolerability of the sgas with regard to eps seems 
proven [151,152,152,158,169]. They do, however produce other side 
effects, of which weight gain [170,171] in combination with an altered 
glucose, cholesterol and lipid metabolism [172-174] seem to be the 
most worrisome. Besides the fact that this can adversely affect quality 
of life and medication adherence [175], weight gain and metabolic 
abnormalities are important risk factors for premature cardiovascular 
morbidity and mortality [176]. It is unclear whether the glucose effects 
are secondary, independent or causative to weight gain. Also, to date, 
research has been inconclusive whether antipsychotics increase weight 
via increased appetite and food intake, decreased activity or decreased 
metabolism. Which pharmacodynamic receptor is responsible for this 
weight gain and metabolic changes, has yet to be determined [177]. 
Taken together, the available preclinical and human data indicate that no 
single neurotransmitter system is responsible for antipsychotic-related 
weight gain. While rodent and indirect human evidence links the weight 
gain potential of antipsychotics to histamine h1 blockade [178], studies 
also implement other neurotransmitter systems, such as dopamine d2 
blockade, 5-ht2c blockade and interactions with central or peripheral 
hormones and peptides involved in energy homeostasis [177]. These 
results are further supported by evidence of an interaction between 
histamine h1 and dopamine d2 blockade [179], genetic data [180] 
and by the fact that antipsychotics without relevant antihistaminergic 
activity, such as aripiprazole, amisulpride and haloperidol, have clearly 
documented weight gain potential, especially in antipsychotic-naive and 
first episode patients [181]. 
There are differences in weight gain between the atypical antipsychotics 
[177]. The risk is highest after the use of clozapine or olanzapine and 
lower (but still present) after risperidone, quetiapine and aripiprazole. 
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Past drug development 
The majority of currently approved pharmacological agents target 
psychotic symptoms as their primary effects, and are largely similar 
in efficacy and effectiveness (except for clozapine in drug-resistant 
schizophrenia). Each new atypical drug has its own individual side- 
effect profile and should therefore be individually evaluated for safety. 
Although currently used antipsychotics can reduce core psychotic 
symptoms and delay symptom exacerbations very effectively in many 
patients, schizophrenia has remained a chronic illness with substantial 
functional impairments, with limited therapeutic developments. The 
introduction of the atypical antipsychotics has provided a larger and more 
diverse armamentarium of treatment options, but companies have mainly 
focussed on alterations of existing medications and on gaining approval 
on new indications for already marketed drugs [190]. Although many new 
mechanisms of action have been proposed, several of which have already 
been examined for a number of decades, these have not led to concrete 
new treatment strategies or novel drug registrations for schizophrenia. 
Therapeutic innovations since the discovery of chlorpromazine were 
mainly limited to pharmacological modifications of the receptor 
specificity, affinity and intrinsic activity. In general, efforts to discover 
and develop new drugs have been relatively unsuccessful compared 
with other disease areas [191-193], and a sceptic could argue that drug 
development for schizophrenia has not progressed appreciably since 
the serendipitous discovery of ‘chemical lobotomy’ with chlorpromazine 
in the early ‘50s [194]. Agid et al mentioned several reasons that could 
underlie this lack of success [191]. Perhaps the most important reason 
is that psychiatry has a diagnostic and classification system that is not 
based on etiology, neurobiology, epidemiology, genetics or response 
to medications, but rather on a constellation of signs and symptoms 
[193]. As with many other neuropsychiatric conditions, schizophrenia 
research and drug development are also thwarted by the complexity of 
the cns, lack of a defined pathology, problematic tissue accessibility, 
co-morbidity, absence of good animal models, and the daunting fact that 
secondary negative symptoms, and that this leads to what is currently 
called the atypical antipsychotic effect. Traditional antipsychotics 
(e.g. haloperidol and chlorpromazine) bind tightly to the dopamine d2 
receptor and slowly dissociate from the d2 receptor in vitro or in vivo 
[184]. The atypical antipsychotic drugs (e.g. quetiapine, clozapine, 
paliperidone, and amisulpride) show rapid dissociation times from the 
cloned d2 receptor [185,186], and clinical dissociation times of hours, 
thus minimizing clinical side effects. 
Aripiprazole is a novel antipsychotic agent that is also considered 
atypical, but with a slightly different mechanism of action. It is a partial 
agonist for the dopamine and 5-ht1a	receptor and an antagonist for the 
5-ht2a receptor.
Another hypothesis for differences in fgas and sgas is the ‘5-ht2 
hypothesis’. Since all antipsychotics block d2 receptors, it has often 
been thought that atypical antipsychotics must differ due to a separate 
receptor mechanism. However, high 5-ht2 occupancy (or a high 5-ht2/d2 
ratio) seems neither necessary nor sufficient for the atypical antipsychotic 
effect [183]. Although this hypothesis could be a relatively easy way to 
explain the differences between atypical and typical antipsychotics, there 
are several arguments against this theory. One argument is the absence 
of an atypical clinical profile of antipsychotic effects, after addition of a 
selective 5-ht2 antagonist to treatment with an ongoing d2 antagonist 
[36]. Many ‘atypical’ antipsychotics have also been developed because 
of their 5-ht2-inhibiting properties, but selective 5-ht2 antagonists that 
lack antidopaminergic activity (such as ritanserin) have failed to show a 
reliable antipsychotic effect [36]. Second, several typical antipsychotics 
have a high affinity for 5-ht2 receptors, and some lose ’atypicality’ at 
high doses, which does not support this theory [187]. Furthermore, 
the relative freedom from extrapyramidal symptoms of the atypical 
antipsychotics is not related to their 5-ht2/d2 ratio’s [188] . Also, this 
ratio is not associated with the therapeutic doses of different classic and 
atypical antipsychotic drugs, contrary to d2-affinity [49,189]. Other less 
well accepted hypotheses for the difference between typical and atypical 
antipsychotics will not be discussed in this introduction [65]. 
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New drug development 
Although most new pharmacological approaches to schizophrenia 
are merely symptomatic, they may still cause relevant improvements 
in patients. Considering the complexity and the multidimensional 
characteristics of schizophrenia, it is likely that newly developed 
medications will increasingly be introduced as parts of a polytherapeutic 
strategy. Each patient will be treated with an individualized drug 
combination, aimed at his or her personal multidimensional disease 
profile [190]. This is also called the ‘magic shotguns’ approach [196]. 
This competes with the strategy of the ‘magic bullet’, that still seems to 
be favoured by the pharmaceutical industry and to be expected by the 
society. In this strategy a single perfect drug will cure the disease without 
side effects. Progressions made with polypharmacy are slower than with 
‘magic bullets’, because of the many complexities of dose determinations 
of combined treatments and interactions, patient selection, and 
problems associated with patents and ownership. On the other hand, 
polypharmacy shows close resemblance to clinical practice, where 
most patients with chronic psychiatric conditions ultimately receive 
drug combinations that have been individually selected and optimized, 
targeted at specific clinical problems, and guided by gradual dose 
escalations and regular assessments of therapeutic and adverse effects. 
Gray gives a good impression of the many pharmacological targets 
which are under investigation for the development of new drugs for 
schizophrenia [190] and for cognitive deficits specifically in schizophrenia 
[197]. The increasing awareness that schizophrenia affects different 
neuropsychological domains such as cognition, mood and social 
functioning, has fuelled the notion that other systems may also be 
involved. Thus, drugs that are primarily in development for dementia  
(e.g. cholinergic or serotonergic enhancers) or depression (like mono - 
ami nergic or vasopressinergic agents) are often also explored as poten- 
tial treatments for abnormal affection, cognition deficits and social 
functioning in schizophrenia. In more recent years, psychotic symptoms 
with other drugs or diseases, animal models and other research findings 
the complexity of behaviour is not simply the sum of its constituents [191]. 
Another important reason for the lack of progress in development of 
schizophrenia drug therapy is the absence of adequate animal models 
to allow determination of clinical efficacy, which therefore often only 
gets fully established after the drug is widely prescribed on the market. 
Current preclinical models for schizophrenia are quite effective at 
predicting whether a candidate molecule will have ‘atypical’ properties. 
However, they are less able to make a prognosis for overall efficacy, and 
completely unable to predict greater efficacy compared to currently 
available antipsychotics [192]. Moreover, in terms of the negative and 
cognitive symptom domains in schizophrenia, none of the commonly 
used animal models are highly predictive, and although it is expected 
that preclinical memory models will be useful for forecasting the ability 
to enhance cognition [190], this has not yet been validated in practice. 
As validity of most currently used animal models is essentially limited 
to the dopamine hypothesis, these models favour development of (even 
more) antidopaminergic antipsychotics, but their predictive value for 
treatments with entirely different mechanisms of action remains to be 
established. Another disadvantage of using small laboratory animals as 
a schizophrenia model is that they lack the complex pre-frontal cortical 
networks that are responsible for many of the clinical manifestations 
of schizophrenia and psychosis. Additionally (or consequently), the 
most relevant (clinical) symptoms such as hallucinations and delusions 
are difficult to assess or measure objectively in animals. Although 
these limitations are generally acknowledged, current animal models 
continue to be used because there are no alternative models available. 
A more rational approach would be to employ human models for the 
pharmacological, cognitive and antipsychotic effects of putative novel 
drugs for schizophrenia. Investigating (new) compounds in healthy 
subjects in an earlier stage of development will increase the predictive 
value for (new) compounds and will provide reliable information to the 
development program at the earliest possible time and reduce exposure 
to vulnerable populations (i.e. schizophrenia patients) [195]. This topic  
is dealt with in chapters 7 and 8. 
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brain. Aripiprazole for instance is a partial d2 agonist, designed to reduce 
hyperactive dopaminergic functions (involved in positive symptoms) 
and to activate reduced dopamine tone in mesocortical (cognitive) 
areas. Other more indirect strategies are currently investigated. Based 
on the fast dissociation theory of atypicality described earlier, new 
agents are now in development that dissociate faster from the dopamine 
receptor [183]. An example is the centrally acting dopamine d2 receptor 
antagonist jnj37822681, which combines specificity for the dopamine  
d2 receptor and a fast rate of dissociation from this receptor [198]. 
Another indirect strategy is targeted at neuropeptides that modify the 
activity of monoaminergic neurotransmitters. Tachykinins for instance 
activate neurokinin nk3 receptors that facilitate the release of the 
biogenic amines dopamine, serotonin and norepinephrine. This opens 
the possibility that antagonism of nk-receptor reduces the excitatory 
activation (or hyperactivity) of some or all of these principal systems, 
without affecting normal dopaminergic baseline activity so much. 
Various nk antagonists are in development for different psychiatric 
disorders[199]. In chapter 3, the effects of the neurokinin (nk)3 
antagonist talnetant (sb223412) were investigated in healthy volunteers.
serotonergic	strategies	
Although there is no definite proof for the earlier mentioned serotonin-
dopamine hypothesis (in which the 5-ht2 receptor is involved), there 
are theoretical grounds for investigating other subtypes of the serotonin 
receptor. Several serotonergic strategies are outlined by Gray et al 
[190,197]. Glennon et al have reviewed three possible new receptors which 
may be implicated in schizophrenia: 5-ht5, 5-ht6 and 5-ht7 [98]. In 
contrast to the 5-ht1 to 5-ht4 receptors, the 5-ht5, 5-ht6 and 5-ht7 
receptors have been less extensively investigated and much less is known 
about their functional properties. 
As no selective ligands are available, little is known about the 5-ht5 
receptor [200]. 5-ht5 receptors have not yet been demonstrated to 
‘function’ in native systems [200]. It is likely that interest in 5-ht5 
pharmacology will follow once selective ligands are available. 
have also implicated other neuropharmacological systems, such as gaba, 
endocannabinoids and glucocorticoids [192]. So far, to our knowledge, 
many of these strategies have been abandoned. 
Since 2008, about around 2600 compounds are in development for 
the treatment of schizophrenia (source: Prous Science Integrity, http://
integrity.prous.com/integrity/servlet/xmlxsl/). These experimental 
compounds show a remarkable pharmacological diversity, with 210 
more or less distinct mechanisms of action. Only roughly one third 
of the compounds is based on known mechanisms of action or on 
derivatives of currently existing antipsychotics. Frequently reported 
mechanisms are glycine-1 reuptake inhibition (203 times), dopamine d2 
antagonism or partial agonism (91), 5-ht2a antagonism (70), tachykinin 
nk3 antagonism (62) and 5-ht6 antagonists (60). In the following 
paragraphs, several active drug development programs targeted at 
different pharmacological receptors are discussed, which are also dealt 
with in other chapters of this thesis. 
dopaminergic	strategies	
Virtually all currently available antipsychotic drugs are mainly aimed at  
positive symptoms, by reducing the excessive mesolimbic parahippoca-
mpal dopaminergic tone that seems to be an essential element of 
psy chotic manifestations. At the same time, such treatments also 
reduce other dopaminergic pathways that do not function excessively 
and are sometimes even less active in patients. Such pathways are 
involved in important physiological functions like extrapyramidal 
regulations, mesolimbic reward system, mesocortical cognitive 
processes, and tuberoinfundibular metabolic and neuroendocrine 
activity. These mechanisms are responsible for significant adverse effects 
of antidopaminergic drugs that contribute to poor compliance and 
cognitive blunting. In recent years, due to new insights in pathogenesis 
and pathophysiology of schizophrenia, new pharmacological targets and 
corresponding compounds have been developed, as for example reviewed 
by Gray et al [190,197]. Some new dopaminergic treatments are designed 
to modulate rather than simply antagonize the activity of dopamine in the 
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The 5-ht6 antagonist sb742457 is developed as a possible ‘add-on’ 
therapy for schizophrenia, to improve the negative symptoms or to 
decrease the cognitive side effects of currently used treatments. Since 
such compounds are designed to treat only part of the schizophrenic 
spectrum, they will usually be combined with other therapies. Therefore, 
interactions with other antipsychotic drugs are relevant, and in chapter 2 
sb742457 was investigated in combination with risperidone. Risperidone 
is a d2/5-ht2a antagonist with low affinity for 5-ht6 receptors, which 
seems to produce a limited improvement on neurocognitive parameters 
in schizophrenic patients [210]. 
glutamatergic	strategies	
Hypofunction of the glutamatergic system is one of the most promising 
non-dopaminergic theories for the pathophysiology of schizophrenia. 
Several targets have been explored to stimulate glutamateric activity 
[190,197], while avoiding potential adverse reactions like seizures or cell 
death [211]. Activation of metabotropic receptors indirectly induce ion 
channel formation and other postreceptor cascades [212]. The selective 
metabotropic glutamate 2/3 (mGlu2/3) receptor agonist ly404039 [213] 
has anxiolytic and antipsychotic effects in animal studies, without causing 
sedation [214] and is thought to work by reducing the presynaptic release 
of glutamate in brain regions where mGlu2/3 receptors are expressed 
[215,216]. In a first exploratory clinical study, it seemed effective in 
patients with schizophrenia and did not show major side effects [217].
Others have tried to stimulate glutamatergic activity through ampa 
or kainate activation. ampakines, which potentiate ampa transmission 
without binding directly to the agonist binding site [218], stimulate mem-
ory-dependent processing in animals [219] and could be useful to treat 
various aspects of schizophrenia. These compounds are currently under 
development for treatment of cognitive dysfunction in various neuropsy-
chiatric disorders [119,220]. Although far less advanced, the ampa/kain-
ate receptor antagonist ly293558, showed effect in an animal model for 
cognitive deficits (ketamine), suggesting a possible utility of ampa antag-
onists in the treatment of the cognitive deficits in schizophrenia [221]. 
Human 5-ht7 receptors are positively coupled to an adenylate cyclase 
second messenger system. Several reasonably selective antagonists and 
agonists have been identified, and a number of leads for other structure 
types have been discovered. 5-ht7 receptors have been implicated in a 
wide variety of pharmacological functions, although the functions and 
possible clinical relevance of this receptor are not yet fully understood. 
Indirect evidence suggests that 5-ht7 receptor antagonism may be 
clinically useful in the treatment of depression and possibly involved in 
anxiety, epilepsy, pain, and schizophrenia [201]. Since the involvement 
of this receptor in schizophrenia is under investigation and no selective 
5-ht7 antagonists have been developed for humans, this will not be 
further discussed in this introduction. 
After rat and mouse 5-ht6 receptors were described in 1993 and 1994 
[202,203] and human 5-ht6 receptors in 1996 [204], research in this area 
increased immensely. The human 5-ht6 receptor is positively coupled 
to adenylate cyclase, has 89% overall sequence homology with the rat 
receptor and is nearly exclusively localized in the central nervous system 
[204]. It is predominantly found in the caudate nucleus, with lower 
concentrations in hippocampus and amygdala [204]. The first 5-ht6-
selective antagonist was described in 1998 [205]. Since then, various 
useful selective 5-ht6 antagonists have been identified, some selective 
5-ht6 agonists have been reported and newer agents are developed with 
improved pharmacokinetic and pharmacodynamic properties [98,206]. 
Several recent lines of evidence have suggested a role of 5-ht6 recep-
tors in cognitive and memory processes, found in healthy animals and in 
animal models of cognitive impairment [98,109,207] and in patients with 
Alzheimer’s disease (ad) [206,208]. Maher-Edwards et al performed an 
exploratory clinical study showing that the 5-ht6 antagonist sb742457 
and the acetylcholinesterase inhibitor donepezil improved global func-
tioning of ad patients [209]. A combined 5-ht6 receptor antagonist and 
cholinesterase inhibitor strategy could be a possible treatment of cogni-
tive disorders such as those seen in Alzheimer’s disease or schizophrenia. 
However, this class of drugs needs to be investigated more thoroughly and 
the role of this receptor in schizophrenia (even more than in ad) still needs 
to be defined. 
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(sr141716) show the most consistent antipsychotic properties in 
dopamine- and glutamate-based (animal and human) models of 
schizophrenia, with profiles similar to atypical antipsychotic drugs [232]. 
cbd is one of the components of cannabis, which may constitute up 
to 40% of cannabis extracts and is devoid of the typical psychological 
effects of cannabis in humans [233]. The first evidence that cbd could 
have antipsychotic effects was obtained in an interactive study of cbd 
and delta9-thc in healthy volunteers published in 1982 [234]. The 
antipsychotic-like properties of cbd have been investigated in animal 
models using behavioural and neurochemical techniques, which 
suggested that cbd this compound may act as an atypical antipsychotic 
drug [233,235,236]. Also, in human models of psychotic symptoms 
in healthy volunteers, the antipsychotic-like activity of cbd was 
demonstrated [236]. Although cbd did not show effect in a study in 
treatment-resistant schizophrenic patients, a preliminary report from  
a 4-week clinical study suggested that cbd is an effective, safe and well-
tolerated treatment for schizophrenic patients [236]. In 2007 Leweke 
et al found that cbd significantly reduced psychotic symptoms in acute 
schizophrenia with potency similar to amisulpride but with fewer side 
effects such as eps, increase in prolactin, and weight gain [237]. 
Although the findings are variable, the selective cb1 receptor antago-
nist rimonabant showed activity in preclinical models of anti psychotic 
efficacy. It failed, however, to demonstrate antipsychotic activity versus 
placebo and haloperidol in a clinical trial [238]. The ability of cbd and 
rimonabant to improve the psychosis-related cognitive impairment has 
not been sorted out yet and these compounds need further investigation 
for this indication [232]. 
Scope of this thesis 
The introduction of this thesis gave an outline of some important 
pharmacological hypotheses of schizophrenia, the pharmacological 
properties of currently used antipsychotics, and compounds with new 
pharmacological mechanisms that are in the development pipeline.  
The most developed way to augment nmda receptor function indirectly  
is through facilitation of glycine, an obligatory co-agonist for glutamate 
at the nmda receptor. As direct agonists of nmda receptors are neurotoxic 
[114], indirect ways to enhance receptor function have been investigated 
[222]. After facilitation of glycine, an obligatory co-agonist for glutamate 
at the nmda receptor, modest improvements in positive and negative 
symptoms and cognitive function in schizophrenic patients have been 
described in exploratory studies [55,211,211,223,224]. However, high 
doses of glycine are needed to significantly elevate cns concentrations. 
Therefore, inhibition of presynaptic glycine reuptake seems a more 
efficient way to increase pharmacological glycine activity in the brain 
[225]. Of the two described glycine transporters (glycine transporter 1 
or GlyT1	and GlyT2) [226], GlyT1 seems to directly affect nmda activity 
[226,227]. Glycine reuptake inhibitors have shown effects in several 
animal models of schizophrenia [228-230]. In a clinical trial, the glycine 
reuptake inhibitor sarcosine showed effects on positive and negative 
symptoms in schizophrenic patients [224,231]. As sarcosine is a low 
potency antagonist requiring gram-level dosing, more potent glycine 
reuptake inhibitors are now investigated, as is for example shown in 
chapters 4-7. In the study described in chapter 4, the first glycine reuptake 
inhibitor to be administered to humans was examined in healthy subjects. 
In the other two studies described in chapters 5 and 6, the glycine 
reuptake inhibitor, was administered to healthy men with and without 
scopolamine, to induce transient and reversible cognitive and memory 
impairments, and to reduce ceiling effects by prevention of performance 
at maximal capacity. 
endocannabinoid	strategies	
As several lines of experimental and clinical evidence point to a dys- 
regula tion of the endocannabinoid system in schizophrenia, there is  
a potential for pharmacological manipulation of the endocannabinoid 
system as a novel approach for treating schizophrenia. Although 
experimental findings are still controversial, the cb receptor inverse 
agonist cannabidiol (cbd) and the cb1 receptor antagonist rimonabant 
40	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia 41	 1	–	introduction
uncertain. The obvious disadvantage is that healthy volunteers do not 
have schizophrenia, making it impossible to demonstrate a therapeutic 
effect. Therefore, new human pharmacological models were developed 
that can be used in healthy volunteers to study aspects of the disease. 
Chapters 5 and 6 used a scopolamine model to induce reversible 
cholinergically mediated cognitive deficits in healthy volunteers, to 
examine how these ‘negative symptoms’ were affected by glycine reuptake 
inhibitors. Chapter 7 describes a pharmacokinetic/pharmacodynamic 
model of this scopolamine challenge test. In chapter 8, the cannabinoid 
∆9-tetrahydrocannabinol (thc) was employed to temporarily cause a 
mild psychotic-like state in healthy subjects, and described how this was 
impacted by haloperidol. Thus, physiological perturbations in healthy 
subjects were used to mimic psychopathophysiological aspects of 
schizophrenia, in order to compare the effects of novel and established 
treatments at an early stage of drug development.
These approaches provide clear examples of how clinical 
pharmacological experiments in healthy volunteers can be used to 
characterize the pharmacological properties of novel compounds in 
development for schizophrenia, which basically underlie the therapeutic 
innovations that current drug development in this field tries to achieve. 
The studies also show that the main pharmacological focus in this 
area has shifted from psychosis to improvement of individual negative 
or cognitive symptom complexes, from direct receptor inhibition 
to indirect receptor modulation, and from single drug strategies to 
combination therapies. The diversity of drug development strategies in 
schizophrenia and related disorders reflects the increasing complexity of 
neuropharmacological hypotheses in this field. Despite these difficulties, 
incremental changes in drug characteristics and treatment strategies may 
well lead to the introduction of new classes or combinations of drugs in 
the future. 
This thesis describes how these pharmacological characteristics can be 
determined in healthy volunteers, at a stage of drug development when 
novel compounds are not yet tested in patients. The different chapters 
of this thesis illustrate how these concepts are used in practice, during 
the early development of new therapeutic strategies for schizophrenia. 
An important aim of these strategies is to identify treatments with an 
improved therapeutic window, since adverse events and therapeutic 
failures in schizophrenia form an important impediment in current 
medical practice. 
One way to try to improve the therapeutic window of a drug therapy 
is by ameliorating the pharmacological mechanism of action, from 
direct, full and non-selective (d2) receptor antagonists to more indirect, 
partial, or selective modulators. Chapters 2 and 4-6 carefully assessed 
the pharmacological characteristics of novel compounds, by using a 
large number of different ‘drug biomarkers’ to create a ‘fingerprint’ of 
the pharmacological effects. This is based on the notion that a drug’s 
mechanism of action underlies both its desired and the undesired 
effects, and therefore provides an indication of the expected therapeutic 
window. Chapter 2 used a positive control to provide an indication of (dis)
advantages of a potential antipsychotic drug from a new class (the nk3 
antagonist talnetant), compared to a widely used therapeutic congener 
(the d2-receptor antagonist haloperidol). 
Another way to improve the therapeutic window is by development of 
combination therapies, each targeted at a different clinical syndrome 
that characterize schizophrenia in addition to the well-known positive 
psychotic symptoms, in particular cognitive deficits (Chapter 3, 
examining a 5-ht6 antagonist). In each of these chapters, we used a 
multifunctional cns test battery (the neuroCart) to make comprehensive 
pharmacological profiles of novel schizophrenia treatments in healthy 
subjects, which were compared with existing medications to identify 
potential pharmacological advantages of the new therapeutic strategies.
All studies were performed in healthy volunteers, which has the 
advantage that patients are not burdened with new drugs, at a stage 
when the therapeutic potential and adverse effect profile are still 
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Figure 1 Dopamine pathways thought to be involved in the pathophysiology and adverse drug reactions of 
schizophrenia
Figure 2 ‘Neuropharmacological combination model’ of non-schizophrenic people (Glu=glutamate; 






































































Figure 3 Visualized ‘integrated neuropharmacological model’ of schizophrenic patients (Glu=glutamate; 
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Introduction 
Several recent lines of evidence have suggested a role of 5-hydroxytrypta-
mine 6 (5-ht6) receptors in cognitive and memory processes. Improve-
ments in memory and other aspects of cognition have been reported 
using different 5-ht6 antagonists, both in healthy animals and in animal 
models of cognitive impairment [1-7]. Several research groups have sug-
gested that 5-ht6 blockade may be involved in learning and memory via 
increased cholinergic transmission [5, 7-10] or modulation of dopaminer-
gic transmission [11], but secondary changes in noradrenergic and glu-
tamatergic neurotransmission may also be involved [12, 13]. Preliminary 
data from studies in patients with Alzheimer’s disease (ad) suggest that 
the beneficial effects of treatments with 5-ht6 receptor antagonists seen 
in animal models may translate into humans [14, 15]. 
In schizophrenia, the role of the 5-ht6 receptor is less well defined. 
There is post-mortem evidence of reduced expression of the 5-ht6 
receptor in the hippocampus of schizophrenic patients [16]. Some of the 
most effective antipsychotic drugs partially bind to 5-ht6 receptors, and 
5-ht6 receptors have been shown to be down-regulated by prolonged 
clozapine treatment in rats [17]. However, it is unknown if the reduced 
expression of 5-ht6 receptors is due to the disease or chronic treatment. 
At present, over a dozen selective 5-ht6 antagonists are at various 
stages of development [14]. sb742457 is a potent 5-ht6 antagonist 
(pKi = 9.6) with high affinity for human 5-ht2a receptors (pKi = 8.0; for 
structural formula see Figure 1). sb742457 has shown efficacy in differ-
ent animal models of cognitive impairment [14]. In humans, reports that 
sb742457 is of clinical benefit in ad patients provided further evidence of 
the therapeutic potential of this approach [18, 19]. Repeated-dose stud-
ies in healthy subjects receiving daily 50 mg showed low occurrence of 
mild adverse events (aes), mostly headache. At this dose, the exposure to 
sb742457 is expected to deliver 5-ht6 receptor occupancy of the central 
nervous system (cns) above 90% (unpublished data). Clinical pharmaco-
kinetic assessment showed that sb742457 has a half-life of approximately 
30 h, reaching steady state after 7 days with an accumulation ratio of 
Abstract
aim Several lines of evidence suggest a possible role of 5-ht6 receptor 
antagonists in cognitive dysfunction of schizophrenia. Atypical anti-
psychotics, such as risperidone, are currently used in these disorders. 
Therefore, the pharmacological interactions between the 5-ht6 antago-
nist sb742457 and risperidone were investigated in the light of possible 
co-medication. 
methods A randomized, double-blind, two-way crossover design was 
used to study the interaction between multiple doses sb742457 50 mg 
and a single dose risperidone 2 mg in 18 healthy subjects. 
results Treatment was well tolerated. The most common adverse event 
was somnolence in 83% during the combination vs. 50% of subjects after 
risperidone, 32% after placebo and 11% after sb742457. Combination 
treatment produced a statistically significant increase in the maximum 
plasma concentration of risperidone and had no effect on sb742457 
pharmacokinetics. Risperidone decreased saccadic peak velocity, 
finger tapping, adaptive tracking, subjective alertness, delayed word 
recognition and body sway and increased electroencephalogram (eeg) 
theta power and prolactin. The only pharmacodynamic interaction of 
risperidone and sb742457 was an increase of absolute eeg alpha (ratio 
= 1.25, 95% ci = 1.11, 1.40, P = 0.0004) and beta power (ratio = 1.14, 95% 
ci = 1.03, 1.27, P = 0.016). No significant effects of sb742457 alone were 
found. 
conclusion The pharmacokinetic interactions between sb742457 and 
risperidone detected in this study were not clinically relevant. The increase 
in eeg alpha and beta power is incompatible with enhanced risperidone 
activity, but could point to mild arousing effects of the combination. Most 
pharmacodynamic changes of risperidone are consistent with previously 
reported data. The potential cognitive effects of sb742457 remain to be 
established. 




Twenty-four healthy male volunteers aged between 18 and 38 years 
with a body weight above 50 kg and a body mass index between 18.5-
29.9 kg m-2 were recruited for the study, with the aim of completing all 
treatments in at least 18 subjects. Subjects were considered ‘healthy’ by a 
responsible study physician, when no clinically significant abnormalities 
were identified on the medical or laboratory evaluation (haematology, 
biochemistry, virology, urinalysis and urine drug screen), blood pressure 
and heart rate or 12-lead ecg before the study starts medical. Exclusion 
criteria included the use of agents known to affect cns functions (inclu-
ding drug or alcohol use), smoking more than five cigarettes a day and 
unable to refrain from smoking during the stay in the research unit. The 
Ethics Review Board of the Leiden University Medical Centre approved 
the study protocol. Written informed consent was obtained from all 
volunteers following a written and oral explanation. 
Study design 
This was a randomized, double-blind, double-dummy placebo control-
led crossover study, consisting of two 11-day multiple dosing periods for 
either sb742457 50 mg or placebo (see Figure 2). On days 8 and 9 of each 
period, a single dose of risperidone 2 mg or placebo was administered  
in a balanced randomized crossover fashion. In this way, the effects of  
risperidone (either alone or with sb742457) could be examined after 
acute administration (on day 8 or on day 9 after placebo treatment on 
the preceding day). There was at least 1 week washout between the two 
multiple-dose periods. Subjects received sb742457 from day 1 until  
day 11. They visited the research centre in the morning on days 1 to 7  
and days 11 to 14 and remained in house from the morning of day 8  
until the morning of day 10. Both sb742457 (capsule) and risperidone 
(tablet) or their matching placebos were administered once daily with  
a glass of water. 
about fourfold (unpublished data and [14]). Preclinical investigations 
showed that sb742457 is a moderate inhibitor of cyp450 3a4. 
For schizophrenia, sb742457 would be considered for development as 
an add-on treatment to be used in combination with antipsychotic drugs 
(e.g. risperidone), known for their lack of clinical effect on cognition [20].
Risperidone is a dopamine 2 (d2)/5-ht2a antagonist with low affinity for 
5-ht6 receptors and limited effects on cognitive parameters [21] and is 
commonly used to control agitation and psychotic features. Therefore, the 
combination of risperidone and sb742457 may constitute a reasonable 
combination in cognitively impaired patients. Risperidone is known 
to produce a series of cns effects (such as sedation, increased theta 
band power of the electroencephalogram (eeg) spectra and increased 
prolactin concentrations) at doses of 1-2 mg in healthy volunteers [22]. 
It is primarily metabolized by cyp2D6,but cyp3a4 is also involved [23].
The main metabolite of risperidone is 9-hydroxyrisperidone, an active 
compound with a half-life of approximately 20 h [24]. The well-known 
profile of cns effects may contribute to the cognitive impairment and 
the negative syndrome complex in some patients. As 5-ht6 activity 
modulates dopaminergic transmission [11], it is hypothesized that some 
of the cns effects due to neuroleptic agents are partially reversed by a 
5-ht6 antagonist like sb742457. In this study the pharmacokinetic and 
pharmacodynamic effects of the interaction between sb742457 and 
risperidone and of sb742457 and risperidone alone were investigated 
in healthy volunteers. In this early stage of development of sb742457, 
the pharmacodynamic effects had not been examined in humans, and 
its effects on risperidone could not be accurately predicted. Therefore, 
a multimodal test battery was used repeatedly, consisting of validated 
neurophysiological and neuropsychological tests. These tests have no 
direct bearing on schizophrenia and they only partly reflect the negative 
cognitive and behavioural) effects of this condition (and the positive 
psychotic effects even less). However the battery accurately covers 
most drug-responsive cns-functional domains, and therefore had a 
large chance of demonstrating pharmacodynamic changes induced by 
risperidone or sb742457 alone, or the effects of their combination. 
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Pharmacodynamics 
On days 8 and 9, a pharmacodynamic test battery was performed twice 
at baseline and 45, 80, 140, 190, 235, 295, 345 min and 8 and 12 h after 
administration of both drugs. The battery takes about 20 min and consists 
of the pharmacodynamic assessments described below, which were 
performed in a quiet room with subdued light with one volunteer per 
room. No more than 1 week before the start of the study, the volunteers 
were familiarized with the test procedures during a training session. 
pharmaco-electroencephalography	
Pharmaco-eeg was performed as a general measure of cns activity [26]. 
The literature suggests that antipsychotics produce distinct profiles of 
eeg changes [27, 28]. eeg recordings were made using silver chloride 
electrodes, fixed with collodion at Fz, Cz, Pz and Oz (international 10/20 
system), as previously described [29]. Fast Fourier transform analysis 
was performed to obtain the sum of amplitudes in the delta-(0.5-3.5 Hz), 
theta-(3.5-7.5 Hz), alpha-(7.5 -11.5 Hz) and beta-(11.5-30 Hz) frequency 
ranges. The square root of the total power (µV) was analyzed. The duration 
of one eeg recording was 64 s (i.e. eight blocks of 8 s). 
saccadic	and	smooth	pursuit	eye	movements	
Eye movements were recorded as previously described [30, 31] and have 
shown effects with many different cns active compounds, including 
gaba-ergic [22, 32, 33], serotonergic [34], noradrenergic [35-37] and 
dopaminergic agents [22, 29]. For saccadic eye movements, the average 
values of latency (reaction time), saccadic peak velocity and inaccuracy 
of all artifact free saccades were calculated. The average percentage of 
smooth pursuit for all stimulus frequencies was used. 
adaptive	tracking	
The adaptive tracking test has proved to be useful for measurement of 
the cns effects of alcohol [38], various psychoactive drugs [26, 39] and 
sleep deprivation [30, 38]. It measures visuo-motor coordination and 
vigilance and was performed as originally described by Borland [39], 
Before administration of the study medication all participants were 
instructed to remain fasted. Smoking was not allowed during the study 
days, volunteers refrained from alcohol and xanthine-containing foods or 
beverages from 24 h before each study period until day 12, and grapefruit 
products were not allowed from 14 days prior to the study until the end of 
the study.  
Pharmacokinetics 
Blood samples (approximately 3 ml) were obtained pre-dose on days  
6 and 7 (for sb742457 measurements only), and days 10, 11 and 12 (for 
sb742457, risperidone and 9-hydroxyrisperidone measurements). On 
days 8 and 9, blood samples were taken for sb742457, risperidone and 
9-hydroxyrisperidone at baseline and 45, 80, 140, 190, 235, 345 min and  
8 and 12 h after administration of both drugs. 
Plasma samples were analysed for sb742457 by Drug Metabolism 
and Pharmacokinetics,GlaxoSmithKline,Ware, uk, using a validated 
analytical method based on protein precipitation, followed by high 
performance liquid chromatography/tandem mass spectrometry  
(hplc/ms/ms) analysis. The lower limit of quantification (llq) for 
sb742457 was 1 ng ml-1, using a 50 ml aliquot of edta plasma with a 
higher limit of quantification (hlq) of 5000 ng ml-1. Plasma samples  
were analysed for risperidone and 9-hydroxyrisperidone by York Bio-
analytical Solutions, York, uk, using a validated analytical method based 
on protein precipitation, followed by hplc-ms/ms analysis.The llq for 
both risperidone and 9-hydroxyrisperidone was 0.1 ng ml-1,using a 50 ml 
aliquot of human plasma with a hlq of 100 ng ml-1 [25]. 
Quality control (qc) samples, prepared at three different analyte 
concentrations and stored with study samples, were analysed with each 
batch of samples against separately prepared calibration standards. For 
the analysis to be considered acceptable, no more than one-third of the 
qc results deviated from the nominal concentration by more than 15%, 
and at least 50% of the results from each qc concentration were within 
15% of nominal. The applicable analytical runs met all predefined run 
acceptance criteria. 
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absence of the state (which is the case under normal circumstances), 
the highest the ‘most extreme state imaginable’. The vas scores were 
performed electronically using custom-written and validated E-prime 
scripts (http:// www.pstnet.com/eprime.cfm). 
finger	tapping	
The finger tapping test was adapted from the Halstead ReitanTest Battery 
[45].The test evaluates motor activation and fluency. Speed of finger 
tapping was measured for the index finger of the dominant hand; a 
session contained five performances of 10 s. The volunteer was instructed 
to tap as quickly as possible on the space bar of a keyboard. The mean 
tapping rate and the standard deviations are used for statistical analysis. 
visual	verbal	learning	test	
Memory includes many different components of learning behaviour, such 
as acquisition, consolidation, storage and retrieval. The Visual Verbal 
Learning Test (vvlt) contains three different subtests that cover most of 
the scope of learning behaviour, i.e. immediate and delayed word recall 
and a delayed word recognition [46].This test is a modified version of the 
auditory verbal learning test [47] in which 30 words are shown. This test 
is known to be sensitive to the cns effects of various compounds such 
as benzodiazepines [32], cannabinoids [40] and scopolamine [48]. The 
outcome measures for the immediate and delayed word recall were the 
average and the maximum number of correct responses. For the delayed 
word recognition, the number of correct items and mean response time 
for correct responses were recorded. 
plasma	prolactin	concentrations	
Prolactin increase induced by antipsychotics is closely related to 
d2-receptor antagonism [22]. Prolactin concentrations were measured 
predose and at 30, 45, 60, 80, 140, 190, 235, 345 min and 8 h after admin-
istration of both drugs as described previously. For this purpose, blood 
samples were collected in plain 3-ml tubes and kept at room temperature 
for 30 to 45 min. Serum was separated by refrigerated centrifugation 
using customized equipment and software (Hobbs, 2000, Hertfordshire, 
uk). The average performance scores over a 3-min period were used for 
analysis, as described previously [29]. 
body	sway	
Changes in body sway have been seen for many different cns active drugs, 
including gaba-ergic compounds [32, 33], dopaminergic agents [29] and 
tetrahydrocannabinol (thc) [40]. The body sway allows measurement 
of body movements in a single plane, providing a measure of postural 
stability. Body sway was measured with an apparatus similar to the Wright 
ataxiameter [28]. With a string attached to the waist, all body movements 
over a period of 2 min were integrated and expressed as millimetre sway 
on a digital display. Measurements of body sway were made in the sagittal 
planes. All assessments were made with the eyes closed, standing with 
feet 10 cm apart wearing comfortable low-heeled shoes. The total amount 
of movement was used for statistical analysis. 
subjective	assessments	
Visual analogue scales (vas) consist of 100 mm line segments. Subjects 
put a mark on a point on the line that best represents their subjective 
state corresponding to the condition tested. The result is a distance (mm) 
calculated from the mark on the line. 
Subjective effects were quantified using a Dutch translation of the  
16	vas originally described by Norris [41].They have been used previously 
to quantify subjective effects of a variety of agents, including sedative [32, 
33], dopaminergic drugs [22, 29], scopolamine (Centre for Human Drug 
Research data on file) and thc [40]. From these measurements, three 
factors are derived as described by Bond and Lader [42], corresponding to 
alertness, mood and calmness [32, 33, 43]. A lower score on these scales 
indicates sedation, excitation and decrease in mood (or contentedness) 
respectively. 
A translated version of the Bowdle psychotomimetic vas [44] showed 
effects of thc [40], zolpidem [43] and scopolamine (Centre for Human 
Drug Research data on file). The lowest extreme is ‘0’, signifying complete 
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corresponding 90% cis for the differences between risperidone in pres-
ence of sb742457 compared with risperidone in presence of placebo were 
obtained using the residual variance from anova. These data were then 
exponentially back-transformed to give estimates of the ratios of geomet-
ric means and 90% cis. Lack of drug interaction between sb742457 and 
risperidone would have been demonstrated if the 90% ci was completely 
contained within 0.80, 1.25. 
pharmacodynamic	analysis		This analysis was exploratory and the 
formal power estimate was performed according to pharmacokinetic 
criteria (see above). However, past experience at the study site and 
published information on eegs indicated that pharmacodynamic signals 
could be seen using 8-12 subjects. All endpoints were analysed using an 
anova model, which was fitted using	proc	mixed in sas. For vvlt and 
prolactin endpoints, the model included session, day, regimen, day x 
regimen, and, when available, baseline as fixed effect terms and subjects 
as a random effect term. For all other endpoints, the model included 
session, day, regimen, time, day x regimen, time x regimen and day x 
time x regimen as fixed effect terms and subjects and subject x session x 
day as random effect terms. 
The following Least Square Means differences were computed to 
investigate the related treatment effect:  
Risperidone effects: placebo sb742457 + risperidone (day 9) vs. placebo 
sb742457 + placebo risperidone (day 8).  
sb-742457 effects: sb742457 + placebo risperidone (day 8) vs. placebo 
sb742457 + placebo risperidone (day 8).  
Effects of sb742457 co-administration on risperidone effects: sb742457 + 
risperidone (days 8 and 9) vs. placebo sb742457 + risperidone (days 8  
and 9). 
No correction for multiple comparisons among the various endpoints 
was performed as this analysis was considered exploratory. 
(2000 g at 4°c for 10 min) within 1 h of collection and transferred to poly-
propylene tubes. Serum specimens were stored at approximately -20°c 
until analysis. The hormone assays were performed by the Central Clinical 
Chemistry Laboratory of the Leiden University Medical Center and were 
performed by electrochemiluminescence immunoassay on a Modular 
Analytics E170 (Elecsys module) immunoassay analyser. The assay had  
a llq of 0.047 mgl-1, an intra-assay precision (expressed as coefficient  
of variation) of 1.81-1.90% and inter-assay precision of 2.39-2.64%. 
statistical	analysis	
pharmacokinetic	analysis		Pharmacokinetic analyses of plasma 
sb742457, risperidone, 9-hydroxyrisperidone and total risperidone active 
moiety concentration-time data were conducted using non-compartmen-
tal methods. 
Main pharmacokinetic endpoints were maximum observed concentra-
tion (cmax) and area under the plasma concentration-time curve up to 
last time point [auc(0,t)] and extrapolated to infinity [auc(0,∞)] of ris-
peridone and 9-hydroxy-risperidone, while cmax and auc over the dosing 
interval were evaluated for sb742457. Plasma concentration-time data 
were evaluated by standard non-compartmental analysis using WinNon-
lin Professional Version. 
The study sample size was based on feasibility. A variability estimate 
of 0.32 for auc(0,∞) of risperidone was taken from published results for 
a risperidone/venlafaxine interaction study [49]. With such variability, it 
was estimated that with 16 evaluable subjects (of the 20 recruited) com-
pleting the study, the lower and upper limits of the 90% confidence inter-
val (ci) for the ratio of geometric means (ratio of sb742457 + risperidone 
and placebo + risperidone) would have been within 20.9% of the point 
estimate. In practice, assuming a true ratio of 1, this precision would have 
lead to a 90% ci of 0.83 to 1.21. 
Following log transformation, total risperidone (active moiety) 
auc(0,t), auc(0,∞) and cmax and sb742457 auc(0,t) and cmax were ana-
lysed using a mixed effects model with session, day, regimen and regimen 
X day as fixed effects and subject as a random effect. Point estimates and 
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oral co-administration of sb742457 (50 mg) at steady state with a 
single dose of risperidone, mean increases in cmax were estimated 
for total risperidone active moiety (15%), risperidone (19%) and 
9-hydroxyrisperidone (6%) compared with placebo (see Figure 3).  
The ratio (and 90% cis) for cmax were 1.19 (1.04, 1.35) for risperidone, 
1.15 (1.02, 1.28) for the total risperidone active moiety and 1.06 (0.96, 
1.17) for 9-hydroxyrisperidone. No substantial increases in auc were 
found. Overall, co-administration of risperidone with steady state 
sb742457 did not alter the pharmacokinetics of sb742457 compared 
with placebo.  
Pharmacodynamic results 
risperidone	effects	
Risperidone caused a considerable number of effects on subjective, 
neurophysiological and performance parameters. Compared with 
placebo, risperidone substantially decreased saccadic peak velocity, 
finger tapping, adaptive tracking, delayed word recognition and body 
sway, while subjective alertness and contentedness deteriorated (as 
assessed by the vas Bond & Lader) and increased eeg theta power and 
prolactin concentrations (differences, 95% ci, and P values are shown  
in Table 2).
sb-742457	effects	
When measured after single doses of risperidone or placebo on both days 
8 and 9, no statistically significant differences were detected on any of the 
pharmacodynamic parameters between subjects daily exposed to 2 weeks 




A single dose of risperidone in subjects during multiple daily doses of 
sb742457 produced significant increases of absolute alpha Pz-Oz and 
Results 
Study population 
Twenty-four volunteers were included in the study and six volunteers were 
withdrawn from the study, resulting in 18 completers. Three subjects 
withdrew for non drug-related aes, one for protocol violation, one for 
personal reasons and one because of a rash (during placebo, see below). 
Volunteers had a mean (min-max) age of 24.8 (18-38) years, were healthy 
and took no relevant concomitant medications.  
Tolerability 
No clinically significant changes were observed for vital signs, respiratory 
functions, physical examination or laboratory parameters. There were 
no serious aes in this trial.The reported aesare shown in Table 1.The 
aes coded as‘possibly related to the study medication’were of mild to 
moderate intensity and resolved spontaneously. The most frequently 
reported ae, irrespective of causality, was somnolence. More subjects 
experienced somnolence following sb742457 in combination with 
risperidone (83%) compared with risperidone alone (50%). On days 8 and 
9, somnolence was reported by three subjects (16%) receiving placebo 
and by two (11%) receiving sb742457 alone. One subject, after exposure 
to placebo sb742457 for 5 days, was withdrawn from the study because of 
the occurrence of a papular rash on chest, back, hands and arms. It was 
not associated with any out-of-range liver enzyme or other laboratory 
values and resolved without treatment after 11 days. Overall, sb742457 50 
mg was generally well tolerated when administered orally once daily for 11 
days, and also when administered at steady state in combination with  
a single 2-mg oral dose of risperidone. 
 
Pharmacokinetic results 
The peak plasma concentration of risperidone was 15 ng ml-1 at 2.3-
2.7 h with an elimination half-life of approximately 4h. Following 
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A battery of quantitative cns tests was used to assess the pharmaco-
dynamic interaction between risperidone and sb742457 in healthy 
volunteers. These tests were chosen for their sensitivity to classic 
antipsychotic agents as well as to a wide range of other cns active 
drugs. Repeated daily exposure to 50-mg sb742457 did not produce 
any detectable effects on any of the pharmacodynamic cns tests 
when compared with placebo. Additionally, this study yielded an 
extensive multidimensional pharmacodynamic profile of risperidone in 
healthy volunteers, showing that this antipsychotic suppresses motor 
performance (eye-hand coordination, finger tapping and postural 
stability), alertness, memory and neurophysiological functions (saccadic 
eye movements and eeg power spectrum). Several of these effects confirm 
the effects of risperidone found in previous studies in healthy volunteers: 
decreased behavioural and cognitive performance, increased theta band 
power of the eeg spectra, decreased saccadic peak velocity and increased 
prolactin concentrations [50-53]. Although the observed increase in 
eeg theta power agrees with the effects described by De Visser et al [22], 
a decrease in eeg alpha and an increase in delta power could also have 
been expected. When risperidone was administered to subjects exposed 
to daily sb742457, the effects were generally similar to those exposed to 
daily placebo, except that sb742457 combined with risperidone caused 
a significant increase of eeg alpha and beta power, compared with 
risperidone alone. Although it is difficult to assign functional significance 
to eeg changes, increases in eeg alpha or beta power are not typically 
because of sedation and have been associated with internally directed 
attention and increased mental load [54]. This result could be interpreted 
as mild subclinical arousing activity of sb742457 in the presence of 
risperidone. Although this finding clearly does not constitute definitive 
proof, this could be considered as an indication for modulation of 
dopaminergic hypofunctionality by 5-ht6 antagonism. 
The effects were too limited to be certain of pharmacological 
interactions between sb742457 and risperidone. This could be related to 
the unknown sensitivity of this study to detect subtle pharmacodynamic 
effects, because the study was powered on the pharmacokinetic 
beta Pz-Oz power compared with placebo sb742457, while no difference 
was observed in other endpoints (i.e. saccadic peak velocity,smooth 
pursuit eye movement,finger tapping, adaptive tracking, vas Bond & 
Lader, vvlt, body sway, prolactin serum concentrations and other eeg 
measures; all values are shown in Table 3). 
Discussion 
The 5-ht6 antagonist sb742457 is under development as a possible treat-
ment for the cognitive symptoms in ad and possibly in schizophrenia. 
This study was set up to evaluate the pharmacokinetic and cns interac-
tions between sb742457 and risperidone, as this 5-ht6 antagonist may  
be used as an add-on therapy in combination with atypical antipsychot-
ics, which may contribute to reduce cognitive impairment in some schizo-
phrenic patients. 
The results indicate that co-administration of sb742457 with 
risperidone did not alter auc (all auc 90% cis were contained within 
the 0.80, 1.25 equivalence interval). There was a minor increase in peak 
exposure (cmax)of the total risperidone active moiety (15%), which  
was caused by an elevation of risperidone concentrations (19%) without  
a change of the active metabolite 9-hydroxyrisperidone. This could  
be related to an inhibition by sb742457 of cyp450 3a4, which is one of 
the cytochrome P450 systems involved in the metabolism of risperidone 
[23]. Although the differences in cmax were statistically significant for 
risperidone and the active moiety, the extent of the increase was very 
modest and, taking into consideration the inter-subject variability,  
does not appear to be of any clinical relevance. 
Risperidone produced its expected ae profile [50], while sb742457 50 
mg was well tolerated when administered orally once daily for 11 days 
either alone or in combination with a single 2-mg oral dose of risperidone. 
The most frequently reported ae, irrespective of causality, was somno-
lence, which occurred in a greater proportion of subjects in the presence 
of risperidone (with or without active sb742457) than with placebo. How-
ever, the numbers of events were too small to draw strong conclusions. 
70	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia 71	 2		–	cns	effects	of	the	risperidone-5-ht6	antagonist	interaction	in	healthy	men
outcomes. However, in other studies with similar population sizes, a 
similar cns battery detected mild enhancing effects of other serotonergic 
agents with diverse pharmacological characteristics and for various 
receptor subtypes [34, 55, 56]. It is also possible that the administered 
dose of sb742457 did not have any beneficial pharmacodynamic effects 
by itself, because of ceiling effects in healthy subjects, or functional 
compensation of 5-ht6 receptor inhibition in this population. 
In conclusion, there was no clinically relevant pharmacokinetic 
drug-drug interaction between sb742457 50 mg and risperidone 2 
mg. Repeated dosing with sb742457 did not increase aes or cause any 
pharmacodynamic effects in healthy young males, whereas a single 
dose of risperidone produced the expected profile of (side) effects. In 
general, the combination of sb742457 and risperidone did not affect cns 
function more than risperidone alone.The only statistically significant 
pharmacodynamic interaction was an increase of eeg alpha and beta 
bands, suggesting a mild arousing activity of sb742457 on some cns-
depressive effects caused by risperidone, possibly mediated by 5-ht6 
receptors. The pharmacological or functional significance of these 
findings remains to be determined, although these interactions might 
indicate that sb742457 penetrates the blood-brain barrier and modifies 
some effects of an antipsychotic drug. 
Table 1 Adverse events reported on days 8 and 9 after sb742457, risperidone, the combination of sb742457 
and risperidone, and placebo 
most frequent aes 
(at least 2 events)
sb742457 risperidone sb742457 + risperidone placebo
N = 19 N = 20 N = 18 N = 19
n (%) n (%) n (%) n (%)
somnolence 2 (11) 10 (50) 15 (83) 3 (16)
headache 1 (5) 2 (10) 2 (11) 3 (16)
dizziness 0 (0) 8 (40) 4 (22) 2 (9)
disturbance in attention 1 (5) 3 (15) 1 (6) 0 (0)
nausea 0 (0) 2 (10) 0 (0) 2 (9)
fatigue 2 (11) 5 (25) 3 (17) 2 (9)
 
 
Table 2 Pharmacodynamic cross-over effects of risperidone versus placebo risperidone (single dose) in 
subjects daily exposed to placebo sb742457 (multiple dose) 
parameter placebo sb742457 + 
risperidone (day 9)a
placebo sb742457 + 
placebo risperidone 
(day 8)a
difference (95% CI) P-valuec
saccadic eye movement
peak velocity (deg/sec) 405.1 475.8 -70.7 (-91.3, -50.1) <0.0001
smooth pursuit eye movement (%) 47.5 52.7 -5.2 (-10.5, 0.1) 0.0562
finger tapping 
average (taps/10sec) 58.0 63.2 -5.2 (-7.8, -2.6) 0.0002
adaptive tracking
average (%) 17.6 22.4 -4.8 (-7.1, -2.5) 0.0001
vasb – Bond and Lader
alertness (mm) 55.7 44.0 11.8 (2.7, 20.8) 0.0124
contentedness (mm) 43.3 35.5 7.8 (1.4, 14.2) 0.0178
Visual Verbal Learning Test
average reaction time correct 
recognitions (msec)
840.12 945.89 -105.77  
(-203.95, -7.59)
0.0353
body sway (mm) 372.8 301.0 ratio 1.24 (1.07, 1.44) 0.0058
Electroencephalogramc
absolute power theta Fz-Cz (µV) 2.56 2.19 ratio 1.17 (1.03, 1.33) 0.0175
absolute power theta Pz-Oz (µV) 2.72 2.34 ratio 1.16 (1.02, 1.33) 0.0299
prolactin serum level
auc (0.5-8) (h*ng/mL) 179.88 41.30  4.36 (3.65, 5.19) <0.0001
Cmax (ng/mL) 53.12 8.19  6.48 (5.25, 8.01) <0.0001
a	lsm = Least Square Means; b	vas = Visual Analogue Scale; c only (almost) statistically significant values are 
reported 
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Table 3 Results of statistical analysis of pharmacodynamic effects of sb742457 multiple dose on risperidone 
single dose (estimated adjusted differences with 95%CI) 
parameter sb742457	+	
risperidone  
(days 8 + 9)a
placebo + risperidone 






inaccuracy (%) 6.3 6.6 -0.3	(-1.0,	0.5) 0.4613
peak velocity (deg/sec) 406.4 400.9 5.5(-9.3,	20.3) 0.4616
latency (sec) 0.221 0.22 0.001	(-0.006,	0.008) 0.7733
smooth pursuit eye 
movement (%)
45.6 43.8 1.8	(-2.0,	5.6) 0.3411
finger tapping
average (taps/10sec) 59.5 57.8 1.7	(-0.2,	3.5) 0.0759
standard deviation 
(taps/10sec)
3.2 3.5 -0.4	(-0.9,	0.2) 0.2211
adaptive tracking
average (%) 16.5 15.7 0.8	(-0.8,	2.5) 0.3204
standard deviation (%) 2.9 3.1 -0.2	(-0.5,	0.1) 0.1823
vasb – Bond and Lader
alertness (mm) 44.2 45.2 -1.0	(-7.5,	5.5) 0.7591
calmness (mm) 31 29.9 1.1	(-5.2,	7.4) 0.7206
contentedness (mm) 32.8 34.1 -1.3	(-5.9,	3.3) 0.563
Visual Verbal Learning Test
# correct immediate recall 11.2 11.06 0.13	(-1.41,	1.67) 0.863
# correct delayed recall 10.1 10.39 -0.29	(-2.68,	2.10) 0.8071
# correct delayed 
recognitions
22.8 23.39 -0.59	(-3.06,	1.87) 0.6301
average reaction time 
correct recognitions (msec) 
909.6 877.8 31.79	(-36.21,	99.79) 0.352




auc (0.5-8) (h*ng/mL) 180.06 177.86 1.011	(0.893,	1.145) 0.8571
cmax (ng/mL) 52.96 51.06 1.037	(0.894,	1.203) 0.6241
electroencephalogramc








































a. Least squares means; b.	vas = Visual Analogue Scale; c. only statistically significant eeg absolute powers 
reported
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Figure 1 Structural formula of sb742457
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Figure 3 Mean plasma concentrations (standard errors) of risperidone active moiety in the 18 healthy 
volunteers that completed the study
76	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia 77	 2		–	cns	effects	of	the	risperidone-5-ht6	antagonist	interaction	in	healthy	men
references	
1  Glennon RA. Higher-end serotonin receptors: 
5-ht5, 5-ht6, and5-ht7. J Med Chem 2003; 46: 
2795-812. 
2 Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh 
P, Moss SF, Bromidge SM, Riley G, Smith DR, 
Bartlett S, Heidbreder ca, Atkins AR, Lacroix 
LP, Dawson LA, Foley AG, Regan CM, Upton N. 
sb-399885 is a potent, selective 5-ht6 receptor 
antagonist with cognitive enhancing properties 
in aged rat water maze and novel object 
recognition models. Eur J Pharmacol 2006; 553: 
109-19. 
3 Li Z, Huang M, Prus AJ, Dai J, Meltzer HY. 5-ht6 
receptor antagonist sb-399885 potentiates 
haloperidol and risperidone-induced dopamine 
efflux in the medial prefrontal cortex or 
hippocampus. Brain Res 2007; 1134: 70-8. 
4  Pouzet B, Didriksen M, Arnt J. Effects of the 
5-ht6 receptor antagonist, sb-271046, in 
animal models for schizophrenia. Pharmacol 
Biochem Behav 2002; 71: 635-43. 
5  Riemer C, Borroni E, Levet-Trafit B, Martin 
JR, Poli S, Porter RH, Bos M. Influence of the 
5-ht6 receptor on acetylcholine release in 
the cortex: pharmacological characterization 
of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-
sulfonyl)phenylamine, a potent and selective 
5-ht6 receptor antagonist. J Med Chem 2003; 
46: 1273-6. 
6  Routledge C, Bromidge SM, Moss SF, Newman 
H, Riley G, Hagan JJ. Characterisation of 
sb-271046: a potent and selective 5-ht6 
receptor antagonist. Br J Pharmacol 2000; 130: 
1606-12. 
7  Woolley ML, Marsden ca, Sleight AJ, Fone 
KC. Reversal of a cholinergic-induced deficit 
in a rodent model of recognition memory by 
the selective 5-ht6 receptor antagonist, Ro 
04-6790. Psychopharmacology (Berl) 2003; 170: 
358-67. 
8  Hirst WD, Abrahamsen B, Blaney FE, 
Calver AR, Aloj L, Price GW, Medhurst ad. 
Differences in the central nervous system 
distribution and pharmacology of the mouse 
5-hydroxytryptamine-6 receptor compared 
with rat and human receptors investigated by 
radioligand binding, site-directed mutagenesis, 
and molecular modeling. Mol Pharmacol 2003; 
64: 1295-308. 
9  Bourson A, Borroni E, Austin RH, Monsma FJ 
Jr, Sleight AJ. Determination of the role of the 
5-ht6 receptor in the rat brain: a study using 
antisense oligonucleotides. J Pharmacol Exp 
Ther 1995; 274: 173-80. 
10  Bourson A, Boess FG, Bos M, Sleight AJ. 
Involvement of 5-ht6 receptors in nigro-striatal 
function in rodents. Br J Pharmacol 1998; 125: 
1562-6. 
11  Gerard C, Martres MP, Lefevre K, Miquel 
MC, Verge D, Lanfumey L, Doucet E, Hamon 
M, el Mestikawy S. Immuno-localization of 
serotonin 5-ht6 receptor-like material in the 
rat central nervous system. Brain Res 1997; 
746: 207-19. 
12  Mitchell ES, Neumaier JF. 5-ht6 receptors: 
a novel target for cognitive enhancement. 
Pharmacol Ther 2005; 108: 320-33. 
13  Russell MG, Dias R. Memories are made of this 
(perhaps): a review of serotonin 5-ht6 receptor 
ligands and their biological functions. Curr Top 
Med Chem 2002; 2: 643-54. 
14  Upton N, Chuang TT, Hunter AJ, Virley DJ. 
5-ht6 receptor antagonists as novel cognitive 
enhancing agents for Alzheimer’s disease. 
Neurotherapeutics 2008; 5: 458-69. 
15  Geldenhuys WJ, Van der Schyf CJ. The serotonin 
5-ht6 receptor: a viable drug target for treating 
cognitive deficits in Alzheimer’s disease. Expert 
Rev Neurother 2009; 9: 1073-85. 
16  East SZ, Burnet PW, Leslie RA, Roberts JC, 
Harrison PJ. 5-ht6 receptor binding sites in 
schizophrenia and following antipsychotic drug 
administration: autoradiographic studies with 
[125I]sb-258585. Synapse 2002; 45: 191-9. 
17  Frederick JA, Meador-Woodruff JH. Effects of 
clozapine and haloperidol on 5-ht6 receptor 
mrna levels in rat brain. Schizophr Res 1999; 
38: 7-12. 
18  Maher-Edwards G, Dixon R, Hunter J, Gold 
M, Hopton G, Jacobs G, Hunter J, Williams P. 
sb742457 and donepezil in Alzheimer disease: 
a randomized, placebo-controlled study. Int J 
Geriatr Psychiatry 2010 Sep 24. [Epub ahead of 
print]. 
19  Chuang ATT, Foley A, Pugh PL, Sunter D, Tong 
X, Regan C, Dawson LA, Medhurst ad, Upton N. 
5-ht6 receptor antagonist sb742457 as a novel 
cognitive enhancing agent for Alzheimer’s 
disease. Alzheimers Dement 2006; 2: S631-2. 
20  Roth BL, Hanizavareh SM, Blum ae. Serotonin 
receptors represent highly favorable molecu lar 
targets for cognitive enhancement in  
schizo phrenia and other disorders. Psycho-
pharmacology (Berl) 2004; 174: 17-24. 
21  Keefe RS, Bilder RM, Davis SM, Harvey pd, 
Palmer BW, Gold JM, Meltzer HY, Green MF, 
Capuano G, Stroup TS, McEvoy JP, Swartz MS, 
Rosenheck RA, Perkins DO, Davis CE, Hsiao 
JK, Lieberman JA. Neurocognitive effects of 
antipsychotic medications in patients with 
chronic schizophrenia in the catie Trial. Arch 
Gen Psychiatry 2007; 64: 633-47. 
22  de Visser SJ, van der Post JP, Pieters MS, Cohen 
AF, van Gerven JM. Biomarkers for the effects of 
antipsychotic drugs in healthy volunteers. Br J 
Clin Pharmacol 2001; 51: 119-32. 
23  Fang J, Bourin M, Baker GB. Metabolism of 
risperidone to 9-hydroxyrisperidone by human 
cytochromes P450 2D6 and 3a4. Naunyn 
Schmiedebergs Arch Pharmacol 1999; 359: 
147-51. 
24  Heykants J, Huang ML, Mannens G, 
Meuldermans W, Snoeck E, Van Beijsterveldt 
L, Van Peer A, Woestenborghs R. The 
pharmacokinetics of risperidone in humans: a 
summary. J Clin Psychiatry 1994; 55 (Suppl.): 
13-7. 
25  Causon R, Allanson J. Validation of an 
analytical method for the determination of 
risperidone and 9-hydroxyrisperidone in 
human plasma using protein precipitation 
and liquid chromatography with tandem mass 
spectrometric detection. York Bioanalytical 
Solutions Study Number YAY/047. DNG 
number: wd2005/00549/00. 2008. 
26  Cohen AF, Ashby L, Crowley D, Land G, Peck AW, 
Miller AA. Lamotrigine (BW430C), a potential 
anticonvulsant. Effects on the central nervous 
system in comparison with phenytoin and 
diazepam. Br J Clin Pharmacol 1985; 20: 619-29. 
27  Sobczak S, Honig A, Schmitt JA, Riedel WJ. 
Pronounced cognitive deficits following an 
intravenous L-tryptophan challenge in first-
degree relatives of bipolar patients compared to 
healthy controls. Neuropsychopharmacology 
2003; 28: 711-9. 
28  Wright BM. A simple mechanical ataxia-meter.  
J Physiol 1971; 218: 27P-28P. 
29  Liem-Moolenaar M, Gray F, de Visser S, Franson 
K, Schoemaker R, Schmitt J, Cohen A, van 
Gerven J. Psychomotor and cognitive effects 
of a single oral dose of talnetant (sb223412) 
in healthy volunteers compared with placebo 
or haloperidol. J Psychopharmacol 2010; 24: 
73-82. 
30  van Steveninck AL, Schoemaker HC, Pieters MS, 
Kroon R, Breimer DD, Cohen AF. A comparison 
of the sensitivities of adaptive tracking, eye 
movement analysis and visual analog lines to 
the effects of incremental doses of temazepam 
in healthy volunteers. Clin Pharmacol Ther 1991; 
50: 172-80. 
31  van Steveninck AL, van Berckel BN, Schoemaker 
RC, Breimer DD, van Gerven JM, Cohen AF. The 
sensitivity of pharmacodynamic tests for the 
central nervous system effects of drugs on the 
effects of sleep deprivation. J Psychopharmacol 
1999; 13: 10-7. 
32  de Haas SL, de Visser SJ, van der Post JP, de 
Smet M, Schoemaker RC, Rijnbeek B, Cohen 
AF, Vega JM, Agrawal NG, Goel TV, Simpson 
RC, Pearson LK, Li S, Hesney M, Murphy 
MG, van Gerven JM. Pharmacodynamic and 
pharmacokinetic effects of tpa023, a gaba(a) 
alpha(2,3) subtype-selective agonist, compared 
to lorazepam and placebo in healthy volunteers. 
J Psychopharmacol 2007; 21: 374-83. 
33  de Visser SJ, van der Post JP, de Waal PP, Cornet 
F, Cohen AF, van Gerven JM. Biomarkers for 
the effects of benzodiazepines in healthy 
volunteers. Br J Clin Pharmacol 2003; 55: 39-50. 
34  Gijsman HJ, van Gerven JM, Verkes RJ, 
Schoemaker RC, Pieters MS, Pennings EJ, 
Hessing TJ, Cohen AF. Saccadic peak velocity 
and eeg as end-points for a serotonergic 
challenge test. Hum Psychopharmacol 2002; 17: 
83-9. 
35  de Visser SJ, van Gerven JM, Schoemaker RC, 
Cohen AF. Concentration-effect relationships 
of two infusion rates of the imidazoline 
antihypertensive agent rilmenidine for blood 
pressure and development of side-effects in 
healthy subjects. Br J Clin Pharmacol 2001; 51: 
423-8. 
36  Kemme MJ, vd Post JP, Schoemaker RC, Straub 
M, Cohen AF, van Gerven JM. Central nervous 
system effects of moxonidine experimental 
sustained release formulation in patients with 
mild to moderate essential hypertension. Br J 
Clin Pharmacol 2003; 55: 518-25. 
37  van der Post JP, de Visser SJ, Schoemaker RC, 
Cohen AF, van Gerven JM. Pharmacokinetic/
pharmacodynamic assessment of tolerance 
to central nervous system effects of a 3 mg 
sustained release tablet of rilmenidine in 
hypertensive patients. J Psychopharmacol 2004; 
18: 221-7. 
38  van Steveninck AL. Methods of assessment of 
central nervous system effects of drugs in man. 










M Liem-Moolenaar1, FA Gray2, SJ de Visser1, KL Franson1,  
RC Schoemaker1, JAJ Schmitt3, AF Cohen1, JMA van Gerven1
1  Centre for Human Drug Research, Leiden, the Netherlands
2  Clinical Pharmacology & Discovery Medicine, Glaxo SmithKline, Harlow, uk
3  Experimental Psychopharmacology Unit, Maastricht University, Maastricht, the Netherlands
j	psychopharmacol	2010;	24:	73-82
39  Borland RG, Nicholson AN. Visual motor 
co-ordination and dynamic visual acuity. Br  
J Clin Pharmacol 1984; 18 (Suppl. 1): 69S-72S. 
40  Zuurman L, Roy C, Schoemaker RC, Hazekamp 
A, Den Hartigh J, Bender JCME, Verpoorte R, 
Pinquier J-P, Cohen AF, Van Gerven JMA. Effect 
of intrapulmonary thc administration in 
humans. J Psychopharmacol 2008; 22: 707-16. 
41  Norris H. The action of sedatives on 
brain stem oculomotor systems in man. 
Neuropharmacology 1971; 10: 181-91. 
42  Bond A, Lader M. The use of analogue scales 
in rating subjective feelings. Br J Med Psychol 
1974; 47: 211-8. 
43  de Haas SL, Schoemaker RC, Van Gerven 
JMA, Hoever P, Cohen AF, Dingemanse J. 
Pharmacokinetics, pharmacodynamics, and 
the pharmacokinetic/pharmacodynamic 
relationship of zolpidem in healthy subjects.  
J Psychopharmacol 2010; 24: 1619-29. 
44  Bowdle TA, Radant ad, Cowley DS, Kharasch ED, 
Strassman RJ, Roy-Byrne PP. Psychedelic effects 
of ketamine in healthy volunteers: relationship 
to steady-state plasma concentrations. 
Anesthesiology 1998; 88: 82-8. 
45  Andrew JM. Delinquents and the tapping test.  
J Clin Psychol 1977; 33: 786-91. 
46  Schmitt JAJ, Jorissen BL, Sobczak S, van 
Boxtel MPJ, Hogervorst E, Deutz NEP, Riedel 
WJ. Tryptophan depletion impairs memory 
consolidation but improves focussed attention 
in healthy young volunteers. J Psychopharmacol 
2000; 14: 21-9. 
47  Rey A. L’examen Clinique en Psychologie. Paris: 
Presses Universitaires de France, 1964. 
48  Liem-Moolenaar M, Zoethout R, de Boer P, 
Schmidt M, de Kam ML, Cohen A, Franson K, 
van Gerven JM. The effects of a glycine reuptake 
inhibitor r231857 on the central nervous system 
and on scopolamine-induced impairments in 
cognitive and psychomotor function in healthy 
subjects. J Psychopharmacol 2010; 24: 1681-7. 
49  Amchin J, Zarycranski W, Taylor KP, Albano 
D, Klockowski PM. Effect of venlafaxine on 
the pharmacokinetics of risperidone. J Clin 
Pharmacol 1999; 39: 297-309. 
50  Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates 
RA. Electroencephalographic and psychomotor 
effects of chlorpromazine and risperidone 
relative to placebo in normal healthy volunteers. 
Br J Clin Pharmacol 1999; 48: 323-30. 
51  Nakagami T, Yasui-Furukori N, Saito M, 
Tateishi T, Kaneo S. Effect of verapamil on 
pharmacokinetics and pharmacodynamics of 
risperidone: in vivo evidence of involvement of 
P-glycoprotein in risperidone disposition. Clin 
Pharmacol Ther 2005; 78: 43-51. 
52  Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual 
A, Cubero P, Prieto D, Palomo T. Negative signs 
and symptoms secondary to antipsychotics: a 
double-blind, randomized trial of a single dose 
of placebo, haloperidol, and risperidone in 
healthy volunteers. Am J Psychiatry 2006; 163: 
488-93. 
53  Barrett SL, Bell R, Watson D, King DJ. Effects of 
amisulpride, risperidone and chlorpromazine 
on auditory and visual latent inhibition, 
prepulse inhibition, executive function and  
eye movements in healthy volunteers.  
J Psychopharmacol 2004; 18: 156-72. 
54  Cooper NR, Croft RJ, Dominey SJ, Burgess 
AP, Gruzelier JH. Paradox lost? Exploring the 
role of alpha oscillations during externally 
vs. internally directed attention and the 
implications for idling and inhibition 
hypotheses. Int J Psychophysiol 2003; 47: 65-74. 
55  van der Post JP, Schram MT, Schoemaker 
RC, Pieters MS, Fuseau E, Pereira A, Baggen 
S, Cohen AF, van Gerven JM. cns effects of 
sumatriptan and rizatriptan in healthy female 
volunteers. Cephalalgia 2002; 22: 271-81. 
56  Dumont GJ, de Visser SJ, Cohen AF, van Gerven 
JM. Biomarkers for the effects of selective 
serotonin reuptake inhibitors (ssris) in healthy 
subjects. Br J Clin Pharmacol 2005; 59: 495-510. 
80	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia 81	 3	–	effects	of	talnetant	in	healthy	men	compared	to	placebo	or	haloperidol
Introduction
Although the atypical antipsychotic drugs are better tolerated than 
most of the older typical antipsychotics, these drugs still produce less 
than optimal improvements in quality of life, work and social function 
and can have serious side effects. It has become increasingly clear that 
the pathophysiology of schizophrenia probably results from more than 
dopaminergic dysfunction alone. 
The neurokinins (nks, also called tachykinins) are one of the largest 
families of peptides and play an important role in neurotransmission  
and neuromodulation in the central and peripheral nervous system 
(Tooney et al, 2000). The neurokinin receptor consists of three different 
receptor subtypes: nk1, nk2, and nk3. Recently, nk3 has become of 
interest with regard to schizophrenia (Spooren et al, 2005). 
The mrna encoding these receptors and nk3 agonist binding sites 
are consistently detected in areas clearly associated with those involved 
in psychosis and location for therapeutic effects of antipsychotic drugs 
(Harrison, 1999; Tooney et al, 2000; Langlois et al, 2001). Other animal 
studies suggest that nk3 receptors are located on the surface of dopamine 
cells within the major dopaminergic cell groups (Stoessl, 1994).
Activation of nk3 receptors leads to the release of the biogenic amines 
dopamine, serotonin, and norepinephrine. Antagonizing these receptors 
therefore reduces the excitatory activation (or hyperactivity) of some or  
all of these principal systems without affecting normal baseline activity. 
This includes a reduction in neurotransmitter release in their target 
regions, including dopamine in ventral and dorsal striatal regions.  
This would be expected to have a desirable effect on the positive 
symptoms of schizophrenia (Spooren et al, 2005). The question  
remains however whether these postulated mechanisms would  
make nk3-receptors a potential target for novel antipsychotic  
agents. 
Additional support comes from a clinical trial in schizophrenia 
patients performed by Meltzer et al (Meltzer et al, 2004). The nk3 receptor 
antagonist osanetant showed consistent effects on positive symptoms 
Abstract
Central Nervous System (cns) effects of talnetant, an nk-3 antagonist  
in development for schizophrenia, were compared to those of haloperi-
dol and placebo. The study was randomised, double-blind, three-way 
crossover of talnetant 200 mg, haloperidol 3 mg or placebo. Twelve 
healthy males participated and eeg, saccadic and smooth pursuit eye 
movements, adaptive tracking, body sway, finger tapping, hormones, 
visual analogue scales (vas) for alertness, mood and calmness and 
psychedelic effects, left/right distraction task, Tower of London and Visual 
and Verbal Learning Task were assessed. Haloperidol showed (difference 
to placebo; 95% CI; p-value) decreases in eeg α power (-0.87µV; -1.51/-
0.22; p = 0.0110), saccadic inaccuracy (2.0%; 0.5/3.6; p = 0.0133), smooth  
pursuit eye movements (-7.5%; -12.0/-3.0; p = 0.0026), adaptive tracking 
(-3.5%; -5.4/-1.7; p = 0.0009), alertness (-6.8 mm; -11.1/-2.4; p = 0.0039), 
negative mood (-4.6 mm; -8.6/-0.6; p = 0.0266), the ability to control 
thoughts (1.2 mm; 0.2/2.3; p = 0.0214), and an increase of serum prolactin 
(ratio 4.1; 3.0/5.6; p < 0.0001). Talnetant showed decreased alpha power 
(-0.69 µV; -1.34/-0.04; p = 0.0390), improved adaptive tracking (1.9%; 
0.1/3.7; p = 0.0370) and reduced calmness on vas Bond and Lader  
(-4.5 mm; -8.0/-1.0; p = 0.0151). Haloperidol effects were predominantly 
cns-depressant, while those of talnetant were slightly stimulatory.  
The results suggest that talnetant penetrates the brain, but it remains  
to be established whether this dose is sufficient and whether the observed 
effect profile is class-specific for nk-3	antagonists.
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Leiden University Medical Center approved the study protocol. Written 
informed consent was obtained from all subjects following a written and 
oral explanation. The study was performed under Good Clinical Practice 
quality systems.
Study design
This was a placebo controlled, randomized, double-blind, three-way, 
cross-over, monocentric study in twelve healthy volunteers, with a two-
week wash-out period. All subjects received single oral doses of talnetant 
200mg, haloperidol 3mg or their matching double-dummy placebos. 
Administration sequence was determined using Latin squares balanced 
for first-order carry-over effects. 
For the dosing sessions all participants were instructed to remain fasted 
from midnight. Smoking, the use of alcohol and quinine- or xanthine-
containing foods or beverages was not allowed during the study days. 
After a standard breakfast at the Centre, patients received the study 
medication. A standardised lunch and dinner was offered at respectively 
4 and 8 hours after drug intake. Water was allowed ad libitum. Subjects 
remained in house until 24 hours after the last study drug administration 
and returned to the clinic at 36 hours, 48, 72 hours and 7-14 days after 
dosing for a post-study follow up. 
Pharmacokinetics
Blood samples were obtained predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 
24, 36, 48 and 72 hours after dosing. Plasma samples were assayed 
for talnetant using a method based upon protein precipitation with 
acetonitrile followed by high performance chromatography/mass 
spectrometry (hplc/ms/ms) employing positive-ion atmospheric pressure 
chemical ionization with a lower limit of quantification (llq) of 5.00 
ng/mL for a 50mL aliquot of human plasma. For haloperidol the method 
was based upon solid phase extraction followed by lc/ms/ms analysis 
employing positive ion electrospray (esi) ionization with llq of 0.0250 
ng/mL for a 200mL aliquot of human plasma. 
and Clinical Global Impression Severity of Illness (cgi-s) comparable  
to haloperidol, without having (worsening or improving) effects on 
negative or depressive symptoms. Strong effects on hallucinatory 
symptoms and an excellent tolerability profile were claimed. Side 
effects noted with osanetant did not differ from those observed with 
placebo treatment. Although the design of the study did not allow firm 
conclusions, osanetant showed evidence of efficacy in the treatment  
of schizophrenia and schizoaffective disorder. 
 Talnetant (sb223412) is a selective, competitive, non-peptide 
neurokinin-3 (nk3) receptor antagonist and is in development for the 
treatment of the positive symptoms of schizophrenia (Dawson L A et al, 
2008). It was well tolerated in healthy volunteers, but the lack of clear 
central nervous system (cns) effects in these early studies also precluded 
any conclusions about brain penetration and relevant pharmacological 
activity. The current study was therefore set up to determine the profile 
and time course of cns-effects of talnetant 200 mg, and to compare these 
to the plasma concentrations. Haloperidol has found to be an effective 
agent in treatment of schizophrenia and has relative specificity for the 
dopamine2 post-synaptic receptor. Additionally haloperidol has clear 
cns-effects in healthy volunteers (Beuzen et al, 1999; Legangneux et al, 
2000; Pretorius et al, 2001). nk3 antagonists are hypothesised not to 
affect baseline dopamine activity, in contrast to haloperidol. Therefore, 
haloperidol was regarded as a good positive control. In this study 




Twelve healthy male and female volunteers aged 18-65 with bmi of 
19-30kg/m3 were recruited by the Centre of Human Drug Research 
(chdr). Exclusion criteria included the use of agents known to affect 
cns performance (including smoking and drug or alcohol abuse) and 
evidence of relevant clinical abnormalities. The Ethics Review Board of the 
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The adaptive tracking test has proved to be useful for measurement of  
cns effects of alcohol(van Steveninck), various psychoactive drugs 
(Borland and Nicholson, 1984; Cohen et al, 1985) and sleep deprivation 
(van Steveninck, 1993). The average performance over a 3- 
minute period was used for statistical analysis. 
visual	and	verbal	learning	task	(vvlt)
Memory (impairment) is a difficult task to study due to the fact that there 
are so many different components of learning behaviour, i.e. acquisition, 
consolidation, storage and retrieval. Learning tasks often test only one 
of these components. However, the Visual Verbal Learning Test (vvlt) 
(Schmitt et al, 2000) contains three different subtests that cover most 
of the scope of learning behaviour, i.e. immediate and delayed word 
recall and a delayed word recognition (Schmitt et al, 2000). This test is an 
adapted version of the Auditory Verbal Learning Test (Rey). Thirty words 
are presented in the same sequence in three trials on a computer screen. 
Each trial ends with a free recall of the words (immediate recall). Thirty 
minutes after the first trial, the subject is requested to recall as many 
words as possible (delayed recall). This is followed by a recognition test, 
consisting of 15 previously presented words and 15 other but comparable 
words, in which the subject has to respond ‘Yes/No’ as quickly as possible 
to indicate recognition of the word (delayed recognition).
At chdr this test has shown the cns effects of various compounds such 
as benzodiazepines (de Haas et al, 2007), cannabis, scopolamine, and 
risperidone [chdr data on file]. Outcome variables for the immediate and 
delayed word recall were the average and the maximum number of correct 
responses. For the delayed word recognition, the number of correct items 
and mean response time for correct responses were analysed. 
tower	of	london
Planning capacity can be assessed by a modified version of the One-touch 
Tower of London (tol) task (Sobczak et al, 2002). This test showed effects 
for several different cns active drugs (Beuzen et al, 1999; Sobczak et al 
2002). The test consists of three coloured balls which must be arranged on 
three sticks to match a picture with the goal positions. The complexity of 
Pharmacokinetics (pk) of talnetant were determined using nonlinear 
mixed effect modelling as implemented in nonmem Version V (GloboMax 
Llc, Hanover, md, usa). A two-compartment model with first order 
absorption was used and parameters were estimated using first order 
conditional estimation on log-transformed data. This procedure 
implements the log-normal residual error model. Inter-individual 
variability in pk parameters was modelled using a constant cv (coefficient 
of variation) error model. The model was parameterised in terms of initial 
(t1/2α) and terminal half life (t1/2b), absorption half life (t1/2α), central 
volume divided by bioavailability (Vc/f), the rate constant describing 
transfer from the peripheral to the central compartment (k32), and 
absorption lag-time (tlag) (using nonmem’s Advan4 and Trans6).
Pharmacodynamics
All pharmacodynamic measurements were performed at -1, 1, 2, 
3, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours relative to drug intake. The 
pharmacodynamic assessments were obtained in a quiet room with 
subdued light with one subject per room using the ‘Neurocart’. This is 
a transportable cns measurement battery used for on-site assessment 
of drug effects and has been used in numerous studies with different 
kinds of cns drugs at chdr (de Haas et al, 2007; van Steveninck, 1993; 
van Steveninck et al 1996). It consists of a series of measurements that 
were chosen for their frequent repeatability, low variability, and their 
sensitivity to a wide range of drug-induced cns-effects. Before the study, 
the subjects were familiarized with the test procedures during a training 
session, no more than one week before the start of the study.
adaptive	tracking
Adaptive tracking measures visuo-motor coordination and vigilance 
(Borland and Nicholson, 1984) and was performed as originally described 
by Borland and Nicolson. The test was adapted for use on a personal 
computer. The adaptive tracking test is more sensitive to impairment of 
eye-hand coordination by drugs than compensatory pursuit tasks or other 
pursuit tracking tasks, such as the pursuit rotor.  
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bar of a computer. The mean tapping rate and the standard deviations are 
used for statistical analysis. 
electroencephalography	(eeg)
eeg was measured to provide measures of cns functions (Cohen 
et al1985). In addition, the literature suggests that antipsychotics 
show distinct profiles of eeg-changes (de Visser et al, 2001; Saletu et 
al, 1987). eeg recordings were made using disposable silver-silver 
chloride electrodes (Medicotest n-oo-s, Olstykke, Denmark), fixed with 
collodion at Fz, Cz, Pz and Oz (international 10/20 system). The electrode 
resistances were kept below 5 kOhm and eeg signals obtained from leads 
Fz-Cz and Pz-Oz. The signals were amplified by use of Nihon Kohden 
AB-621G bioelectric amplifier (Nihon Kohden Corporation, Tokyo, Japan) 
with a time constant of 0.3 seconds and a low pass filter at 100 Hz. For the 
fast Fourier analysis, data collection and analysis were performed using 
customised ced software (Cambridge Electronics Design, Cambridge, uk) 
and stored on hard disk for subsequent analysis. Data blocks containing 
artefacts were identified by visual inspection and these were excluded 
from analysis. Fast Fourier transform analysis was performed to obtain 
the absolute power in the delta- (0.5-3.5 Hz), theta- (3.5-7.5 Hz), alpha- 
(7.5-11.5 Hz) and beta- (11.5-30 Hz) frequency ranges. The duration of eeg 
measurements was 2 minutes per session and eyes were closed. 
eye	movement	analysis
Saccadic and smooth pursuit eye movements were recorded as described 
previously (van Steveninck et al, 1996; van Steveninck, 1993) and have 
shown effects on many different cns active drugs, including gaba-
ergic (de Visser et al 2001; de Haas et al, 2007), serotonergic (Gijsman 
et al, 2002), noradrenergic (de Visser et al, 2001; van der Post et al 2004; 
Kemme et al, 2003), and dopaminergic drugs (de Visser et al, 2001). The 
following equipment was used: a micro-computer based system for data 
recording and analysis (Cambridge Electronics Design, Cambridge, uk), 
Nihon Kohden equipment for stimulus display, signal collection and 
amplification (Nihon Kohden Corporation, Tokyo, Japan) and disposable 
the problem is altered by varying the minimum number of moves to reach 
the goal positions. Each trial consisted of a two- to seven move problem. 
Prior to each problem, the subjects are informed about the minimum 
number of moves in which the problem can be solved. Performance was 
indicated by the slope coefficient of the linear regression of the median 
response time as a function of the number of steps. 
body	sway
An apparatus similar to Wright’s ataxiameter was used to measure 
postural stability, by integrating the amplitude of body movement, 
transferred through a string attached to the subject’s waist (tno/nipg, 
Leiden, The Netherlands) (Wright, 1971). Two-minute measurements 
were made in the antero-posterior direction with the eyes closed, standing 
with feet slightly apart wearing comfortable low-heeled shoes. The total 
amount of movement (in centimeters over 2 min) was used for statistical 
analysis. 
left/right	distraction	task
A parametric version of the well-known colour-word response conflict task 
(Stroop, 1935) was used to measure inhibition by an intervention (Laeng 
et al, 2005). In the past it has been used to measure the effects of several 
compounds including antipsychotics (Cuesta et al, 2001). The words Left 
and Right are displayed either at the left or the right side of a computer 
screen. Response instructions were to respond quickly (by pressing a cor-
responding button) to the location of the word irrespective of its meaning. 
The output parameters are the response time and accuracy of responding 
as a function of task difficulty. 
finger	tapping
The finger tapping test evaluates motor activation and fluency and was 
adapted from the Halstead Reitan Test Battery (Yeudall et al, 1987). The 
test Speed of finger tapping was measured for the index finger of the 
dominant hand; a session contained five performances of ten seconds. 
The volunteer was instructed to tap as quickly as possible on the space 
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were derived (Bond and Lader, 1994). A lower score on these scales 
indicate sedation, excitation and decrease in mood (or contentedness) 
respectively.
In addition, 13 vas described by Bowdle (Bowdle et al, 1998) assessed 
the psychedelic effects of the drug. The lowest extreme is usually ‘0’, 
signifying complete absence of the state (which will be the case under 
normal circumstances). The highest end of the scale is equivalent with the 
‘most extreme state imaginable’. 
Statistical analysis
All pd endpoints were analysed separately by mixed model analyses of 
variance (using sas	proc	mixed) with subject subject-by-treatment and 
subject-by-time as random effect and treatment, occasion (= period), 
time and treatment by time as fixed effects, where the baseline value was 
included as covariate. Graphs of the Least Squares Means estimates over 
time by treatment were presented with 95% confidence intervals as error 
bars. Calculation of time and treatment by time effects was for graphical 
presentation purposes only. Treatment effect was reported as the contrast 
between placebo and either haloperidol or talnetant where the average of 
the measurements up to (and including) 10 hours was calculated within 
the statistical model. All calculations were performed using sas software 
(v8.2,	sas Institute, Inc., Cary, nc, usa). 
Results
Participant characteristics
Eight males and five females were included in the study. One participant 
was withdrawn after the first dosing session (talnetant) due to a protocol 
deviation (undisclosed psychiatric history). Twelve subjects completed the 
study. Mean (sd) age, height, weight, and body mass index (bmi) of the 
subjects were 24 (4.6), 178 (7.3), 74.3 (9.1), and 23.6 (3.19) respectively.
surface electrodes (Medicotest n-oo-s, Olstykke, Denmark). Average 
values of latency (= reaction time), peak saccadic velocity and inaccuracy 
of all artefact-free saccades were used as parameters for saccadic eye 
movements. Saccadic inaccuracy was calculated as the absolute value 
of the difference between the stimulus angle and the corresponding 
saccade, expressed as a percentage of the stimulus angle. The higher the 
percentage, the worse the performance of the eye movement test. For 
smooth pursuit, the target moved sinusoidally over 20 degrees of eyeball 
rotation, at frequencies ranging from 0.3-1.1 Hz. The main parameter was 
the percentage of time that the eyes were in smooth pursuit of the target. 
cortisol	and	prolactin	(prl)
It is well known that antipsychotics can cause prolactin increase which 
can lead to clinically undesirable effects(de Visser et al, 2001). Blood 
samples were collected in plain 3mL tubes in order to assess serum levels 
of cortisol and prolactin (prl). Serum was separated by refrigerated 
centrifugation (2000 g at 4°c for ten minutes) within one hour of 
collection, and transferred to appropriately labelled polypropylene tubes. 
Serum specimens were stored at -20°c until analysis. 
visual	analogue	scales	(vas)
Visual analogue scales consist of 100 millimeter line segments. Subjects 
put a mark on a point on the line that best represents their subjective 
state corresponding to the condition tested. The result is a distance 
(millimeters) calculated from the mark on the line. 
These measures have been shown effects on many different cns active 
drugs, including sedative agents (van Steveninck et al, 1996; de Haas et al, 
2007; Norris, 1971), and dopaminergic drugs (de Visser et al, 2001). 
Subjective effects were quantified using a Dutch translation of the 
16 visual analogue scales (vas) originally described by Norris (Norris, 
1971) and applied to drug effect by Bond and Lader. From the set of 16 
scales, three factors corresponding to alertness (from nine scores), mood 
(or contentedness; from five scores), and calmness (from two scores) 
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Haloperidol affected the vas of psychedelic effects on item five (‘it  
was difficult to control my thoughts’) in comparison to placebo  
(table 3). The effects mainly occurred six hours post-dose. 
Haloperidol caused impairment in the number of correct items after 
delayed recall (table 4). 
Haloperidol caused a prolactin elevation (figure 3), with an increased 
cmax (ratio of 4.1; 95% ci, 3.0, 5.6) and a higher Area Under the Curve 
(auc) up to 10hr (ratio of 3.1; 95% ci, 2.5, 3.8). Later time-points were not 
analysed. The time-course showed a clear drug effect from 3-12 hours 
after dosing, with a maximum around 5-6 hours (figure 3). 
Haloperidol did not affect any other pd measures.
talnetant	effects
Talnetant was tolerated very well at a dose of 200mg, and it was 
comparable to placebo in its adverse effects profile. Talnetant was 
associated with a similar amount of somnolence reports (i.e. three) and 
headache (i.e. one) as placebo. No other adverse effects were reported for 
talnetant. There were no withdrawals due to adverse events and no serious 
or severe adverse events. 
The alpha power decreased for talnetant (table 1). The time-course in 
figure 1 (right panel) showed a decrease for six hours after dosing, which 
remained detectable for the rest of the ten-hour observation period.  
Talnetant improved adaptive tracking performance compared to placebo 
(difference of 1.9%; 95% ci, 0.1, 3.7%; not shown in table). The time-
course of the effects suggested a slow increase up to four hours, after 
which the performance stabilised for the remainder of the observation 
period (figure 2). 
Talnetant reduced feelings of calmness, as indicated by lower scores  
on the visual analogue scales (vas) according to Bond and Lader (table 3). 
Talnetant did not affect any other pd measures. The data did not allow 
an analysis of quantitative pharmacokinetic/pharmacodynamic relation-
ships. However, the average time-courses of the effects of talnetant were 
in agreement with the concentration profile of the compound.
Pharmacodynamic results
Since haloperidol was used as a reference dopaminergic agent, the  




Haloperidol at a single dose of 3mg was generally well tolerated, with 
no more than mild adverse events in most subjects. There were no 
withdrawals due to adverse events and no serious or severe adverse 
events. Nonetheless, we found a considerable number of effects on 
neurophysiology and performance. Six subjects reported somnolence  
and five fatigue. In the results section, differences between treatments 
were defined as a statistically significant effect at a p-value of 0.05 
or lower, without corrections for the number of assessments. The 
corresponding confidence intervals are shown in the tables 1-4. 
Haloperidol 3mg caused decreases in alpha power for the summed leads 
of Pz-Oz and Fz-Cz (table 1). Only absolute power was reported, but 
similar results were found for total and relative power (data not shown). 
Haloperidol effects started at one hour after dosing (figure 1). 
Haloperidol increased saccadic inaccuracy compared to placebo (table 
2). Haloperidol also affected smooth pursuit eye movements. Compared 
to placebo, treatment with haloperidol caused poorer performance and a 
clear steady decrease in smooth pursuit eye movements after haloperidol 
administration was seen. 
Adaptive tracking performance deteriorated after haloperidol 
(difference of -3.5%; 95% ci, -5.4, -1.7%; not shown in table). The time-
course of the effects (see figure 2) showed a clear and consistent reduction 
in tracking performance in the 4-10 hour observation period. 
Haloperidol reduced alertness and mood (or contentedness) as 
indicated by the visual analogue scales (vas) according to Bond and  
Lader (table 3). The time-profiles for vas-alertness and mood showed 
transient decreases around 4-6 hours after dosing. 
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before using similar tests (Beuzen et al, 1999; Legangneux et al, 2000; 
Pretorius et al, 2001). As haloperidol is a relatively selective d2 antagonist, 
comparison of the effects of talnetant and haloperidol might give an 
indication how talnetant would affect the dopaminergic system in  
healthy subjects. 
For this study, a 3 mg dose of haloperidol was selected. While the 
therapeutic dose range for psychosis in patients is 4 to 10 mg per day, 
King (King, 1997) recommended a maximum dose of haloperidol 3 
mg for healthy volunteer studies. In doses of 1 or 2 mg it is not reliably 
distinguished from placebo(King ,1997; Legangneux et al, 2000).  
Above 3 mg, there is a dose-dependent rise in reported adverse effects 
reaching 80 percent at 6 mg (King, 1994). 
From this study it was apparent that the pharmacological effects  
of the two compounds (in the used doses) differ. Haloperidol caused 
more (predictable) adverse effects than talnetant or placebo. In addition, 
there were also several differences in the cns-effect profile. The only 
comparable effects of haloperidol and talnetant were on eeg alpha 
power. A reduction in alpha power is shown by many cns-active drugs, 
particularly but not exclusively by sedative compounds, and it is not 
specific for dopaminergic activity (Chavanon et al, 2007). Other than this, 
talnetant effects differed from those of haloperidol. The combination of 
improved adaptive tracking and reduced calmness could be an indication 
for slight stimulation. However, these conclusions should be critically 
evaluated. 
First, the talnetant effects were small and it could be argued that  
these were spurious. The study included many endpoints, and there was 
no correction for multiple comparisons. The increase in adaptive tracking 
and decrease in alpha power were marginally significant. Additionally, as 
the calmness vas is an individual item of the vas Bond & Lader, it can be 
questioned whether this subscale is sufficiently reliable. However, in our 
experience false-positive statistically significant results are quite rare with 
this study design, which uses conservative statistical methods based on 
overall average response, and robust cns-function tests. So far, we have 
never observed unexpected statistical significance for stimulatory effects. 
talnetant	versus	haloperidol
Most effects of talnetant differed from those of haloperidol, both in 
extent and character (table 6). It was associated with fewer reports of 
somnolence (i.e. three versus six) and fatigue (no reports versus five)  
than haloperidol. The alpha power decreased for talnetant and 
haloperidol to a comparable extent. 
Contrary to what was observed for haloperidol, talnetant did not affect 
saccadic inaccuracy or smooth pursuit eye movements. Also in contrast 
with haloperidol, talnetant improved adaptive tracking performance 
compared to placebo. Talnetant reduced calmness of the visual analogue 
scales (vas) according to Bond and Lader, for which no change was 
seen after haloperidol. Contrary to the effects seen with haloperidol, 
talnetant had no subjective effects on alertness or mood, nor on ‘difficulty 
controlling thoughts’ or any of the other Bowdle vas-scores. Talnetant 
also did not affect memory, which showed impairments in delayed recall 
with haloperidol. There were no talnetant effects on serum prolactin level, 
which also differed from the increase seen with haloperidol.
Pharmacokinetic results
Plasma data are portrayed in figure 4 and nonmem pk parameters 
estimates in table 5. The haloperidol plasma profile was similar to 
that of talnetant, showing a long elimination time with peak plasma 
concentrations of about 1ng/mL at around 5h and a terminal half life  
of approximately 30h. 
Discussion
This study was performed to evaluate the effects of talnetant, a potential 
nk3 receptor antagonist, on a battery of quantitative cns-tests in 
healthy volunteers, prior to studying its effects in patients. These tests 
were chosen for their sensitivity to classic neuroleptic agents and other 
cns-active drugs (de Visser et al, 2001). Haloperidol was chosen as a 
positive control to prove the sensitivity of the test battery as it was tested 
94	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia 95	 3	–	effects	of	talnetant	in	healthy	men	compared	to	placebo	or	haloperidol
suggesting that talnetant might not exhibit the typical adverse events 
of antipsychotic drugs. Possibly, talnetant may be slightly stimulant, 
but the clinical consequences of this property remain to be established. 
As expected, haloperidol also showed clear effects on serum prolactin. 
Talnetant did not cause any hormonal changes, suggesting that this drug 
might not induce hyperprolactinaemia and its associated problems in 
patients.
Summarising, it remains to be seen if the identified effects of talnetant 
are either dose-dependent or class-specific for nk3 antagonists. The 
results suggest that talnetant 200 mg will not exhibit the (side) effect 
profile of antipsychotics, but the clinical relevance of these effects and the 
therapeutic dose still need to be established. Clearly, other studies with 
different nk3 antagonists, are needed to confirm that this drug class may 
cause slight cns-stimulation in healthy subjects. 
The reliability of the design is also confirmed by the effects of haloperidol, 
which were consistent with earlier reported studies in healthy volunteers 
(Legangneux et al, 2000; Pretorius et al, 2001) and with the expected effects 
of haloperidol in clinical studies (McCue et al, 2006).
Second, in the current study the mild stimulant effects of talnetant 
were only examined at a single dose of 200mg. The effects of higher 
doses cannot be predicted from these findings. The reason is that 
some drugs show a dose-related cns-excitation. For example Selective 
Serotonin Reuptake Inhibitors (Dumont et al, 2005) are mildly stimulatory 
at low doses, and slightly depressant at higher levels. This study has 
identified several measurements that can be studied across a wider dose 
range to investigate the dose-response relationships. Unfortunately, 
the identification of clear drug-response patterns for talnetant (i.e. a 
pharmacokinetic-pharmacodynamic (pk/pd) relationship) was precluded 
by the small effect size and the protracted concentration profile. This was 
partly due to talnetant’s relatively long tmax and t1/2, and the relatively 
short evaluation period of cns-effects.
Third, it is still unknown how the effects found in healthy volunteers can 
be extrapolated to patients. Studies in patients are needed to determine 
whether talnetant will have the desired effect in schizophrenia and 
whether the therapeutic window will be improved in comparison with 
the currently used antipsychotics. The only clinical data available to date 
demonstrated that osanetant, also an nk3 receptor antagonist, showed 
antipsychotic activity without any sedative adverse effects(Meltzer 
et al, 2004). The side effect profile of talnetant observed in this study 
seems consistent with the lack of adverse effects reported for osanetant. 
Although the effective therapeutic dose is still unknown, the short-
term cns pharmacodynamic effects of talnetant 200 mg in this study, 
which may provide indications for acute dose-related clinical events 
in patients, favour talnetant over haloperidol. Most adverse events on 
these treatments were mild and thought to be unrelated to treatment. 
Adaptive tracking is a measure of visuo-motor coordination and vigilance 
and smooth eye pursuit of visual coordination and attention. These 
parameters show basically opposing effects of haloperidol and talnetant, 
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Table 3 Pharmacodynamic vas effects of haloperidol and talnetant versus placebo
 














talnetant -  
placebo
95% CI 
talnetant -  
placebob
vas Alertness Bond and 
Lader (mm)
81.1 74.3 -6.8 -11.1, -2.4 80.1 -1.0 -5.2, 3.2
vas Calmness Bond and 
Lader (mm)
90.8 88.8 -2.1 -5.6, 1.4 86.3 -4.5 -8.0, -1.0
vas Mood Bond and 
Lader (mm)
89.5 84.9 -4.6 -8.6, -0.6 87.3 -2.2 -6.2, 1.7
Psychedelic vas score 5 
(mm)
0.4 1.7 1.2 0.2, 2.3 0.9 0.5 -0.5, 1.5
a. ls mean is the Least Squares Means estimate; b. If 0 is included in the 95% Confidence Interval (95% CI) the 
difference is not conventionally different at the 5% level
 
Table 4 Pharmacodynamic word recall effects of haloperidol and talnetant versus placebo 














talnetant -  
placebo
95% CI 
talnetant -  
placebob
Immediate word recall 
number correct -trial 3
17.75 16.08 -1.67 -4.27, 0.94 17.00 -0.75 -3.36, 1.86
Delayed word recall 
number correct
13.33 10.42 -2.92 -5.30,  
-0.54




22.50 24.00 1.50 -1.52, 4.52 24.58 2.08 -0.93, 5.10
Delayed word recogni-
tion average reaction 
time correct (msec)
945.36 900.54 -44.82 -148.6, 
58.93
878.23 -67.13 -170.9, 
36.61
a. ls mean is the Least Squares Means estimate; b. If 0 is included in the 95% Confidence Interval (95% CI) the 
difference is not conventionally different at the 5% level
Table 1 Pharmacodynamic eeg effects of haloperidol and talnetant versus placebo
 














talnetant -  
placebo
95% CI 




8.27 7.40 -0.87 -1.51, -0.22 7.58 -0.69 -1.34, -0.04
Beta-power 
summed leads (mV)
3.45 3.54 0.09 -0.16, 0.34 3.57 0.13 -0.13, 0.38
Delta-power 
summed leads (mV)
8.24 8.44 0.20 -0.67, 1.08 8.04 -0.20 -1.09, 0.69
Theta-power 
summed leads (mV)
5.58 5.62 0.05 -0.32, 0.41 5.70 0.12 -0.25, 0.49
a. ls mean is the Least Squares Means estimate; b. If 0 is included in the 95% Confidence Interval (95% CI) the difference is not 
conventionally different at the 5% level
 
Table 2 Pharmacodynamic eye movement effects of haloperidol and talnetant versus placebo
 














talnetant -  
placebo
95% CI 




471.3 467.1 -4.2 -21.4, 12.9 475.8 4.5 -12.8, 21.7
Saccadic Latency 
(sec)
0.204 0.213 0.009 -0.003, 
0.021




5.6 7.6 2.0 0.5, 3.6 6.3 0.7 -0.8, 2.3
Smooth pursuit (%) 57.9 50.4 -7.5 -12.0, -3.0 58.5 0.6 -4.0, 5.1
a. ls mean is the Least Squares Means estimate; b. If 0 is included in the 95% Confidence Interval (95% CI) the difference is not 
conventionally different at the 5% level
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Figure 1 Adjusted (for baseline) mean time profile of eeg α-power summed leads with 95% CI for placebo and 
lower 95%CI for talnetant (circle, talnetant; square, haloperidol; dot, placebo).
Figure 2 Adjusted (for baseline) mean time profile of average performance on adaptive tracking with 95% CI 
for talnetant and lower 95% CI for haloperidol (circle, talnetant; square, haloperidol; dot, placebo).













































Table 5 Pharmacokinetic Parameter estimates for talnetant (n = 13)  
Meana semb cvc
T1/2α (hr) 2.56 1.20 15.7%
T1/2b (hr) 42.1 5.15 34.9%
t1/2a (hr) 1.17 0.504 29.0%
Vc/F (L) 22.8 7.56 18.7%
k32 (hr-1) 0.105 0.0224 3.9%
tlag (hr) 0.704 0.118 28.1%
cl (L/hr)d 0.957 0.0976 36.1%
a.	population average; b.	standard error of the population average; c.	inter-individual coefficient of variation - residual error  
(cv)	= 10.2%; d.	obtained from an alternative parameterization
Table 6 Overview of haloperidol and talnetant effects compared to placebo on different pharmacodynamic 
tests a	
Pharmacodynamic test Haloperidol Talnetant
Alpha-power summed leads - -
Beta/Delta/Theta-power summed leads 0 0
Saccadic Peak Velocity and Latency 0 0
Saccadic Inaccuracy + 0
Smooth pursuit -- 0
Average adaptive tracking --- +
vas Alertness Bond and Lader -- 0
vas Calmness Bond and Lader 0 -
vas Mood Bond and Lader - 0
Psychedelic vas score 5 + 0
Immediate word recall number correct -trial 3 0 0
Delayed word recall number correct - 0
Delayed word recognition number correct and average reaction time correct 0 0
auc up to 10hr and cmax cortisol serum level 0 0
auc up to 10hr and cmax prolactin serum level ++++ 0
a.	classified as follows: ‘0’ indicates no statistically significant decrease or increase; ‘-‘ or ‘+’ indicates a decrease or increase 
showing a p-value less than 0.05; ‘--‘ or ‘++’ indicates a decrease or increase showing a p-value less than 0.01; ‘---‘ or ‘+++’ 
indicates a decrease or increase showing a p-value less than 0.001; ‘----‘ or ‘++++’ indicates a decrease or increase showing a 
p-value less than 0.0001
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Figure 4 Average (+sd) plasma concentration profile of talnetant and haloperidol














































Figure 3 Average (+sd) serum concentration profile of prolactin (circle: talnetant; square: haloperidol;  
dot: placebo)
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Introduction
Traditional models of schizophrenia emphasize the importance of 
dopaminergic (da) dysregulation, particularly with regard to the positive 
symptoms [1,2]. An alternative model is based on the effects of non-
competitive antagonists of N-methyl-D-aspartate (nmda) glutamate 
receptors, which induce psychotic symptoms in healthy subjects 
and exacerbate symptoms in schizophrenic patients. These effects 
seem to resemble schizophrenia more closely than those induced by 
dopamine activation [3-6]. Moreover, dysfunction of glutamatergic 
neuronal systems would be consistent with the dopamine hypothesis 
of schizophrenia [7-11]. Due to major concerns over potentially serious 
adverse events of indiscriminate glutamatergic stimulation, which could 
affect key functions such as learning, memory and neuronal excitation 
and cell death, research has focused on alternative strategies to augment 
nmda receptor function [12]. One alternative pathway is through the 
glycine receptor site, an obligatory co-agonist at the nmda receptor 
[3]. Direct glycine agonists appear to show some effect in treatment-
resistant schizophrenia [3], but this requires gram-level doses. Inhibition 
of presynaptic reuptake of GlyT1 transporters can also increase local 
endogenous glycine levels [13,14]. As reviewed by Javitt [3], glycine 
reuptake inhibitors (e.g. D-cycloserine, glycine and D-serine) have 
been effective in a variety of rodent schizophrenia models [15-19] and in 
schizophrenic patients [20-22], but these agents are neither potent nor 
selective. sch 900435 is a selective and highly potent GlyT1-reuptake 
inhibitor (Figure 1 - structural formula), which effectively increases 
extracellular glycine levels in rat brain regions and spinal cord, but does 
not affect strychnine-sensitive GlyT2-transporters. Based on its general 
facilitation of nmda-receptor activity throughout the nervous system, its 
effects could be expected to influence a wide range of cns-effects. Lastly, 
preclinical studies suggested that sch 900435 could have a steep dose-
effect relationship for adverse events. Therefore, a strategy was chosen 
for the early development of sch 900435 that allowed for careful stepwise 
assessment of the pharmacological and clinical characteristics of the 
Abstract
aim  To report the first three studies with sch 900435, a highly selective 
glycine-1 reuptake inhibitor in development for treating schizophrenia, 
using systematic evaluations of pharmacodynamics to understand the 
observed (adverse) effects. 
methods  Three double-blind, placebo-controlled studies (single dose, 
visual effect analysis and multiple dose) were performed. In the single and 
multiple dose study sch 900435 (0.5-30mg) was given to healthy males 
and frequent pharmacokinetic and pharmacodynamic measurements 
were performed. The visual effects study, which was performed after the 
single and before the multiple dose study, focussed on the visual system 
and incorporated visual electrophysiological measures of macular, retinal 
and intracranial visual pathway function. 
results  In the single dose study increases in smooth pursuit eye 
movements (8, 12, 30mg), pupil/iris ratio (20 and 30mg), vas colour 
perception (30mg) and changes in spontaneous reports of short-lasting 
visual disturbance were found, while fsh (8, 12, 20mg), lh (8-30mg) and 
eeg alpha2 activity decreased (12, 20, 30mg). A subsequent dedicated 
visual effects study demonstrated that visual effects were transient 
without underlying electrophysiological changes. This provided enough 
safety information for starting a multiple ascending dose study, which 
showed rapid development of tolerance for visual effects. 
conclusions		Several cns effects and gonadotropic changes resulted 
from administration of 8mg and higher, providing evidence for cns 
penetration and pharmacological activity of sch 900435. Transient visual 
symptoms were reported to which rapid tolerance occurred. It remains to 
be established whether these effects are specific for this pharmacological 
class and whether this class of drugs offers any antipsychotic activity in 
patients.
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performed regularly throughout the study. Blood samples were obtained 
pre-dose and frequently up to 72 hours after sch 900435 administration. 
Frequent measurements of a multimodal cns test battery containing 
a wide range of drug-responsive cns-domains up to eight hours 
after dosing were obtained: Visual Analogue Scales (vas measuring 
subjective alertness, mood, calmness, psychedelic effects, sleep quality), 
pharmaco-electroencephalography (pharmaco-eeg), saccadic pursuit 
eye movements (measure of alertness), smooth pursuit eye movements 
(measure of motor coordination), adaptive tracking (visuo-motor 
coordination), body sway (postural stability), pupillometry (pupil-
iris ratio) and neuroendocrine effects (serum prolactin, lh, fsh and 
testosterone levels). 
Both a general treatment effect and a simple linear effect was tested for 
the pd parameters. aues (Area Under Effect-time curves) were calculated 
per subject and divided by the corresponding time span, resulting in 
a weighted average response used for ancova analysis. If the general 
treatment effect was significant, contrasts of all treatments versus 
placebo were calculated. Differences between treatments were defined  
as statistically significant at a p-value of 0.05 or lower. 
If the treatment effect was significant and the linear effect suggested 
a dose effect relation, an additional regression analysis of the relevant 
parameter on log dose was performed. The slope of the regression 
was considered significantly different from zero at a p-value of 0.05 
or lower. Conclusions about pk with respect to dose proportionality/
dose independence were primarily based on descriptive statistics of pk 
parameters and on summary plots. An additional exploratory Analysis  
of Variance (anova) was performed to test for dose proportionality 
and dose independence. Detailed methods (pharmacodynamic 
measurements and statistics) are described in appendix I. 
Results and discussion
Sixteen healthy males were included in the single dose study. Two subjects 
were withdrawn due to visual symptoms (described in more detail below) 
drug. During the first administration of sch 900435 in human, each 
dose escalation step was based on a detailed evaluation of the interim 
analyses of pharmacokinetics (pk), pharmacodynamics (pd) and clinical 
effects of the preceding doses. A multimodal test battery was used to 
frequently measure a wide range of effects, covering most drug sensitive 
cns-domains and vital functions. This article describes the three studies 
in human volunteers performed to determine a dosing regimen of sch 
900435, that were expected to be safe and therapeutically relevant for 
subsequent patient dose finding studies. Each study was approved by an 
independent Ethics Review Board and full written informed consent was 
obtained from all subjects.
Single ascending dose (SD) study 
Subjects and methods
Sixteen healthy male volunteers between 18 and 45 years were recruited 
for the first administration of single ascending doses of sch 900435 at the 
Centre for Human Drug Research in Leiden, The Netherlands. Exclusion 
criteria and study restrictions included the use of agents known to affect 
cns performance (including nicotine, alcohol or drugs) and evidence 
of relevant clinical or psychiatric abnormalities. Subjects remained in 
house until 72 hours after the last study drug administration. The study 
was double-blind, placebo controlled and randomized. Each subject 
was assigned to one of four dosing groups in a four-way crossover study 
(three active ascending doses and one randomized placebo dose), with 
a minimum wash-out period of one week (table 1a). Based on preclinical 
evaluations, the original dosing regimen was planned to cover a range 
from 0.5 mg (the human starting dose based on animal safety data) to 
135 mg (predicted to lead to plasma levels in the anticipated therapeutic 
range). According to the protocol, doses could be adapted based on 
investigator-blinded interim assessments. 
Adverse events, laboratory safety parameters, ecg, oral body 
temperature, blood pressure and heart rate measurements were 
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Pharmacokinetics (pk) were dose-linear over the tested dose range. 
The mean concentration-versus time profiles (figure 2) showed that the 
last parts of the curves for all doses ran essentially parallel and that the 
terminal elimination phase started approximately 16 hours after dosing. 
The terminal half-lives varied from 6.6 to 7.8 hours, and clearance from 
4.5 to 6.1 L/h. 
In agreement with the adverse event reports, significant increases were 
observed in the ‘colours’ item of the Bowdle visual analogue scale (table 
3). The increases did not exhibit a linear dose-response relationship 
across all doses (table 4) but were consistent at 30 mg (figure 3). After a 
maximum at approximately 40 minutes, all effects had disappeared by 3 
hours following dosing (figure 4). Pupillometry demonstrated an increase 
of pupil/iris ratio at 20 mg sch 900435 (table 3), with the largest effect at 
30 mg (table 3, figure 5). 
Smooth pursuit (0-4 hours) showed a statistically significant increase 
at 8, 12, and 30 mg (largest difference) (table 3). The regression analysis 
showed a statistically significant dose-response relationship for smooth 
pursuit eye movements (table 4). It should be noted that the smaller 
number of subjects in the higher dose groups (the 20 mg dose group for 
smooth pursuit eye movements) may have prevented the detection of a 
treatment effect from reaching statistical significance (the same could  
be true for the 30 mg dose group for fsh levels).
Both lh and fsh decreased statistically significantly compared 
to placebo (table 3, figure 5). lh started to diminish after 12 mg and 
fsh after 8 mg; the effect was more pronounced with higher doses. 
Testosterone showed a decrease at 8 and 20 mg (table 3). The lh level 
decrease followed sch 900435 administration within one hour and 
was virtually normalized after ten hours. fsh levels diminished after 
five to six hours, and remained reduced during the full observation 
period. Regression analysis showed indications for linear dose response 
relationships for all three hormones (table 4). 
Signs of pharmacological activity in this single ascending dose study 
were evident from doses starting at 8 mg. Clear increases in pupil size  
and subjective changes of visual perception were noted after 20 and  
and 14 subjects completed the study. The mean (range) age of the 
subjects was 24 (19-32) years. 
After interim assessment of the first dose, it was observed that exposure 
in terms of plasma auc was 10-fold higher in humans than that which was 
allometrically predicted. No pharmacodynamic or adverse effects were 
noted after the starting dose, but the original anticipated dose range was 
reduced from 0.5-135 mg to 0.5-30 mg (table 1b). 
No statistically significant changes in vital signs, respiratory function, 
physical examination or laboratory parameters were observed during the 
study. There were no serious adverse events (saes). The most frequently 
reported adverse events (aes) during the in-house study period were 
dizziness, somnolence, headache, fatigue and abnormal vision (table 
2). All were mild to moderate and self-limiting. At 3 mg, one subject 
developed anxiety and other psychological effects in addition to visual 
changes, which led to his withdrawal. In the subsequent two dosing 
groups, four of 12 subjects reported visual changes (one each at 3 and 
8 and two at 12 mg), often described as spots of enhanced contrast or 
intensity accompanied by blurred vision and dizziness. These symptoms 
occurred around 30 minutes after drug administration, and disappeared 
within minutes to a few hours after the start of the symptoms. They were 
considered to be drug-related, but were of limited duration and intensity. 
All four subjects in the fourth dosing group reported spots in the visual 
fields (starting at 20 or 30 mg) similar to those observed in previous 
groups. It was decided to withdraw one of these subjects as he reported 
recurrent symptoms, which, although moderate, increased in the third 
visit (30 mg) compared to the second visit (20 mg). Ophthalmologic 
examinations did not reveal any subjective or objective visual system 
abnormalities, either during the study or at follow-up. 
Peak concentrations of sch 900435 26,7 ng/mL (for 0.5 mg) to 1170 
ng/ml (for 30 mg) and were reached between 30 and 50 minute after 
dosing. Maximal drug plasma concentrations were higher in subjects 
who reported visual aes than those who did not (approximately 770 ng/mL 
versus 140 ng/mL). Peak concentrations of 26.7 ng/mL (for 0.5 mg) to 1170 
ng/mL (for 30 mg) sch 900435 were reached 0.5-0.8 hours after dosing. 
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exclusion and inclusion criteria and study restrictions were similar to the 
single ascending dose study. Inclusion criteria for the study included a 
normal eye examination and good visual acuity (6/9 or better in each eye). 
Each treatment period lasted one day and was separated by a wash-out of 
at least 3 days. Subjects were further randomized into one of three groups 
of eight subjects in which pk, pd and several pd eye assessments were 
performed. In group 1 (fully dark adapted with dilated pupils; duration: 
approximately 12 minutes, in cycles of 25 minutes) the following pd 
tests were performed: dark adaptation - measuring the threshold of 
light detection without electrophysiology, rod specific single flash, red 
flash, intermediate, International Society for Clinical Electrophysiology 
of Vision (iscev) standard and iscev + 0.6 lv (see appendix ii). In group 
2 (light conditions with dilated pupils; duration: approximately 20 
minutes, in cycles of 25 minutes) the following tests were taken: single 
flash Cone response - 2 Hz, flicker response - 30 Hz, on-/off- response, 
S-Cone response and Photopic Negative Response (see appendix ii). In 
group 3 (light conditions with undilated pupils; duration: approximately 
45 minutes) the following tests were performed: vep - pattern reversal/
flash, pattern erg, Color Contrast Sensitivity, visual Acuity, pupillometry 
(see appendix ii) and neuroendocrine effects. pk, pd and statistics are 
described in more detail in appendix ii. Endocrinologic investigations 
(performed in groups 1 and 2 only) included repeated measurements 
of lh, fsh and testosterone. aes, laboratory safety parameters, ecg, 
blood pressure and heart rate measurements were performed regularly 
during the study. sch 900435 blood samples were obtained predose and 
frequently up to 24 h post-dose (for pk methods see single ascending dose 
study appendix I).
Results and discussion
Twenty-four (three groups of eight) subjects were included. There were 
no saes or clinically relevant changes in laboratory safety parameters, 
vital signs, and ecg data. The majority of the aes were considered to be 
of mild intensity (102 out of 109 aes), four aes were of moderate intensity 
30 mg. The effects resolved rapidly and were no more than mild to 
moderate, but were initially disconcerting and were not anticipated. 
Therefore, a more specific study on the effect of the drug on visual system 
function was therefore initiated before a multiple dosing was started.
Visual effects study
Based on the conjecture that the visual symptoms were more likely 
to reflect a retinal rather than central origin, consultation with 
ophthalmology experts and a review of the literature revealed that the 
retina is rich in glycine receptors. It appeared that although cns-studies 
of glycinergic or glutamatergic agents did not specifically describe visual 
disturbances [18,23,24], such effects have been reported with high-dose 
intravesicular glycine administration in men, following prostate surgery 
[25,26]. Based on the combination of drug-induced pupil dilation and 
abnormal vision, direct retinal effects were considered more probable 
than autonomically induced mydriasis or central visual impairment. 
Detailed assessments of retinal architecture and function in rats and dogs 
exposed to sch 900435 did not demonstrate any electrophysiological or 
structural abnormalities of the retina or other components of the visual 
system after repeated dosing (data on file). In the first-in-human study, 
all symptoms were mild and rapidly reversible without any sequelae, 
both subjectively and during follow-up. Moreover, the resolution of 
visual symptoms was faster than the reduction of plasma concentrations, 
suggesting that the visual effects may not have functional consequences. 
This was investigated in a dedicated ophthalmologic study with sch 
900435 at Moorfields Eye Hospital in London, uk.
Subjects and methods
The visual effects study was a double-blind, placebo-controlled, four-
period crossover study involving the administration of three single 
oral doses of sch 900435 (5, 13 and 20 mg) in which the placebo was 
randomized in an ascending order in 24 healthy male subjects. The 
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and heart rate measurements were followed up regularly (see for the study 
design table 7). pd and safety assessments in the md study were based 
on the results of the sd and visual effects study: Visual Analogue Scales 
(vas), pharmaco-eeg, pupillometry and neuroendocrine effects (lh, fsh, 
testosterone) (table 7). In addition, the cognitive effects of multiple dose 
treatment with sch 900435 were examined with the following tests from 
the Cognitive Drug Research (cdr) test battery: simple reaction time, 
digit vigilance, choice reaction time, spatial working memory, numeric 
working memory, immediate word recall, word recognition, postural 
stability and tracking. At screening and follow-up, visual examinations 
were performed at Moorfields Eye Hospital, London, and subjects were 
given a questionnaire consisting of eight questions to ascertain visual 
symptoms. The primary aim of this md study was to examine the clinical 
course of the events that had been observed during single dosing. 
Descriptive and summary statistics for the vas and aes were used as 
statistical models were considered to have a chance of obstructing the 
identification of isolated but relevant clinical observations. The statistical 
analyses performed on pk, pharmaco-eeg and results of the cdr test 
battery are described in more detail in appendix iii.
Results and discussion
Forty healthy male subjects, with a mean (range) age of 25.9 (18-42) 
years, were included in the study. There were no clinically relevant 
abnormal findings in the laboratory safety parameters, vital signs or  
ecg data. The most common aes reported by subjects receiving sch 
900435 were eye disorders and cns disorders (table 8). These symptoms 
were mostly noted between 0.5 and 1 hours post-dose after both single 
and multiple doses and did not appear to be prolonged. None of the aes 
were severe and no saes were reported during the study. One subject was 
withdrawn from the study on day 12 (before the morning administration 
of sch 900435) due to a persistent focussing difficulty; those symptoms 
disappeared by the evening of day 12. Notably, the number of reported 
visual symptoms following sch 900435 12 mg twice daily (after dose 
and three were of severe intensity. One visual ae followed after 13 mg sch 
900435 and two following 20 mg and were similar to the events that were 
also described in the sd study. The symptoms were transient and resolved 
without intervention. 
Pharmacokinetics and hormone results were also similar to those 
observed in the sd study (data not shown), with the exception of the 
fsh profile which showed no decrease in this study. Overall, there was 
no consistent change in any ophthalmologic test result in any subject, 
other than those that may be expected from normal variation. The 
visual symptoms questionnaire was the most sensitive and specific 
determination of visual disturbance (table 5). Although the results  
should be treated with caution because of the well documented 
consequences of multiple hypothesis testing (only unadjusted 95% 
confidence intervals were calculated) and influence of extraneous factors 
(e.g. subject tiredness and dizziness, adaptation/intolerance to the 
testing), the data provided no indication for clinical concerns to perform 
a multiple (ascending) dose study. This could possibly be an explanation 
of the reporting of blurred vision and apparent film over the eyes pre-dose 
and following administration of placebo. 
Multiple (ascending) dose (md) study
Subjects and methods
The multiple ascending dose study was performed at Guys Drug Research 
Unit, London, uk. Selection criteria and study restrictions were similar 
to the visual effects study. The study design of the multiple dose (md) 
study was double-blind, placebo-controlled and parallel group. Multiple 
(ascending) oral doses between 4 and 30 mg were given once or twice 
daily to 40 (five groups of eight) healthy male subjects for 13 days (table 
6). 
Similar to the sd and visual effects study, pk samples were obtained 
frequently for up to 72 hours after the last sch 900435 dose, and aes, 
laboratory safety parameters, ecg, oral body temperature, blood pressure 
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daily (compared to once daily) dosing of sch 900435 improve tolerance  
to the subjective visual disturbances that primarily occur shortly after  
the initiation of treatment. 
Discussion
The changes in visual vas scales, the reported visual symptoms and 
the pupil dilation that were observed in the sch 900435 studies are all 
compatible with a direct retinal effect of sch 900435. Visual spots can 
be a manifestation of cortical spreading depression such as that which 
occurs during a migraine aura, and it cannot be excluded that a similar 
phenomenon caused the visual symptoms that occurred with sch 900435. 
This would be consistent with a potential role of enhanced glutamatergic 
activity, which among other biochemical derangements has been 
postulated to play a role in cortical spreading depression [27]. On the 
other hand, visual auras typically migrate and this was not reported 
by participants in our studies. Also, no other migrating neurological 
deficits or headaches occurred. Furthermore, pupillary abnormalities 
are usually not observed in occipital visual disturbance. A transient 
change in retinal function may then explain the visual symptoms, even 
in the absence of any detectable changes in retinal function as measured 
electrophysiologically. 
Glycine is one of the essential neurotransmitters modulating visual 
signals in the retina [28]. The retinal amacrine cells appear to possess 
a specific uptake mechanism for glycine [29] and contribute to the 
generation of the oscillatory potentials (OPs) in the electroretinogram.  
In different animal models these potentials were found to be blocked  
by glycine [29,30]. In a recent study with a glycine reuptake inhibitor  
in healthy humans a high incidence of visual effects was described [31]. 
Visual effects included visual disturbance, blurred vision, photophobia, 
diplopia, and photopsia and were only reported in the higher dose 
ranges. The time course of the effects in the current study was also 
compatible with an acute pharmacological effect. In the sd study, the 
reported visual symptoms and pupil dilation were both clearly related to 
titration) were lower than following 16 mg once daily (table 8). Similarly, 
the incidence of lethargy, dizziness and somnolence was less during dose 
titration (table 8). 
No clinically relevant deviations in pd effects were shown. Mean vas 
data seemed to show increases in dizziness, decreases in alertness and 
in activeness, sleepiness and nausea and drowsiness on day four, while 
these effects had diminished or cleared a few days later, suggesting some 
adaptation to treatment. Although a decrease in pupil diameter was seen 
(as opposed to the dilation seen in the single dose study), this change was 
not sustained, not evident under the other conditions or in the other dose 
groups and it can not exclude that this finding was coincidental in this 
small group of subjects. There were also no clear results on eeg power and 
the cognitive data. 
Similarly to the sd study, fsh, lh and testosterone significantly 
decreased during multiple dosing (see figure 7 for lh; the figures for the 
other hormones were similar and were therefore not shown). There was 
no difference in hormone reductions between the first and last days of 
dosing. The effect was generally largest following administration of 16 mg 
sch 900435. 
The pk parameters of the multiple (ascending) dose study were as 
expected from the single dose study and the visual effects study (data 
therefore not shown). Steady state concentrations were reached between 
2 and 6 days of daily dosing. Mean accumulation of sch 900435 exposure 
(auc) at steady state after once daily dosing ranged between 5% and 11% 
and was 22% after 12 mg twice daily treatment. The elimination half-life 
was increased 20% after 10 days of daily dosing. pk of sch 900435 was 
dose-proportional at steady state in the dose range 4 - 16 mg once daily 
and 12 mg twice daily. 
In summary, the incidence of central nervous and visual symptoms 
measured by ae reporting increased when the dose of sch 900435 
was higher than 8 mg once daily. The other pd measurements did not 
show relevant or consistent changes in the doses tested in this study, 
except limited but statistically significant decreases in gonadotrophic 
hormones. Clinically, the results indicate that dose titration and twice 
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the time-courses of the hormonal effects and the linear relation between 
dose and effect agree better with a common effect on lh and fsh release, 
most likely due to reduction of GnRH release [39], and suggesting the site 
of action of sch 900435 to be the hypothalamus. These gonadotrophic 
responses are dose dependent and quite consistent, which makes 
these hormones (and lh in particular), the most reliable and sensitive 
pharmacodynamic indicators of a central sch 900435 effect that were 
identified in these studies. 
In general, animal studies of glycine reuptake inhibitors and glycine 
agonists showed central nervous system depression (i.e. reduction in 
motor activity) [7,40,41]. In apparent contrast, sch 900435 produced 
slight improvements of smooth pursuit eye movements in the sd study, 
which seemed to be dose dependent, and hence to be related to the 
pharmacological activity of the drug. Improved smooth pursuit could 
point to a mild stimulant effect of sch 900435. On the other hand, the  
eeg demonstrated small statistically significant reductions in alpha2 
power (10.5 - 12.5 Hz), which are more in line with cns depression. 
However, this alpha reduction could be secondary to the visual symptoms 
caused by sch 900435, since eeg alpha rhythm is particularly sensitive 
to visual input (e.g. eye opening or closure) and subjective well being 
(e.g. suppression by nausea and dizziness). These findings should be 
replicated before firm conclusions can be drawn.
Since experience with indirect nmda-receptor activators in humans 
was limited, a cautious and adjustable approach to development of 
these drugs in humans is required. The present paper describes how a 
novel glycine reuptake inhibitor, which had a steep in dose-response 
curve for adverse events in test animals and showed unanticipated and 
initially disconcerting visual symptoms in humans, was safely introduced 
in healthy volunteers using an adaptive research strategy consisting of 
frequent interim analyses of pk characteristics and of data-intensive pd 
effects, and a return to dedicated animal studies before the drug was 
reintroduced in humans. Unanticipated visual effects were detected from 
adverse event reports, and could be interpreted and pursued more reliably 
using frequent measurements of visual analogue scales for a broad range 
peak plasma concentrations. Although no formal concentration-effect 
analyses were performed, it seemed that the subjective visual changes 
(assessed with the Bowdle vas colours) resolved more rapidly than the 
plasma concentrations, perhaps as a result of habituation. In addition, 
high peak concentrations could be avoided by a slow release formulation 
which has been developed for this reason. The visual system is highly 
adaptive, so the question remained whether symptoms faded because 
of (retinal) adaptation to ongoing functional impairments. Preclinical 
multiple-dose studies showed no morphological abnormalities in the 
eyes of experimental animals and the dedicated ophthalmologic study 
found no electrophysiological or functional indications of significant 
retinal impairment. In the md study, the incidence of aes related to eye 
disorders increased with ascending doses of sch 900435. However, 
reports of visual disturbances were less frequent with dose titration than 
without. This provided further confidence that the rapid resolution of the 
visual symptoms after a single dose or during dose titration reflects the 
development of pharmacological tolerance without further functional 
consequences. Similarly, in the vas data there was an indication for 
tolerance to dizziness, alertness, sleepiness, nausea, activeness and 
drowsiness. 
In all three studies decreases in sex hormones were observed after 
sch 900435 (with the exception of fsh in the visual effects study), and 
the relation between these effects and the dose was linear. Literature 
on the relationship between nmda receptor stimulation and fsh, lh or 
testosterone production in humans is sparse, and most studies show 
no clear association [32,33] or contradict the present findings [34]. 
In preclinical experiments, an increase of fsh was found [35,36]. The 
testosterone reductions found in this study are compatible with the 
diminished gonadotrophic hormone concentrations, particularly of 
lh. The differences in the response of lh and fsh after sch 900435 
administration are partly related to the differences in half-life. lh has an 
elimination half-life of around one to two hours [37], while that of fsh is 
in the region of five hours [38]. Although a direct effect of sch 900435 on 
the expression of any of these hormones individually cannot be excluded, 
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Appendix I 
Description of pharmacodynamic tests and statistics  
single ascending dose study 
Different measures of the effects of sch 900435 on the central nervous 
and visual systems were used in this study. A multimodal test battery was 
performed regularly, to keep close track of any potential drug-related 
changes in cns-functionality. 
visual	analogue	scales	(vas)
Subjective effects were quantified using a Dutch translation of the 16 
visual analogue scales (vas) originally described by Norris [1] and applied 
to drug effect by Bond and Lader [2]. The Dutch translation showed effects 
on many different cns active drugs, including sedative agents [3,4], 
do pa minergic drugs [5], scopolamine [6], and thc [7]. From the set  
of 16 scales, three factors corresponding to alertness, mood and calmness 
were derived. 
Bowdle described 13 vas’s to quantify the psychotomimetic effects  
of ketamine [8]. A translated version of the Bowdle vas showed concen-
tration-related effects in thc [7], scopolamine [6], and zolpidem [9]. 
The Leeds Sleep Evaluation Questionnaire (lseq) contains 14-item 
visual analogue scales related to the subjective aspects of sleep and 
waking [10]. 
pharmaco-electroencephalography
Pharmaco-eeg was performed as a general measure of cns activity [11]. 
The literature suggests that antipsychotics show distinct profiles of eeg-
changes [12,13]. eeg recordings were made using silver-silver chloride 
electrodes, fixed with collodion according to the international 10/20 
system. The electrode resistances were kept below 5 kOhm. The duration 
of one eeg measurement was 3 minutes. The signals were amplified and 
stored on a Vitaport-8® system. A/D converted data were subjected to a 
windowed Fast Fourier transform analysis giving a frequency resolution  
of subjective symptoms, and pharmacodynamic measures of multiple 
systemic and cns effects, including pupil size. This strategy is particularly 
useful for chemical entities with novel mechanisms of action, which have 
a higher chance of showing unanticipated effects. 
Intensive pharmacodynamic measurements can also provide 
indications for cns-penetration and dose-related pharmacological 
activity, especially since the early studies in healthy volunteers almost 
always cover a large dosage range. The establishment of dose-related 
changes provides strong evidence for a drug-related effect. This is clearly 
demonstrated by the consistency of almost all effects that were observed 
during the first study, even though they were unexpected and may even 
have initially seemed spurious. It cannot be ascertained whether the 
indications for cns penetration and pharmacological activity of sch 
900435 are due to GlyT1 reuptake inhibition, although this is suggested 
by the high potency and selectivity of sch 900435 at this site. The retina, 
which is particularly rich in glycine- and glutamate-containing cells 
[42], has a structure similar to the blood brain barrier. The observed 
visual spots in the sd study together with the dose-responsive hormone 
changes and neurophysiological effects could indicate that sch 900435 
passes the blood retinal barrier and penetrates into the cns. Long-
term studies and investigations with other glycine reuptake inhibitors 
are needed to confirm whether retinal and gonadotropic changes are 
pharmacological effects of this novel drug class. Although these studies 
provided indications that sch 900435 has a pharmacological effect in 
the cns at doses that are well tolerated after titration, the antipsychotic 
effects and the therapeutically active doses of sch 900435 and of glycine 
enhancement strategies in schizophrenia in general [43,44] remain to be 
established. 
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The subject was instructed to look into the lens of a digital camera after 
at least five minutes adaptation in ambient lighting. A picture of the eyes 
was taken using a single flash. All pictures were imported and stored in 
Adobe Illustrator 9, to determine the diameters of the pupil and the iris in 
millimetres. For each eye, these values were recorded, and the pupil/iris 
ratio was calculated as a measure of pupil size. 
neuroendocrine	effects
In humans lh has proven to be a sensitive marker of nmda activity 
[29,30]. Prolactin was also measured as an indication of (indirect) 
dopamine activity [5]. 
After collection, blood samples for lh, fsh, testosterone, and prolactin 
were kept at room temperature for about 30 minutes to allow coagulation. 
Serum was separated by centrifugation (2,000´g at 4°c for 15 minutes) 
and stored in a deep freezer at - 40 °c. The hormones were performed 
according to Good Laboratory Practice analysed by Organon Development 
GmbH using a validated fluoro-immunoassay.
Reference values for men were 2 - 80 U/L for lh, 2-10 U/L for fsh, 10-40 
nmol/L for testosterone and < 15 µg/L for prolactin. For cortisol reference 
values were time dependent: 0,20 - 0,60 µmol/L (8 AM), 0,10 - 0,30 µmol/L 
(11 PM) and < 0,18 µmol/L (11 PM). 
The assays had llqs of 0.25 mU/mL (fsh), 0.6 mU/mL (lh), 0.14 ng/
mL (testosterone), 0.25 ng/mL (prolactin), an intra-assay precision 
(expressed as coefficient of variation) of 0.8-1.8% (fsh), 1.4-2.2% (lh), 
3.3-5.2% (testosterone), 2.8-3.2% (prolactin) and inter-assay precision 
of 1.4-1.6% (fsh), 1.8-2.6% (lh), 2.7-8.6% (testosterone), and 4.5-6.3% 
(prolactin).
Pharmacokinetics
Plasma (K-edta) was centrifuged within 15 minutes after sampling and 
stored at -40 degrees Celsius. Plasma samples were assayed for sch 
900435 using a validated liquid chromatographic method with mass 
spectrometric detection with a lower limit of quantification of 0.1 ng/mL.
of 0.25 Hz. Summary parameters were calculated using the frequency 
bands as defined by Hermann from a factor analysis of human eeg [14]. 
saccadic	and	smooth	pursuit	eye	movements
Saccadic and smooth pursuit eye movements were recorded as described 
previously [3,15,15-17] and have shown dose- and concentration-related 
effects on many different cns active drugs, including gaba-ergic [4,5,18], 
serotonergic [19], noradrenergic [20-22], and dopaminergic drugs [23]. 
adaptive	tracking
The adaptive tracking test has proved to be useful for measurement of 
cns effects of alcohol, various psychoactive drugs and sleep deprivation 
[3,17]. The adaptive tracking test was performed as described earlier and 
can be divided into two tasks: the pursuit and the fitts task [24-26]. 
During the pursuit task, the subject was instructed to keep a dot inside 
a moving circle by operating a joystick. If this effort was successful, the 
speed of the moving circle was increased. Conversely, the velocity was 
reduced if the test subject could not maintain the dot inside the circle. 
The fitts task was to measure quick motor responses and the subject was 
asked to aim at targets with a pen as quickly as possible without missing 
the target. 
body	sway
The body sway meter records body movements in a single plane, providing 
a measure of postural stability. Changes in body sway were seen for many 
different cns active drugs, including gaba-ergic drugs [4,18,27], and thc 
[7] and was performed as previously described [23]. 
pupillometry
Pupil size was included as a measure of autonomic tone and ocular 
function. In the sd study, exploratory pupillometry was performed using 
digital photometry. Twa et al showed that estimation of pupil size by 
digital photography was more repeatable and accurate than estimates  
by common clinical techniques over a wide range of illumination [28]. 
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Appendix II 
Description of pharmacodynamic tests and statistics  
visual effects study
visual	electrophysiology
A series of electrophysiological tests were performed to obtain a com-
prehensive overview of various retinal and pupillary functions. Subjects 
were divided in different groups, to allow investigations under differ-
ent lighting conditions. All eyes were dilated before full field testing 
using tropicamide (1%) and/or phenylephrine hydrochloride (2.5%). 
Measurements were performed according to the standards of the Inter-
national Society for Clinical Electrophysiology of Vision (iscev), as 
described by Marmor and Zrenner (2004) [31] unless cited otherwise. 
One group of subjects was tested under dark conditions, with a number 
of tests that lasted approximately 12 minutes and was repeated every 
25 minutes. Subjects who were examined under dark conditions were 
adapted to the dark for twenty minutes after pupillary dilation, before the 
minimum luminance of a test spot required to produce a visual sensation 
was determined [31]. The full field (‘Ganzfeld’) erg protocol incorporated 
the iscev standard and used a commercial system (retiscan System; 
Roland Consult, Wiesbaden, Germany). Small disc electrodes were placed 
on the skin at the side of the subject’s eye, and corneal soft gold foil 
recording electrodes were placed under red light. Rod specific erg was 
recorded after a single flash. The rod response was identified as the first 
signal measured after dark adaptation. Additional recordings included 
the use of a red flash stimulus [32]. Maximal ergs were recorded after a 
brighter maximal flash (Standard + 0.6LU). 
Another group was examined under light conditions. The duration  
of testing was approximately 20 minutes, in cycles of 25 minutes. These 
subjects also underwent standard iscev ergs after pupillary dilation and 
a standard period and intensity of light adaptation [31]. Cone responses 
The assay had an llq of 0.1 ng/mL, an intra-assay precision (expressed 
as coefficient of variation) of 1.4-6.5% and inter-assay precision of 
2.0-24.6%.
Statistical analysis
For the pd parameters both a general treatment effect and a simple linear 
effect was tested. 
To calculate the treatment effect, aues (Area Under Effect-time curves) 
per subject were calculated with the linear trapezoidal rule using proto- 
col times, and divided by the corresponding time span, resulting in a 
weighted average response. aues of the whole time period, of the period 
0-4 hours and 0-90 minutes (only for pupil size) of the pd variables were 
analyzed with an analysis of variance with fixed factors treatment and 
visit, random factor subject and pre-value as covariate (ancova analysis). 
If the treatment effect was significant, contrasts of all treatments versus 
placebo were calculated. The different time spans of the aucs were chosen 
as there were very fast, short lasting effects and slower, more long lasting 
effects. 
If the treatment effect was significant and the linear effect suggested a 
dose effect relation, an additional regression analysis of the concerning 
parameter on log dose was performed. This was performed by calculating 
the regression of relationship between the change from baseline aues and 
the log10 dose with subject, intercept and slope as random factors and 
visit as fixed factor. Slopes being different from zero were tested with an 
alpha of 0.05 two sided.
Conclusions with respect to dose proportionality/dose independence 
were primarily based on descriptive statistics of pk parameters and on 
summary plots of (dose-normalised-(dn))cmax and (dn-)auc versus dose. 
An additional exploratory Analysis of Variance (anova) was performed on 
dn-cmax, dn-auc, t1/2, (weight-normalised-(wn))Clapp, and (wn-)Vz,app 
and an appropriate non-parametric test on tmax and tlag to test for dose 
proportionality/dose independence. 
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Ring 5, 15.1-28.5˚). The traces within the ring were averaged and the 
amplitude and latency of p1 and n1 from each ring summation was 
analysed.
Colour contrast sensitivity was measured psychophysically by 
determining thresholds along isoluminant protan, deutan, and tritan 
colour confusion axes using the Arden colour contrast sensitivity system 
[37]. Pupillometry was performed using a similar method as described in 
the single ascending dose study (see Appendix I). 
neuroendocrine	effects
See Appendix I single ascending dose study. 
visual	analogue	scales	(vas)
See Appendix I single ascending dose study. This Bond and Lader vas  
was extended with a Bastani mood rating scale [1,2].
Additionally, subjects were given a visual questionnaire to ascertain 
visual symptoms. The questionnaire consisted of eight questions and 
subjects answered whether they agreed or not and if they agreed then 
whether the symptoms were mild or severe. The eight questions were as 
follows:
Your vision is blurred
There appears to be a film over your eyes
You have difficulty assessing how far away objects are
You are seeing flashes of light
You are seeing dark patches 
You are having more difficulty than usual focusing
You would not feel safe driving a car with your vision as it is
Do you have any other visual symptoms or disturbance?
The final question had space for a description of other symptoms if 
present.
Pharmacokinetics
See Appendix I single ascending dose study. 
were measured after a single white flash preceded by background 
illumination to suppress rod function. Under the same conditions 30 Hz 
flicker responses were obtained with repeated single flash stimuli. 
Long duration photopic stimulation was used to record ON and OFF 
erg responses using previously described techniques [33]. In brief, an 
amber stimulus of 120 ms or 200 ms duration (luminance 560 cd/m2) 
was presented upon a bright green background (luminance 160 cd/m2) 
close to peak rod spectral sensitivity and thus suitable to suppress rod 
function. A- and b-waves occur at onset of the flash, and a d-wave at light 
offset. These responses represent different functional pathways of retinal 
rods and cones. Human S-cones mediate the signals of short wavelength 
sensitive cones [34]. S-cone responses were measured using a chromatic 
stimulus erg as described by Yamamoto et al [35]. 
Under photopic conditions, the erg shows an a-wave that arises from 
cones and off-bipolar cells, and a b-wave that originates from on- and 
off-bipolar cells with a possible contribution from Mueller cells. The late 
negative component subsequent to the b-wave is called the photopic 
negative response. This measurement was performed as described by 
Holder et al [36]. 
A third group of subjects was investigated under light conditions with 
undilated pupils. These tests lasted approximately 45 minutes. Flash 
visual evoked potentials (veps) were performed according to the iscev 
standard for clinical vep testing [36]. Pattern erg was recorded using a 
black and white checkerboard stimulus, with 98% contrast and a mean 
luminance of 80 cd/m2. The stimulus frequency was 4.5 reversals/sec. 
The field size was 15˚ x 11˚, with a check size of 45 min. The amplifier 
gain was set to 200•103, band pass filter 1-100 Hz, with a sampling rate 
of 2 kHz. Optimum spectacle correction was used. Fixation was enabled 
by a red central fixation target and the patient’s fixation was monitored 
using cctv (closed circuit television). The amplitude and latency of the 
Perg P50 and N95 components were analysed. The p1 and n1 components 
of the first order kernel of the mferg were analysed using the retiscan 
software. Trace arrays were divided into 5 concentric rings centred on the 
fovea (Ring 1, 0-2.1˚; Ring 2, 1.4-6.7˚; Ring 3, 5.7-12.0˚; Ring 4, 9.5-19.8˚; 
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extracted for the frontal (F3 or F4 channel), central (C3 or C4 channel), 
parietal (P3 or P4 channel) and occipital (O1 or O2 channel) positions at 
pre-dose, 0.5, 1, 2, 4 and 6 h post-dose on Days 5 and 13 and matching 
time points on Day -1. The following variables were recorded:total 
power [µV2], peak power [µV2]; peak frequency [Hz]; mean frequency 
(frequency (1-30 Hz) below which 50 % of total power is located) [Hz]; 
spectral edge (frequency (1-30 Hz) below which 90 % of total power is 
located) [Hz]; vigilance index: (alpha1 + alpha2)/(theta + delta) [ASI]; 
and power [µV2] and centroid frequency [Hz] for the delta (1-4 Hz), theta 
(4-8.5 Hz), alpha1 (8.5-10.5 Hz), alpha2 (10.5-12.5 Hz), beta1 (12.5-18.5 
Hz) and beta3 (21-30 Hz) frequency bands.
cognitive	testing
A battery of tasks from the Cognitive Drug Research (cdr, Goring-
On-Thames, uk) was administered and consisted of the following 
tests (described in [38]): simple reaction time, digit vigilance, choice 
reaction time, spatial working memory, numeric working memory, 
immediate word recall, word recognition, postural stability and tracking. 
Postural stability measures the ability to stand upright without moving 
waist assessed using the cdr meter that was modelled on the Wright 
Ataxiameter [13]. A cord from the meter was attached to the subject who 
was required to stand as still as possible with feet apart and eyes closed for 
one minute. During the tracking test the subject used a joystick to track 
a randomly moving target on the screen for 1 minute. The distance off-
target per second was recorded. 
pupillometry
See Appendix I single ascending dose study. In the multiple (ascending) 
dose study, the pupil size was measured more extensively than in the 
single (ascending) dose study in three different conditions (0.04 lux/
scotopic, 0.4 lux/low mesopic, 4.0 lux/high mesopic) after the subject 
was dark adapted to the room for 5 minutes using a Procyon P2000SA 
Pupillometer (Keeler Instruments, Broomall, Pa.).  
Statistical analysis
Only descriptive and summary statistics were performed for the elec-
trophysiological parameters, hormones, laboratory tests (hematology, 
serum blood chemistry, urinalysis and any urine microscopy) and phar-
macokinetics. An Analysis of Variance (anova) on log-transformed  
pharmacokinetic parameters (for tmax after ranking) with factor group; 
all tests at the 5% level of significance.
Appendix III 
Based on the outcomes of the single ascending dose trial, a selection of 
tests was made for the multiple (ascending) dose study. These measure-
ments were partly targeted at cognitive effects, which were difficult to 
assess in great detail after single doses and to the visual effects that  
were observed after the first administration in man.
visual	analogue	scales	(vas)
See Appendix ii visual effects study. 
pharmaco-electroencephalography
During the multiple ascending dose study, more extensive eeg 
examinations were performed than when the drug was first administered 
to humans. A Walter Graphtek Polygraph System running validated PL 
Windsor acquisition and Fourier analysis software was used to collect 
full 21-lead eegs, including three minutes eyes closed vigilance control 
(primary condition), three minute resting, hyperventilation and photic 
stimulation. Clinical neurophysiologist excluded subjects with clinically 
significant abnormalities at screening, and recordings with persistent 
artefacts. Electrodes were attached according to the international 10-20 
system using similar materials and methods described for the single 
ascending dose study. Data from each subject’s dominant side was 
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Neuroendocrine effects
See Appendix I single ascending dose study (prolactin concentrations 
were not determined in this study). 
Statistical analysis
Only descriptive and summary statistics were performed for the 
parameters of this study except for pharmacokinetics, pharmaco-eeg 
parameters (total power, delta, theta, alpha1, alpha2 and vigilance 
index) and cdr parameters (simple reaction time, digit vigilance, choice 
reaction time, spatial working memory, numeric working memory, 
immediate word recall, word recognition, postural stability and tracking). 
sch 900435 concentrations in plasma and derived pk parameters 
were summarized using descriptive statistics. Analysis of variance, 
to determine time to reach steady state during multiple dosing, was 
conducted using the Helmert contrast transformation on pre-dose 
concentrations. Testing on dose proportionality/independence and 
regimen effects was done using analyses of variance on pk parameters. 
Food-effect testing was based on cmax and auc0-12 of sch 900435. 
Only the primary eeg parameters in both vigilance controlled and 
rested conditions were statistically analysed. Analysis was performed 
separately at each electrode location (frontal, central, parietal and 
occipital). The mixed model described below was used to estimate the 
effect of each dosing regimen (as ratio of placebo, averaged over time on 
each day separately) with 95 % ci. 
For each log-transformed primary pharmaco-eeg parameter, day and 
location separately, a repeated measures analysis model was fitted using 
proc	mixed in sas® Version 8.2 with time-matched log-transformed 
value on Day -1 as baseline covariate and fixed effects terms for time, 
dose and time x dose interaction term. The repeated nature of the data 
on each subject was modelled with autoregressive covariance structure 
[AR(1)]. Data for placebo were pooled across all cohorts (Groups i, ii, 
iii and iv). Since only two subjects received placebo in each cohort, no 
attempt was made to adjust for cohort. Data were included in the model 
from all available time points (0, 0.5, 1, 2, 4 and 6 h) and the difference in 
the average value over post dose time points (i.e. excluding 0 time point) 
of each dosing regimen relative to placebo was estimated with 95 % ci. 
These estimates and confidence limits were back transformed to give 
the effect as a ratio of placebo with 95 % ci. No adjustments for multiple 
comparisons were made since these analyses are considered exploratory. 
The influence of any outliers was explored on the statistical significance of 
results, where necessary.
For the cdr parameters repeated measures analysis of variance (anova) 
was conducted on the ‘difference from baseline’ scores using sas®	proc	
mixed. A pooled placebo treatment was used. Fixed terms were fitted to 
the model for treatment (up to 6 levels), day (2 levels), time (4 levels) and 
the 2-way and 3-way interactions. A random effect of subjects-within-
sequence was fitted to the model. Significance of the interactions was 
tested at the p<0.05 level. The interactions were assessed sequentially, 
highest order first, and non-significant interaction terms were removed 
from the model. Pairwise comparisons of the active treatments and 
placebo were performed to clarify any statistically significant interaction 
effects. 
132	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia 133	 4	–development	of	a	glycine-1	reuptake	inhibitor:	cns	effects	in	healthy	men
Table 3 Contrasts with placebo on dose groups ancova analysis single ascending dose study (reported for 
doses sch	900435 with statistically significant contrasts and higher) 













Pupil/iris ratio right eye 
(0-90 minutes) b
na 20 0.41 0.44 -0.030 0.0145 -0.05 - -0.01
30 0.48 -0.065 <0.0001 -0.09 - -0.04
vas colours (0-4 hours) mm 30 1.45 10.94 -9.48 <0.0001 -13.05 - -5.91
vas dizzy (0-4 hours) mm 12 43.72 49.57 -5.85 0.0170 -10.59 - -1.10
20 50.34 -6.62 0.0388 -12.88 - -0.36
30 52.14 -8.42 0.0118 -14.89 - -1.95
lh (0-final hours) U/L 8 3.04 2.21 0.82 0.0025 0.31 – 1.34
12 2.69 0.35 0.0864 -0.05 – 0.74
20 2.10 0.93 0.0009 0.41 – 1.46
30 1.90 1.14 0.0002 0.58 – 1.70
lh (0-4 hours) U/L 8 2.93 2.17 0.76 0.0335 0.06 – 1.45
12 2.15 0.78 0.0062 0.24 – 1.32
20 1.77 1.16 0.0017 0.46 – 1.86
30 1.58 1.35 0.0003 0.65 – 2.05
fsh (0-final hours) U/L 8 2.91 2.50 0.42 0.0015 0.18 – 0.66
12 2.67 0.25 0.0131 0.06 – 0.45
20 2.63 0.28 0.0301 0.03 – 0.54
30 2.68 0.24 0.1068 -0.05 – 0.52
Testosterone (0-final hours) nmol/L 8 5.88 4.93 0.95 0.0110 0.24 – 1.66
12 5.45 0.43 0.1269 -0.13 – 0.99
20 4.66 1.22 0.0024 0.47 – 1.98
30 5.26 0.62 0.1440 -0.22 – 1.46
eeg alpha2 (0-4 hours) µV 12 3.45 3.35 0.11 0.0449 0.00– 0.21
20 3.28 0.17 0.0099 0.044 – 0.30
30 3.18 0.27 0.0002 0.14 – 0.41
Smooth pursuit  
(0-final hours)
% 8 50.94 58.00 -7.06 0.0172 -12.80 - -1.32
12 54.43 -3.49 0.1195 -7.93 – 0.95
20 51.16 -0.22 0.9397 -6.01 – 5.57
30 57.26 -6.32 0.0433 -12.45 - -0.20
Smooth pursuit (0-4 hours) % 8 50.281 56.17 -5.89 0.0289 -11.14 - -0.64
12 56.37 -6.09 0.0042 -10.14 - -2.04
20 53.00 -2.71 0.3086 -8.01 – 2.59
30 57.50 -7.22 0.0130 -12.85 - -1.60
a. Significant p-values are indicated in bold (lower than 0.05); b. only results for the right eye were shown as these were similar 
to the left eye; c. mm = millimetre; U/L = units / liter; µV = microvolt.  
Table 1 Dosing groups with corresponding sch	900435 (mg) and placebo (p) treatment in single ascending 
dose study 
 
a.	Dosing as originally planned in protocol
Group i Group ii Group iii Group iv Group v
0.5 2.0 8.0 p 8.0 12 18 p 18 27 40 p 40 60 90 p 90 135 p
0.5 2.0 p 8.0 8.0 12 p 18 18 27 p 40 40 60 p 90 90 p 135
0.5 p 2.0 8.0 8.0 p 12 18 18 p 27 40 40 p 60 90 p 90 135
p 0.5 2.0 8.0 p 8.0 12 18 p 18 27 40 p 40 60 90
	
b.	Actual dosing during study
Group i Group ii Group iii Group iv
0.5 1.0 2.0 p 2.0 3.0 5.0 p 5.0 8.0 12 p 12 20 30 p
0.5 1.0 p 2.0 2.0 3.0 p 5.0 5.0 8.0 p 12 12 20 p 30
0.5 p 1.0 2.0 2.0 p 3.0 5.0 5.0 p 8.0 12 12 p 20 30
p 0.5 1.0 2.0 p 2.0 3.0 5.0 p 5.0 8.0 12 p 12 20 30
Table 2 Most frequent Adverse Events single ascending dose study 
Reported aea sch 900435 
dose
Placebo (%) 0.5 mg (%) 30 mg (%) 0.5-30 mg (%) 0.5-30 mg 
+ placebo (%)
n of subjects 16 4 4 16 32
n of aes 10 5 15 85 95
Dizziness 1 (10.0) 0 (0.0) 3 (20.0) 14 (16.5) 15 (15.8) 
Somnolence 2 (20.0) 1 (20.0) 3 (20.0) 13 (3.5) 15 (15.8)
Headache 1 (10.0) 0 (0.0) 0 (0.0) 12 (14.1) 13 (13.7)
Fatigue 2 (20.0) 1 (20.0) 1 (6.7) 8 (9.4) 10 (10.5)
Abnormal vision 0 (0.0) 0 (0.0) 3 (20.0) 6 (7.1) 6 (6.3)
a. Not all aes from each dose are shown for reasons of clarity; there were no relevant differences in these omitted groups 
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Table 5 Results of visual analogue scales in visual effects study - number of subjects responding ‘yes’ to the 
question [number of subjects considering the effect as severe] 
Question/Study time Placebo sch 900435
5 mg 13 mg 20 mg
n 24 24 24 24
Your vision is blurred
Pre-dose 9 [2] 11 [3] 12 [2] 12 [2]
1.5 hours post-dose 7 10 [1] 16 [1] 14 [1]
8 hours post-dose 0 1 0 1
There appears to be a film over your eyes
Pre-dose 1 2 2 1
1.5 hours post-dose 1 2 3 3 [1]
8 hours post-dose 0 0 0 0
You have difficulty assessing how far away objects are
Pre-dose 2 1 2 2
1.5 hours post-dose 2 2 3 [1] 8 [1]
8 hours post-dose 0 0 0 0
You are seeing flashes of light
Pre-dose 0 0 0 0
1.5 hours post-dose 0 0 5 [1] 7 [1]
8 hours post-dose 0 0 0 0
You are seeing dark patches
Pre-dose 0 0 0 0
1.5 hours post-dose 0 0 2 [1] 3 [1]
8 hours post-dose 0 0 0 0
You are having more difficulty than usual focusing
Pre-dose 7 [1] 11 [2] 8 7 [1]
1.5 hours post-dose 6 7 [1] 14 [1] 10 [1]
8 hours post-dose 1 2 1 1
You would not feel safe driving a car with your vision as it is
Pre-dose 5 [1] 4 3 5
1.5 hours post-dose 4 6 11 [1] 12 [1]
8 hours post-dose 3 1 0 1
Do you have any other visual symptoms or disturbance?
Pre-dose 0 0 0 0
1.5 hours post-dose 0 0 2 [1] 3 [1]
8 hours post-dose 1 1 0 0
Table 4 Regression analysis table of dose-linearity single ascending dose study 
Parameter Unitb p-value slopea Estimate of the slope 95% CI
Log pupil/iris ratio right eye (0-90 minutes) na 0.573 0.004 0.017 / -0.010
Log vas colours (0-4 hours) na 0.157 0.081 0.198 / -0.035
vas dizzy (0-4 hours) mm 0.062 2.302 4.722 / -0.119
lh (0-final hours) U/L 0.032 -0.356 -0.031 / -0.682
lh (0-4 hours) U/L 0.004 -0.501 -0.164 / -0.838
fsh (0-final hours) U/L 0.020 -0.193 -0.042 / -0.344
Testosterone (0-final hours) nmol/L 0.012 -0.424 -0.101 / -0.747
eeg alpha2 (0-4 hours) mV 0.142 -0.053 0.020 / -0.126
Smooth pursuit (0-4 hours) % 0.001 3.305 5.125 / 1.485
a. Statistically significant p-values (lower than 0.05) are indicated in bold;	b. na = not applicable; mm = millimetre;  
U/L = units / liter; mV = microvolt.   
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Table 8 Number of subjects (%) with aes possible or probably related to sch	900435 for ‘eye disorders’ and 
‘cns disorders’ in the multiple (ascending) dose study  
Treatmenta
Placebo 4mg q.d. 8mg q.d. 16mg q.d. 12mg b.i.d. Dose 
titration
n=10 n=6 n=6 n=6 n=6 n=6
Eye disorder
Accommodation disorder 0 0 0 0 1 (17) 0
Eye pain 0 0 0 0 0 2 (33)
Eyelid irritation 0 0 0 1 (17) 0 0
Ocular discomfort 0 0 0 0 1 (17) 0
Photopsia 0 0 0 3 (50) 0 1 (17)
Vision blurred 0 0 1 (17) 5 (83) 2 (33) 4 (67)
Visual disturbance 0 0 1 (17) 3 (50) 2 (33) 1 (17)
Central Nervous System disorders
Balance disorders 0 0 0 0 1 (17) 0
Coordination abnormal 0 0 0 2 (33) 0 0
Dizziness 1 (10) 0 1 (17) 3 (50) 2 (33) 5 (83)
Dizziness postural 0 0 1 (17) 3 (50) 3 (50) 2 (33)
Headache 2 (20) 0 0 1 (17) 3 (50) 2 (33)
Lethargy 0 0 0 2 (33) 2 (33) 6 (100)
Memory impairment 0 0 0 0 0 1 (17)
Somnolence 1 (10) 0 0 4 (67) 1 (17) 3 (50)
Tremor 1 (10) 0 0 0 0 0
Tunnel vision 0 0 0 1 (17) 0 0
a. q.d. = once daily; b.i.d. = twice daily
Table 6 Treatment groups multiple (ascending) dose study 
 
Dose group Treatment	a,c Study day b
1 2 3 4 5 6 7 8 9 10 11 12 13
1 4 mg o.d. x x x x x x x x x X x
2 8 mg o.d. x x x x x x x x x X x
3 16 mg o.d. x x x x x x x x x X x
4 12 mg o.d. x
12 mg b.i.d x x x x x x x x X
16mg o.d. x
5 (dose titration) 8 mg b.i.d x x x
12 mg b.i.d x x x
16 mg b.i.d x x x
20 mg b.i.d x x X
30 mg o.d. x
a o.d. = once daily; b.i.d. = twice daily; b x = dose administered; c doses for groups 4 and 5 were determined following blinded 
review of the data for groups 1 to 3
Table 7 Study design pharmacodynamic measurements multiple (ascending) dose study 
Days
Assessment -1 1 2 3 4 5,7,9,11 6,8,10 12 13 14 15
Visual assessments On medical need only
sch 900435 dosing X X X X X X X X
Pharmaco eeg X	a Day 5 a Xd
lseq X X X X
vas, pupillometrya X X Day 7 X X
Visual questionnaire a X X X X X X X X
lh, fsh, testosterone b X X X X X
pk sampling c X X X X X X X X X X
Cognitive Test batteryd X X X
a	Pre-dose and 0.5, 1, 2, 4 and 6 hours post-dose; b Groups I-IV only: Days 1, 3, 6, 8, 10, 13: pre-dose, 2, 6 and 12 h post-dose; 
Day 15:pre-dose; c PK sampling times were frequent pre-dose and post-dose and were different depending on the treatment 
group; d Pre-dose and 1, 4 and 6 hours post-dose (in the morning).
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Figure 3 Average graph of aue change from baseline 0-4 hours vas Colours by log dose (standard deviations 
as error bars) in single ascending dose study
Figure 4 Adjusted (for baseline) mean time profile of different doses of vas Colours with 95% CI for highest 










































































Figure 1 Structural formula of sch	900435
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Figure 7 Mean changes from baseline lh values against time following administration of sch	900435 or 
placebo in multiple ascending dose study
Day 1 Day 6 Day 8 Day 10 Day 13
Treatment Placebo 4 mg od 8 mg od
























Figure 5 Adjusted (for baseline) mean time profile of different doses of LH with 95% CI for highest dose and 
lower 95% CI for lowest dose in single ascending dose study.
Figure 6 Average graph of aue change from baseline 0-90 minutes pupil/iris ratio right eye by log dose 
(standard deviations as error bars) in single ascending dose study
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Abstract 
In this study the effects of r213129, a selective glycine transporter  
1 inhibitor, on central nervous system function were investigated in 
healthy males in the absence and presence of scopolamine. This was  
a double-blind, placebo-controlled, 4-period crossover ascending  
dose study evaluating the following endpoints: body sway, saccadic and 
smooth pursuit eye movements, pupillometry, electroencephalography, 
visual analogue scales for alertness, mood, calmness and psychedelic 
effects, adaptive tracking, finger tapping, Visual and Verbal Learning 
Task, Stroop test, hormone levels and pharmacokinetics. r213129 dose 
levels were selected based on exposure levels that blocked the GlyT1 
sites >50% in preclinical experiments. Forty-three of the 45 included 
subjects completed the study. Scopolamine significantly affected almost 
every central nervous system parameter measured in this study. r213129 
alone compared with placebo did not elicit pharmacodynamic changes. 
r213129 had some small effects on scopolamine-induced central nervous 
system impairments. Scopolamine-induced finger tapping impairment 
was further enhanced by 3 mg r213129 with 2.0 taps/10 seconds (95% 
ci -4.0, -0.1), electroencephalography alpha power was increased by 10 
mg r213129 with respectively 12.9% (0.7, 26.6%), scopolamine-induced 
impairment of the Stroop test was partly reversed by 10 mg r213129 with 
59 milliseconds (-110, -7). Scopolamine produced robust and consistent 
effects in psychomotor and cognitive function in healthy volunteers.  
The most logical reason for the lack of r213129 effects seems to be that 
the central nervous system concentrations were too low. The effects of 
higher doses in healthy volunteers and the clinical efficacy in patients 
remain to be established. 
Introduction 
It has been proposed that hypofunction of the glutamatergic system,  
and specifically a hypofunction of N-methyl-D-aspartate (nmda) recep-
tor-mediated neurotransmission, contributes to the pathophysiology 
of schizophrenia (Javitt, 2006; Stone et al, 2007). If schizophrenic symp-
toms are the result of diminished functioning N-methyl-D-aspartate 
(nmda) receptors, stimulation of the nmda receptors might be a possible 
mechanism for new schizophrenia medication. 
As direct agonists of nmda receptors are neurotoxic (Stone et al, 2007), 
indirect ways to enhance receptor function have been investigated  
(Javitt, 2002). One way to indirectly augment nmda receptor function  
is through facilitation by glycine, an obligatory co-agonist for glutamate 
at the nmda receptor (Javitt, 2006). So far, explorative clinical trials using 
glycine enhancement strategies have shown (modest) improvements in 
positive and negative symptoms and cognitive function in schizophrenic 
patients (Go¬ et al, 1999; Go¬ and Coyle, 2001; Javitt, 2006; Lane et al, 
2005). However, gram-level doses of glycine are needed to significantly 
elevate central nervous system (cns) concentrations. Inhibition of 
presynaptic glycine reuptake may be a more e~cient way to increase 
pharmacological glycine activity in the brain (Kemp and McKernan, 
2002). 
The action of glycine is essentially terminated by rapid reuptake, 
mediated by at least two glycine transporters, glycine transporter 1 
(GlyT1) and glycine transporter 2 (GlyT2) (Aragon and Lopez-Corcuera, 
2003). As the distribution of GlyT1 overlaps with that of nmda receptors 
(Smith et al, 1992) and electrophysiological studies have shown that 
the responses of nmda receptors are enhanced after inhibition of GlyT1 
(Aragon and Lopez-Corcuera, 2005), it is suggested that GlyT1 is involved 
in nmda activity. Glycine reuptake inhibitors have been e¬ective in a 
variety of schizophrenia animal models (Chen et al, 2003; Depoortere et al, 
2005; Harsing et al, 2003; Javitt et al, 1999; Le Pen et al, 2003) and several 
have recently entered early phase clinical trials in humans. To date, a few 
of the clinical trials studying the glycine reuptake inhibitor sarcosine 
in schizophrenia have been published and show e¬ects on positive and 
negative symptoms (Lane et al, 2005; Tsai et al, 2004). The disadvantage 
of sarcosine is that it is a low potency antagonist that also requires gram-
level dosing. Therefore other selective, more potent glycine reuptake 
inhibitors may be more e~cient. 
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r213129 (see Figure 1 for the structural formula) is a selective inhibitor 
of the GlyT1 and it is hypothesized to have beneficial e¬ects on positive 
and negative symptoms and cognitive performance of patients with 
schizophrenia (Go¬ et al, 1999; Go¬ and Coyle, 2001; Javitt, 2006; Lane  
et al, 2005). 
Preclinical studies have supported the potential therapeutic value  
of this compound (Johnson & Johnson, data on file). r213129 appeared 
more potent than sarcosine, evidenced by a lower ic50, and increased 
extracellular glycine levels in the prefrontal cortex in rats and glycine 
levels in the cerebrospinal fluid in dogs. r213129 also had e~cacy 
in preclinical models for schizophrenia. It normalized the disturbed 
prepulse inhibition paradigm in dopamine transporter knockout mice 
and decreased amphetamine-induced hyperactivity in rats with neonatal 
lesions of the hippocampus. Furthermore, a reduction of the potentiation 
of amphetamine-induced dopamine release in the prefrontal cortex of 
rats receiving phencyclidine was detected. In animal models, e¬ects on 
cognition were inconsistent. 
Three doses of r213129 (3, 10 and 30 mg) were used in this study 
based on exposure levels that block the GlyT1 site for more than 50% 
(data on file). In previous clinical studies, r213129 was well tolerated in 
healthy men in single and multiple doses up to 50 mg. The main focus 
of these studies was to test the tolerability and pharmacokinetics of 
the compound, although some cns e¬ects were evaluated. No clear or 
consistent pharmacodynamic changes in the electroencephalography 
and cognitive function tests following single doses of 1, 3, 10, 30, and  
50 mg and multiple dose administration of 10, 30 and 50 mg r213129 
were measured in these studies. 
As Tsai et al and Lane et al have shown that the glycine reuptake 
inhibitor sarcosine has e¬ects on positive and negative symptoms and 
cognitive function in schizophrenia (Lane et al, 2005; Tsai et al, 2004), 
the hypothesis is that r213129 may also have e¬ects on these symptoms. 
Since it is not possible to detect changes in positive and negative 
symptoms in healthy volunteers and to evaluate the positive e¬ects 
on cognitive function in subjects already performing at their maximal 
capacity, cns biomarkers have been studied in healthy subjects (in the 
absence and presence of the scopolamine model). By using a battery of 
quantitative cns tests sensitive to several cns-active drugs (De Visser et 
al, 2001b, 2003; Gijsman et al, 2002; Kemme et al, 2003; Van der Post et 
al, 2004), evidence for cns brain penetration can be shown, and a global 
impression of the e¬ects of r213129 could be obtained. In addition, to 
get an indication of potential pro-cognitive e¬ects of r213129 in healthy 
men, scopolamine was used to induce a transient and reversible thought 
and memory disturbance. Although the scopolamine model does not 
capture the complexity of cognitive decline in human psychopathology, 
it has become the most frequently used model for studies of cognitive 
impairment in experimental animals and healthy volunteers (Broks et al, 
1988; Hall et al, 1990; Riedel and Jolles, 1996; Vitiello et al, 1997). 
A methodological disadvantage of the model is the sedation induced 
by scopolamine possibly contributing to the impairment of memory and 
cognition. However, in many studies measures of sedation of scopolamine 
were unrelated to the adverse e¬ect on memory (Bartus et al, 1982; Caine 
et al, 1981; Curran et al, 1991; Drachman and Leavitt, 1974; Kopelman 
and Corn, 1988), and no cognitive impairment was produced by, for 
example, lorazepam in a dose inducing similar sedation as scopolamine 
(Sunderland et al, 1989). Moreover, stimulant drugs that were added to 
scopolamine were unable to reverse the scopolamine-induced cognitive 
impairment (Bartus, 1978; Drachman, 1977; Martinez et al, 1997), whereas 
cholinergic agents were (Ghoneim and Mewaldt, 1977). 
In primates, an interaction between cholinergic and glutamatergic 
systems on cognitive function has been demonstrated (Matsuoka and 
Aigner, 1996a, b; Sirvio et al, 1992). The exact mechanism behind this 
interaction has not been resolved, but suggestions have been made.  
One is that glycine would increase acetylcholine release in certain neuro-
nal tissues (Fishkin et al, 1993; Matsuoka and Aigner, 1996b). Another is 
the presence of nmda receptor sites on cell bodies of cholinergic neurons 
and a subsequent increased acetylcholine release by glycine (agonists) 
due to depolarization of the receptor (Fishkin et al, 1993; Matsuoka and 
Aigner, 1996b). Various other preclinical experiments have demonstrated 
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a reversal of scopolamine-induced impairments using agonists for the 
glycine site on the nmda receptor (Andersen et al, 2002; Kishi et al, 1998; 
Zajaczkowski and Danysz, 1997). To the best of the authors’ knowledge 
there is only one study in healthy volunteers with the partial glycine site 
agonist, D-cycloserine, showing significant improvement of scopol-
amine-induced memory impairment (Jones et al, 1991). 
Therefore in this study, the objectives were to study the cns profile of 




A total of 45 male subjects aged 18-55 with body mass index (bmi) of 
18-28.5 kg/m2 were recruited by the Centre of Human Drug Research. 
After signing an informed consent, subjects were medically screened 
within three weeks prior to study participation. Exclusion criteria included 
the use of agents known to a¬ect cns performance (including nicotine, 
drugs or alcohol) and evidence of relevant clinical abnormalities. The use 
of medication and the above-mentioned agents were not allowed during 
the study period. The Ethics Review Board of the Leiden University Medical 
Centre approved the study protocol. 
Study design 
This study was a double-blind, placebo-controlled, four-period crossover 
ascending dose study. The periods were separated by a washout period of 
at least one week. 
Drugs 
Scopolamine 0.5 mg or placebo was given intravenously over a period 
of 15 minutes starting at T= 0 and 3, 10, or 30 mg of r213129 or placebo 
was orally administered at T = 0.5 hours. The four treatments were 
scopolamine+placebo, scopolamine+one dose of the novel compound, 
placebo+placebo and placebo+one dose of the novel compound, with 
washout periods of at least one week. Each treatment group consisted  
of 15 subjects. 
Safety 
Adverse events, electrocardiogram (ecg), body temperature, blood 
pressure and heart rate measurements were performed throughout  
the study. ecgs were assessed using Cardioperfect ecg recorder (Welch 
Allyn). Blood pressure and heart rate were measured using an auto mated 
device (Nihon Kohden, Life Scope ec, Tokyo, Japan). 
Pharmacodynamics 
Eleven blocks of pharmacodynamic (pd) measurements were 
performed: pre-dose (twice before scopolamine administration)  
and 0.75, 1.0, 1.5, 2.0, 2.5, 3.5, 4.5, 6.5 and 8.5 hours post-dose.  
Average baseline values for each variable were obtained by calcu - 
lation of the mean of two baseline assessments. Pharmacodynamic  
tests were performed in a quiet room with ambient illumination 
with only one subject in the same room per session. Tests were 
performed in the following order: body sway, saccadic eye move-
ments, smooth pursuit measurement, pupillometry, pharmaco-
electroencephalography (eeg), visual analogue scale (vas) Bond & 
Lader, vas Bowdle, adaptive tracking, finger tapping, Stroop test, and 
Visual and Verbal Learning Task (vvlt). Blood for hormones (follicle-
stimulating hormone (fsh), luteinizing hormone (lh), and prolactin) 
was taken regularly from four minutes until 24 hours after scopolamine 
administration. Subjects had a standardized breakfast one hour before 
scopolamine administration. All subjects were thoroughly trained and 
familiarized with the psychometric tests within 14 days preceding study 
start to minimize learning e¬ects during the study. 
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adaptive	tracking
The adaptive tracking test has proved to be useful for measurement of cns 
e¬ects of alcohol, various psychoactive drugs and sleep deprivation (Van 
Steveninck et al, 1991, 1993). The adaptive tracking test was performed as 
originally described by Borland and Nicholson (Borland and Nicholson, 
1984) using customized equipment and software. Adaptive tracking is 
a pursuit-tracking task with a circle moving randomly on a computer 
screen. The subject must try to keep a dot inside the moving circle by oper-
ating a joystick. If this e¬ort is successful, the speed of the moving circle 
increases. Conversely, the velocity is reduced if the test subject cannot 
maintain the dot inside the circle. The average performance and the stan-
dard deviation of scores over a 3.5-minute period were used for analysis, 
including a 0.5 minute run-in time, during which data were not recorded. 
body	sway
Changes in body sway have been seen for many di¬erent cns active drugs, 
including gaba-ergic drugs (De Haas et al, 2007, 2008; De Visser et al, 
2003) and thc (Zuurman et al, 2008). The body sway meter records body 
movements in a single plane, providing a measure of postural stability. 
Body sway was measured with an apparatus similar to the Wright 
ataxiameter (Wright, 1971). With a string attached to the waist, all body 
movements over two minutes were integrated and expressed as mm sway 
on a digital display. The contribution of vision to postural control was 
eliminated by asking subjects to close their eyes. Subjects were instructed 
to wear the same pair of comfortable, low-heeled shoes on each session. 
Before starting a measurement, subjects were asked to stand still, with 
their feet approximately 10 cm apart and their hands in a relaxed position 
alongside the body. 
finger	tapping
The finger tapping test was adapted from the Halstead Reitan Test Battery 
(Andrew, 1977). The test evaluates motor activation and fluency. Speed of  
finger tapping was measured for the index finger of the dominant hand 
and a session contained five performances of 10 seconds. The volunteer 
was instructed to tap as quickly as possible on the space bar of a com-
puter. The mean tapping rate and the standard deviations were used  
for statistical analysis. 
saccadic	and	smooth	pursuit	eye	movements
Saccadic and smooth pursuit eye movements have shown dose-and 
concentration-related e¬ects on many di¬erent cns-active drugs, 
including gaba-ergic (De Haas et al, 2007, 2008; De Visser et al, 2003), 
serotonergic (Gijsman et al, 2002), noradrenergic (De Visser et al, 2001b; 
Kemme et al, 2003; Van der Post et al, 2004), and dopaminergic drugs 
(chdr, data on file) which were recorded as described previously (Van 
Steveninck, 1994; Van Steveninck et al, 1993, 1996, 1997, 1999). Average 
values of saccadic peak velocity (spv), latency (= reaction time) and 
inaccuracy were calculated for all artefact-free saccades. The average 
percentage of smooth pursuit for all stimulus frequencies was used as 
response parameter. 
pharmaco-electroencephalography
Pharmaco-eeg was performed as a general measure of cns activity  
(Cohen et al, 1985). The literature suggests that antipsychotics show 
distinct profiles of eeg changes (Sobczak et al, 2003; Wright, 1971). 
Pharmaco-eeg was measured as previously described (De Haas et al, 
2008). Fast Fourier transform analysis was performed to obtain the  
sum of amplitudes in the delta-(0.5-3.5 Hz), theta (3.5-7.5 Hz),  
alpha-(7.5-11.5 Hz) and beta-(11.5-30 Hz) frequency ranges.  
The square root of the total power (in µV) was analysed. 
visual	and	verbal	learning	task
At chdr the vvlt test has shown the cns e¬ects of various compounds 
such as benzodiazepines (De Visser et al, 2003), antidopaminergic 
(De Visser et al, 2001a), and cannabinoid drugs (Zuurman et al, 2008). 
Memory function (impairment) includes di¬erent aspects of learning 
behaviour, i.e. acquisition, consolidation, storage and retrieval. The vvlt 
(Schmitt et al, 2000) contains three di¬erent subtests that cover most 
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of these memory components, i.e. immediate and delayed word recall 
and a delayed word recognition. This test is an adapted version of the 
Auditory Verbal Learning Test (Rey, 1964) with an increased number of 
items to reduce ceiling e¬ects. Thirty words are presented in the same 
sequence in three trials on a computer screen. Each trial ends with a 
free recall of the words (immediate recall). Thirty minutes after the 
first trial, the subject is requested to recall as many words as possible 
(delayed recall). This is followed by a recognition test, consisting of 15 
previously presented words and 15 other but comparable words, in which 
the subject has to respond ‘Yes/No’ as quickly as possible to indicate 
recognition of the word (delayed recognition). Outcome variables for the 
immediate and delayed word recall were the average and the maximum 
number of correct responses. For the delayed word recognition, the 
number of correct items and mean response time for correct responses 
were analysed. 
stroop	test
The Stroop e¬ect is helpful in understanding attention, perception 
and reading as well as the cognitive and neural mechanism of mental 
inhibition, interference and controlled versus automatic processing 
(Stroop, 1935). Individual di¬erences in the degree of Stroop interference 
are considered to be among the most reliable or stable measures (Laeng 
et al, 2005). Two single-trial computerized versions of the classic colour-
word Stroop tasks are presented to the test subjects. In the first trial, 
20 coloured items are presented at random. The subjects are asked to 
respond as quickly and as accurately as possible by pressing the keys 1, 
2 or 3 on the number pad with the index finger, middle finger and ring 
finger of the dominant hand, corresponding with the correct answer. 
In the second trial, directly after the first trial, 20 colour and word pairs 
are presented randomly to the subject, forming either congruent or 
incongruent matches. The subjects are again asked to respond as fast as 
possible by pressing the keys 1, 2 or 3 on the number pad, corresponding 
with the correct answer. Three colours are shown, which are green, red 
and blue. The coloured items are presented in a random order. The words 
that are used are ‘Rood’ (red), ‘Groen’ (green) and ‘Blauw’ (blue). The 
outcome parameters are the number of correct answers and the reaction 
time in both the basic and conflict situation.  
visual	analogue	scales
The Bond and Lader vas was performed to measure subjective alertness, 
mood and calmness and the Bowdle vas of psychedelic e¬ects to evaluate 
psychedelic e¬ects. These were performed as previously described (De 
Haas et al, 2008). The psychedelic e¬ects measured by the vas Bowdle 
cluster into two distinct total sum scores: internal perception (reflects 
inner feelings that do not correspond with reality, including mistrustful 
feelings); and external perception (reflects a misperception of an external 
stimulus or a change in the awareness of the subject’s surroundings) 
(Zuurman et al, 2008). The Bowdle vas was expanded with an additional 
subscore for ‘feeling high’. 
pupillometry
Estimation of pupil size by digital photography is more repeatable and 
accurate than estimates by common clinical techniques over a wide range 
of illumination (Twa et al, 2004). Pupil diameter was determined using 
a digital camera (Canon PowerShot A620). After at least five minutes 
adaptation in ambient lighting, the subject was instructed to look into 
the lens. A sharp picture of the eyes was taken using a single flash. The 
program Qpupil (designed by the ‘Division of Image Processing (lkeb)’, 
Leiden University Medical Center, the Netherlands) automatically analy-
ses the ratio between the diameter of the iris and the pupil of both eyes. 
hormones
Blood samples for lh, fsh and prolactin were collected and kept 
at room temperature for at least 15 and maximally 60 minutes 
before storage. The hormones were analysed by the Central Clinical 
Chemistry Laboratory (Leiden University Medical Center) using an 
electrochemiluminescence-immunoassay (eclia) for prolactin, and  
a fluoroimmunoassay for lh and fsh. 
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Pharmacokinetics 
r213129
Blood samples (5 ml) for plasma concentrations of r213129 were drawn 
pre-dose, and at 1.0, 1.5, 2.0, 2.5, 3.5, 4.5, 8.5, 10 and 24 h post dose. 
Samples were protected from light at all times to prevent degradation 
of the compound. Plasma samples were analysed to determine r213129 
concentrations using a validated, selective and sensitive liquid lc-ms/ms 
method (Lower Limit Of Quantification (lloq) = 1 ng/ml). r213129 was 
performed by the Department of Bioanalysis, j&j	prd, Belgium. 
scopolamine	
Blood samples (4 ml) for plasma concentrations of scopolamine were 
drawn at 0.5, 0.75, 1.0, 2.5, 6.5 h after the scopolamine infusion was 
stopped. Samples were protected from light at all times. Plasma samples 
were analysed to determine scopolamine concentrations using a vali-
dated, selective and sensitive liquid lc-ms/ms method (lloq = 10 pg/ml). 
Scopolamine bioanalysis was performed by Pharma Bio-Research Group 
b.v.,	Zuidlaren, the Netherlands. 
Statistical analysis
pharmacodynamics
pd parameters were analysed by mixed model analyses of variance (using 
sas	proc	mixed) with treatment, period, time and treatment by time as 
fixed e¬ects, with subject, subject by time and subject by treatment as 
random e¬ects, and with the baseline value as covariate, where baseline 
is defined as the average of the available values obtained prior to dosing. 
This resulted in ls means estimates that indicate the change from baseline 
where baseline in the graph is set at 0 for t = 0 min. Treatment e¬ects were 
reported as the contrasts between placebo and scopolamine, where the 
average of the measurements up to and including 8.5 hours (22 hours for 
neuroendocrine parameters) were calculated within the statistical model. 
Contrasts were reported along with 95% confidence intervals and analyses 
were two-sided with a significance level of 0.05. 
pharmacokinetics
Summary statistics of the plasma concentration data and estimated phar-
macokinetic parameters for r213129 and scopolamine were calculated. 
The following pharmacokinetic parameters for r213129 and scopolamine 
were determined using Pharsight’s WinNonlin pharmacokinetic analysis 
software (version 4.0.1): cmax,C0.5h (scopolamine), tmax, auclast, auc∞, 
t1/2 term., cl/f (r213129), and cl (scopolamine). 
Results 
Subject characteristics 
Forty-three of the 45 included healthy male subjects completed the study. 
Two subjects decided to stop participation of the study. For one subject the 
reason for withdrawal was non-compliance. The other subject experienced 
a vasodepressive reaction after both scopolamine administrations. 
Subjects were on average 29.0 years old (range: 18-55). 
Clinical effects 
Scopolamine induced well-characterized anticholinergic e¬ects 
(increased pupil size, dry mouth, drowsiness, and impaired eye focusing) 
in 42 of the 44 subjects. Another reported e¬ect was nausea in six of the 
44 subjects. r213129 at all doses of 3, 10, and 30 mg was comparable with 
placebo in its adverse e¬ects profile. 
Pharmacokinetic results 
The mean concentration-versus-time profile of r213129 for 3 mg is 
presented in Figure 2. For all doses of r213129, peak concentrations of 
around 200, 500, and 1400 ng/ml for the respective doses were reached 
between two and four hours after dosing, and the terminal elimination 
half-life was between 12 and 15 hours. Clearance was between 1.2 and 
1.5 l/h. Pharmacokinetics were dose-linear for the tested doses. When 
combined with scopolamine, the pharmacokinetic profile was slightly 
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altered for some parameters due to an anticholinergic delay of stomach 
emptying. After combination with scopolamine the area under curve (auc) 
of 3 mg r213129 changed from approximately 3400 to 3800, of  
10 mg from 9300 to 11000, and of 30 mg from 26500 to 32000 ng h/ml. 
The scopolamine concentration 0.5 hours after the end of dosing 
(with and without r213129) varied between 1200 and 1300 pg/ml and the 
terminal elimination half-life between 1.4 and 1.6 hours. Clearance was 
around 190 l/h. Scopolamine was not a¬ected by the addition of r213129. 
Pharmacodynamic results 
scopolamine
Scopolamine resulted in a considerable number of cns e¬ects and a¬ected 
almost every parameter measured in this study (Table 1 shows a selection 
of results, as the complete report is shown in another article describing the 
pk-pd of scopolamine). Scopolamine deteriorated adaptive tracking, body 
sway and finger tapping rate performance compared with placebo. Both 
saccadic peak velocity and smooth pursuit performance decreased after 
scopolamine compared with placebo. 
Alpha and beta power (Fz-Cz and Pz-Oz) decreased after scopolamine 
compared with placebo. Delta power (Fz-Cz and Pz-Oz) after scopolamine 
was statistically significantly higher than after placebo. Theta power (Fz-
Cz and Pz-Oz) after scopolamine did not di¬er significantly from placebo. 
Scopolamine deteriorated all parameters of the vvlt: delayed word recall 
(number correct), immediate word recall (number correct), and delayed 
word recognition (both number correct and reaction time). Similarly, all 
parameters of the Stroop test were deteriorated compared with placebo 
(number correct or reaction time and basic situation or conflict situation). 
vas alertness was significantly lower after scopolamine than after 
placebo, vas calmness was higher, and vas mood was not changed by 
scopolamine. vas results of internal perception, external perception and 
feeling high were all higher after scopolamine. 
All measured hormone levels increased after scopolamine compared 
with placebo, as did pupil size. 
r213129
r213129 alone compared with placebo did not show pharmacodynamic 
changes on any of the parameters in this study.  
r213129	and	scopolamine
r213129 had some small e¬ects on scopolamine-induced cns impairment 
(see Table 1). Scopolamine-induced finger tapping impairment was 
further impaired by 3 mg r213129 with 2.0 taps/ 10 seconds (95% ci 
-4.0, -0.1). eeg alpha power (Fz-Cz and Pz-Oz) statistically significantly 
increased with, respectively, 12.9% and 16.0% after the combination 
of 10 mg r213129 and scopolamine compared with scopolamine alone 
(respectively, 95% ci 0.7, 26.6% and 0.3, 34.2%). The scopolamine-
induced impairment of the number of correct Stroop responses (in the 
conflict situation) was reversed by 3 mg r213129 with 0.6 items (95% ci 
0.0, 1.1). The scopolamine-induced impairment of the reaction time  
(in the con flict situation) was partly reversed by 10 mg r213129 with  
59 milliseconds (95% ci -110, -7). r213129 had no significant impact  
on the scopolamine e¬ects at a dose of 30 mg. 
Discussion 
In this study the cns e¬ects of the new glycine reuptake inhibitor  
r213129 were investigated using a battery of quantitative cns tests, 
sensitive to classic neuroleptic agents and other cns-active drugs.  
As this study was performed in healthy volunteers, a scopolamine model 
was used to examine the potential reversal of cognitive impairments 
by r213129. Based on experiments with the partial glycine agonist 
D-cycloserine in animals (Andersen et al, 2002; Kishi et al, 1998; 
Zajaczkowski and Danysz, 1997) and healthy subjects (Jones et al, 1991),  
it was hypothesized that scopolamine-induced (cognitive) deficits would 
be reversed by r213129. 
This study found that scopolamine produced very robust and consistent 
e¬ects in healthy volunteers, across a wide range of cns functions. Most 
of the cns impairments of scopolamine were expected, and are in line 
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with those observed in previous studies (Ebert and Kirch, 1998; Ebert et 
al, 1998, 2001; Renner et al, 2005). However, we are unaware of previous 
reports of increases in the gonadotrophic hormones lh and fsh after 
anticholinergic agents. We also found an increase in prolactin, which  
has previously been found by Benkert et al (1981) using the anticholinergic 
agent biperiden. Most e¬ects disappeared after eight hours, except 
for pupil size increases, which were still detectable at the end of each 
scopolamine occasion. 
r213129 did not have any cns e¬ects on its own in this study. Since we 
have been unable to find reports on other glycine reuptake inhibitors in 
healthy volunteers, it is di~cult to interpret whether this lack of e¬ects 
is due to insu~cient brain penetration, low pharmacological activity, or 
absence of physiological changes during glycine reuptake inhibition in 
healthy humans. There may also be methodological reasons that pre-
cluded us from detection of small cns e¬ects, although in our experience 
almost all cns-active drugs have some impact on the tests that we used in 
this study (De Haas et al, 2007; De Visser et al, 2001b; Kemme et al, 2003; 
Van der Post et al, 2004; Van Steveninck et al, 1991; Zuurman et al, 2008). 
Our study showed some modifications of the e¬ects of scopolamine, 
but these were small and did not seem consistent. Three tests showed 
statistically significant changes, some of which could be qualified as 
improvements and others as deteriorations. r213129 slightly reversed 
some aspects of scopolamine-induced cognitive deterioration on the 
Stroop test and the scopolamine-induced reduction in alpha eeg power, 
which might be indicative for improved alertness, but motor impairment 
(finger tapping rate) was slightly worsened. In addition, the e¬ects were 
not consistently dose-related in the 3-30 mg dose range. 
Several reasons for these marginal e¬ects should be considered. 
The most likely explanation could be that the doses of r213129 did not 
adequately cover the dose-response curve. Three di¬erent doses of 
r213129 were investigated in this study. If r213129 had a bell-shaped 
dose-response curve, which was also suggested by other studies with 
D-cycloserine (Andersen et al, 2002; Jones et al, 1991), the selected 
dose levels could in part have been too high. However, the small and 
non-dose-related e¬ects that were observed in this study could also 
suggest an indication of very early cns changes that were too small and 
hence too variable to consistently exceed the detection limit. r213129 
showed a limited blood-brain barrier penetration, which could increase 
the variability of its cns e¬ects in the low 3-30 mg dose range. 
In this case, (considerably) higher doses may lead to both larger and more 
consistent e¬ects, provided that the brain penetration increases  
at a higher dose range. 
Another possible explanation for the lack of consistent e¬ects is that 
the scopolamine model in healthy subjects may have been unsuitable,  
or the impact of scopolamine may have been too strong to pick up 
possible cognition-enhancing properties of r213129. Considering the 
clear e¬ect of scopolamine on all parameters of this study, the 0.5 mg 
dose could possibly have been too high and may have overshadowed  
any possible r213129 e¬ects, particularly if these were small. The 0.5 mg 
dose of scopolamine was selected based on an earlier study of Ebert et al, 
showing that an intravenous dose of 0.5 mg scopolamine was suitable 
for pk-pd modelling using eeg, and still had an acceptable side e¬ect 
profile (Ebert et al, 2001). Support for reversal of the scopolamine model 
by glycine reuptake inhibitors primarily comes from several preclinical 
studies that show reversal of scopolamine-induced impairments by 
D-cycloserine in various animals (Andersen et al, 2002; Fishkin et al,  
1993; Ohno and Watanabe, 1996; Pitkanen et al, 1995; Sirvio et al, 1992). 
The evidence in healthy humans, however, is much more limited. A study 
similar to ours in scope and objectives showed reversal of scopolamine-
induced memory deficits by D-cycloserine (Jones et al, 1991). However, 
this was only a short communication without more comprehensive 
publication or replication (as far as we could find), and it only showed 
e¬ects of the 15 mg dose, but not at 5 or 50 mg. 
A third factor which might explain the absence of results of r213129 
is the composition of the cns battery. The selected tests might not 
have been sensitive to the e¬ects of a glycine reuptake inhibitor. In our 
experience false-negative results are quite rare with these tests, which  
are chosen for their sensitivity to a wide range of cns-active compounds 
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(De Haas et al, 2007; De Visser et al, 2001b; Kemme et al, 2003; Van der 
Post et al, 2004; Van Steveninck et al, 1991). This is confirmed by the 
scopolamine e¬ects in this study, which were very clear and consistent. 
The previous study with D-cycloserine described reversal of memory 
e¬ects that were also assessed in our study (immediate and delayed 
word recall and delayed word recognition) (Jones et al, 1991). It cannot be 
excluded, however, that the e¬ects of r213129 in healthy volunteers would 
have been detectable with other cognitive tests or impairment models. 
In summary, scopolamine proved to be a robust and consistent model 
of cns impairment in healthy volunteers. Most of the scopolamine-
induced changes were in agreement with the findings of previous studies. 
r213129 had no cns e¬ect by itself, and produced marginal changes 
of scopolamine-induced cns impairment, without a consistent dose-
response relationship. The most logical explanation for this lack of clear 
e¬ects in this study seems to be that the r213129 brain concentrations 
were too low and variable to detect any e¬ects in this healthy 
volunteer study. Studies with higher doses would be required to show 
pharmacological activity of this compound in healthy volunteers. This 
could provide support for the dose selection for the patient studies that 
are required to investigate the clinical e~cacy of this glycine reuptake 
inhibitor, which still remains to be established. 
Table 1 Pharmacodynamic effects for placebo, scopolamine, and the combination of scopolamine and 
r213129d	










95% CI P value Diffe- 
rence a
95% CI P value
Adaptive tracking (%) 22.16 12.82 9.33 8.42, 
10.25
<0.0001
Body sway (mm) 288 450 56.3% 44.3, 
69.2%
<0.0001
Finger tapping rate 
(taps/10 sec)
65.3 62.0 3.3 1.9, 4.6 <0.0001 60.0 (3) -2.0 -4.0, 
-0.1
0.0415
Saccadic Peak Velocity 
(deg/sec)
484.1 454.8 29.2 21.2, 
37.3
<0.0001
Smooth pursuit (%) 46.60 41.52 5.07 2.53, 
7.62
0.0001
eeg alpha Fz-Cz (µV) 2.99 2.04 -31.8% -36.8, 
-26.4%
<0.0001 2.31 (10) 112.9% 100.7, 
126.6%
0.0383
eeg alpha Pz-Oz (µV) 5.87 3.20 -45.4% -50.4, 
-39.8%
<0.0001 3.72 (10) 116.0% 100.3, 
134.2%
0.0450
Delayed word recall  
(# correct)
11.8 6.9 4.9 3.6, 6.2 <0.0001
Immediate word recall 
(# correct)
12.0 8.0 4.0 3.1, 4.8 <0.0001
Delayed word 
recognition (# correct)
25.4 22.7 2.7 1.0, 4.3 0.0018
Stroop (conflict, # 
correct)
19.5 18.7 0.8 0.4, 1.1 0.0002 19.3 (3) 0.6 0.0, 1.1 0.0496
Stroop (conflict, rt, 
msec)
648 771 -123 -157, -89 <0.0001 713 (10) -59 -110, -7 0.0259
fsh (U/L) 3.75 3.97 5.8% 3.1, 
8.6%
<0.0001
lh (U/L) 4.65 5.41 16.4% 10.4, 
22.7%
<0.0001
Prolactin (µg/L) 7.56 8.57 13.3% 7.1, 
19.8%
<0.0001
a If 0 is included in the 95% Confidence Interval (95% CI) the difference is not conventionally different at the 5% level;	b rt = 
Reaction time; c	rsm	is the Least Squares Means estimate; d the interaction effects are only indicated in case of a significant 
effect; e	dose (mg) of r213129 inducing a change in scopolamine
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Figure 1 Structural formula of r213129
































r213129 (3 mg) + scopolamine
r213129 (3 mg) + placebo
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produce significant/reproducible cns-effects or to affect the scopolamine 
challenge in healthy volunteers. The effects of higher doses in healthy 
volunteers and the clinical efficacy in patients remain to be established. 
Introduction  
As extensively reviewed in previous reports, hypofunction of n-methyl- 
d-aspartate (nmda) neurotransmission is hypothesised to play an 
important role in the pathophysiology of schizophrenia (Javitt, 2006; 
Stone, et al, 2007). r231857 (Figure 1 - structural formula) selectively 
inhibits the glycine transporter 1 (GlyT1). Tsai and Lane et al have shown 
that the glycine reuptake inhibitor sarcosine causes some improvements 
of positive and negative symptoms and cognitive function in 
schizophrenia (Lane, et al, 2005; Tsai, et al, 2004). Hence, the hypothesis is 
that r231857 may also have beneficial effects on these symptoms. 
Preclinical studies have supported a potential therapeutic potential 
of this compound (Johnson and Johnson, data on file). r231857 is more 
potent than sarcosine, evidenced by a lower ic50 (the half maximal 
inhibitory concentration). It increased extracellular glycine levels in 
the prefrontal cortex in rats and glycine levels in the cerebrospinal fluid 
in dogs. It was also effective in some animal models of schizophrenia. 
Importantly, r231857 normalised the disturbed prepulse inhibition 
paradigm in dopamine transporter knockout mice. It also decreased 
amphetamine-induced hyperactivity in rats with neonatal lesions of 
the hippocampus and reduced the potentiation of amphetamine-
induced dopamine release in the prefrontal cortex of rats receiving 
phencyclidine. r231857 was well tolerated by healthy men in single and 
multiple doses up to 640 mg but central nervous system (cns) effects 
of electroencephalogram (eeg), Cognitive Drug Research (evaluating 
memory function and attention) and Addiction Research Center  
Inventory 49-Item Questionnaire (arci49) were not observed in  
these studies (Johnson and Johnson, data on file). 
To obtain an indication of cns penetration and pharmacological 
activity, a battery of quantitative cns-tests was used that is sensitive  
Abstract 
The effects of the selective inhibitor of the glycine transporter 1, might 
be an indication that r231857 penetrated the cns, they were not 
r231857, in development for schizophrenia, on the central nervous 
system consistent or dose-related. r231857 had some small effects on 
(cns) were investigated in healthy males in the absence and presence 
of scopolamine-induced cns-impairment, which were also not clearly 
scopolamine. This was a double-blind, placebo-controlled, four-
period dependent on dose. Scopolamine proved to be an accurate, 
reproducible crossover ascending dose study. Pharmacokinetics, 
body sway, saccadic and safe model to induce cns impairment by an 
anticholinergic and smooth pursuit eye movements, pupillometry, 
pharmaco-mechanism. r231857 lacked consistent dose-related effects 
in this study, electroencephalogram (eeg), Visual Analogue Scales 
(vas) for alertness, probably because cns concentrations were too 
low to produce significant/ mood, calmness and psychedelic effects, 
adaptive tracking, finger tapping, reproducible cns-effects or to affect 
the scopolamine challenge in healthy Stroop test, Visual and Verbal 
Learning Task (vvlt) and hormone levels volunteers. The effects of 
higher doses in healthy volunteers and the were assessed. r231857 was 
administered alone and together with clinical efficacy in patients remain 
to be established. scopolamine to investigate the potential reversal 
of anticholinergic cns impairment by the glycine reuptake inhibitor. 
Forty-two of the 45 included subjects completed the study. Scopolamine 
significantly affected almost every cns parameter measured in this study. 
r231857 alone showed some pharmacodynamic changes compared with 
placebo. Although these effects might be an indication that r231857 
penetrated the cns, they were not consistent or dose-related. r231857 
had some small effects on scopolamine-induced cns-impairment, which 
were also not clearly dependent on dose. Scopolamine proved to be an 
accurate, reproducible and safe model to induce cns impairment by an 
anticholinergic mechanism. r231857 lacked consistent dose-related 
effects in this study,probably because cns concentrations were too low to 
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the use of agents known to affect cns performance (including nicotine, 
drugs or alcohol), history or presence of psychiatric disease and evidence 
of relevant clinical abnormalities (checked by a physical examination and 
haematology, biochemistry and virology). The use of medication was not 
allowed during the study period. The Ethics Review Board of the Leiden 
University Medical Center approved the study protocol. 
Study design 
This study was a double-blind, placebo-controlled, four-period crossover 
ascending dose study. The periods were separated by a washout period of  
at least 1 week. 
Drugs and study design 
Scopolamine 0.5 mg or placebo was given intravenously over a period of 
15 min starting at T = 0 and 80, 160 or 320 mg of r231857 or placebo was 
orally administered at T = 0.5 h. This study was a double-blind, placebo-
controlled, four-period crossover ascending dose study. The four treat-
ments given, separated by at least 1 week, were scopolamine + placebo, 
scopolamine + r231857, placebo + placebo and placebo + r231857. After 
these four periods, the dose of r231857 was escalated and given to another 
group of 15 subjects in a four-period crossover fashion. Three dose groups 
of r231857 were treated, resulting in 45 subjects in total. The three doses 
of r231857 used in this study (80, 160 and 320 mg) were expected to cause 
plasma concentrations, corresponding to levels that block the GlyT1 site 
for more than 50% in preclinical experiments, which was considered suf-
ficient to cause a significant functionally relevant effect. Exploration of 
higher levels of exposure and inhibition was thwarted by pharmaceutical 
formulation issues that occurred with the production of higher doses. 
The selection of the scopolamine dose was based on an earlier study of 
Ebert, et al showing that an intravenous dose of 0.5 mg scopolamine demon-
strated clear concentration-dependent effects using electroencephalogra-
phy, while still having an acceptable side-effect profile (Ebert, et al, 2001).
to a wide range of cns-active drugs including neuroleptics (de Visser, 
et al, 2001, 2003; Gijsman, et al, 2002; Kemme, et al, 2003; van der Post, 
et al, 2004). It is difficult to demonstrate cognitive improvements in 
healthy volunteers, which would be an important therapeutic objective 
in schizophrenic patients. To induce transient and reversible thought 
and memory disturbances, which in some ways mimic those observed in 
patients with negative symptoms and cognitive dysfunction, a scopola-
mine challenge test was used (Ebert, et al, 1998; Green, et al, 2005; Koller, 
et al, 2003; Riedel, et al, 1995). Various preclinical experiments have 
demonstrated a reversal of scopolamine-induced impairments using 
agonists for the glycine site on the nmda receptor (Andersen, et al, 2002; 
Kishi, et al, 1998; Zajaczkowski and Danysz, 1997). Similar findings were 
obtained in one study in healthy volunteers with the partial glycine site 
agonist, D-cycloserine (Jones, et al, 1991). The neuropharmacological 
mechanism behind the cholinergic-glutamatergic interaction has not 
been elucidated. It has been proposed that glycine increases acetyl-
choline release in the striatum and hippocampus (Nishimura and 
Boegman, 1990; Ransom and Deschenes, 1989; Scatton and Lehmann, 
1982). Another is the presence of nmda receptor sites on cell bodies of 
cholinergic neurons and a subsequent increased acetylcholine release  
by glycine (agonists) due to depolarisation of the receptor (Fishkin,  
et al, 1993; Matsuoka and Aigner, 1996). 
In the current study, the objectives were to study the cns profile of 
r231857 alone and its effects on scopolamine-induced (cognitive and 
psychomotor) impairments in healthy male subjects. 
Methods 
Subjects 
A total of 45 male subjects aged 18-55 with body mass index (bmi) of 
18-28.5 kg/m2 were recruited by the Centre of Human Drug Research. 
After signing an informed consent, subjects were medically screened 
within 3 weeks before study participation. Exclusion criteria included 
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psychometric tests within 14 days before start of the study to minimise 
learning effects during the study. The pharmacodynamic measurements 
are described extensively elsewhere (Liem-Moolenaar, 2009). 
Pharmacokinetics 
r231857	
Blood samples (5 mL) for plasma concentrations of r231857 were  
drawn predose and at 1.0, 1.5, 2.0, 2.5, 3.5, 4.5, 8.5, 10 and 24 h post- 
dose. Samples were protected from light at all times to prevent 
degradation of the compound. Plasma samples were analysed to 
determine r231857 concentrations using a validated, selective and 
sensitive liquid chromatography-tandem mass spectrometry (lc-ms/ms) 
(Lower Limit Of Quantification (lloq) = 1 ng/mL). r231857 was per - 
formed by the Department of Bioanalysis, J&J prd, Belgium. 
scopolamine	
Blood samples (4 mL) for plasma concentrations of scopolamine were 
drawn at 0.5, 0.75, 1.0, 2.5 and 6.5 h after the scopolamine infusion  
was stopped. Samples were protected from light at all times. Plasma  
samples were analysed to determine scopolamine concentrations using  
a validated, selective and sensitive liquid lc-ms/ms method (lloq =  
10 pg/mL). Scopolamine bioanalysis was performed by Pharma Bio-
Research Group B.v., Zuidlaren, the Netherlands. 
Statistical analysis 
pharmacodynamics	(pd)	
pd parameters were analysed by mixed model analyses of variance (using 
sas	proc	mixed) with treatment, period, time and treatment by time as 
fixed effects, with subject, subject by time and subject by treatment as 
random effects and with the baseline value as covariate, where baseline 
is defined as the average of the available values obtained before dosing. 
This resulted in least square means (lsm) estimates that indicate the 
Safety 
Adverse events, electrocardiogram (ecg), body temperature, blood 
pressure and heart rate measurements were performed throughout the 
study. ecgs were assessed using Cardioperfect ecg recorder (Welch 
Allyn, New York, us). Blood pressure and heart rate were measured using 
an automated device (Nihon Kohden, Life Scope ec, Tokyo, Japan). 
Haematology, biochemistry and urinalysis were performed. 
Pharmacodynamics 
Eleven blocks of pharmacodynamic measurements were performed: 
predose (twice before scopolamine administration) and 0.75, 1.0, 1.5, 
2.0, 2.5, 3.5, 4.5, 6.5 and 8.5 h post-dose. Average baseline values for 
each variable were obtained by calculation of the mean of two baseline 
assessments. Pharmacodynamic tests were performed in a quiet room 
with ambient illumination with only one subject in the same room per 
session. Tests were performed in the following order: body sway, saccadic 
eye movements, smooth pursuit measurement, pupillometry, pharmaco-
eeg, Visual Analogue Scales (vas) Bond and Lader, Bowdle, adaptive 
tracking, finger tapping, Stroop test and Visual and Verbal Learning 
Task (vvlt). Blood for hormones (follicle-stimulating hormone [fsh], 
luteinizing hormone [lh] and prolactin) was taken regularly from 4 min 
until 24 h after scopolamine administration. lh and fsh were measured 
as animal studies of both r231857 and the related compound r213129 
showed an increase in serum prolactin levels and decrease in lh. The 
prolactin rise was confirmed after single and multiple administration 
of r231857 in healthy volunteers (Johsnon and Johnson, data on file). 
Because of the presumed role of excitatory amino acids in the regulation 
of the release of such hormones, these hormones are potentially 
interesting endocrine markers for pharmacodynamic activity of GlyT1 
inhibitors (Brann and Mahesh, 1995; Mahesh and Brann, 2005). 
Subjects had a standardised breakfast 1 h before scopolamine adminis-
tration. All subjects were thoroughly trained and familiarised with the 
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The incidence of these events seemed slightly higher following dosing 
with r231857 than with placebo. For headache, this was 6 of 43 after all 
three doses of r231857 compared with 4 of 44 for placebo, for somnolence 
5 of 43 compared with 2 of 44 and for nausea 2 of 43 compared with 0 of 
44. However, these numbers are too small to draw any conclusions. 
Pharmacokinetic results 
The mean concentration-versus-time profile of r231857 is presented 
in Figure 2. After administration, r231857 was rapidly absorbed with 
a time of maximum concentration 1 h or less after dose administration 
and a maximum concentration of 370, 1200 and 2050 ng/mL for the three 
different doses. The terminal elimination half-life was short, that is, less 
than 3 h (range: 1.6-2.8 h) and clearance ranged between 125 and 160 
L/h. Pharmacokinetics were dose-linear for the tested doses, with the 
exception of slightly more than dose proportional pharmacokinetics 
between 80 and 160 mg. When combined with scopolamine, the 
pharmacokinetic profile of r231857 was slightly altered for some 
parameters (see Figure 2). For all doses, but mainly at the highest dose, 
the maximum concentration was reduced. Consequently, exposure was 
also reduced when 320 mg r231857 was combined with scopolamine 
(from approximately 2700 to 1900 ng.h/mL). 
The average scopolamine concentration 0.5 h after the end of dosing 
(with and without r231857) was 1335 pg/mL and the terminal elimination 
half-life was 1.5 h. Clearance was 186 L/h. Scopolamine was not affected 
by the addition of r231857.  
Pharmacodynamic results 
scopolamine	
Scopolamine resulted in a considerable number of cns-effects and 
affected almost every parameter measured in this study (Table 1). 
Scopolamine deteriorated adaptive tracking, body sway and finger 
tapping rate performance compared with placebo. Both saccadic peak 
change from baseline, where baseline in the graph is set at 0 for t = 0 min. 
Treatment effects were reported as the contrasts between placebo and 
scopolamine, where the average of the measurements up to and including 
8.5 h (22 h for neuroendocrine parameters) were calculated within the 
statistical model. Contrasts were reported along with 95% confidence 
intervals and analyses were two sided with a significance level of 0.05. 
pharmacokinetics	(pk)	
Summary statistics of the plasma concentration data and estimated 
pharmacokinetic parameters for r231857 and scopolamine were 
calculated. The following pharmacokinetic parameters for r231857 
and scopolamine were determined using Pharsight’s WinNonlin 
pharmacokinetic analysis software (version 4.0.1): cmax, C0.5h 
(scopolamine), tmax, auclast, auc∞, t1/2term, cl/f (clearance/
bioavailability) (r231857) and cl (scopolamine). 
Results 
Participant characteristics 
Forty-two of the 45 included healthy male subjects completed the study. 
There was no difference in demographics (age and bmi) between the three 
different dose groups of r231857.  
Three subjects decided to stop participation in the study for personal 
reasons. Subjects were on average 27.5 years old (range: 18-55). 
Clinical effects 
Scopolamine induced the well-known anticholinergic effects 
(characterised by increased pupil size, dry mouth, drowsiness and 
impaired eye focusing) in 43 of the 44 subjects. Other reported effects 
were dizziness in 4 and headache in 3 of the 44 subjects. 
The most frequently reported adverse events for r231857 were 
headache (12 of 45), somnolence (10 of 45) and nausea (5 of 45).  
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Scopolamine-induced increases in the vas colour perception scale were 
further increased after 320 mg r231857 by 1.2 mm (95% ci 0.4, 2.0) and 
scopolamine-induced hormone increases were reversed after 160 mg 
r231857 by 6.3% for fsh (95% ci -9.6, -2.8%) and by 17.3% for lh (95% ci 
-25.9, -7.7%). 
Discussion 
Scopolamine showed similar effects to our previous study in another 
cohort of healthy subjects (Liem-Moolenaar, 2009), which demonstrates 
the accuracy and reproducibility of this model for cognitive and 
psychomotor impairment. Scopolamine impaired almost every tested 
cns-parameter. The concentration effect relationships of the scopolamine 
challenge will be discussed in more detail elsewhere (data on file). 
In this study, the glycine reuptake inhibitor r231857 alone showed 
some marginal and inconsistent effects compared with placebo. The 80 
mg dose caused a small deterioration of adaptive tracking performance 
and the 160 mg dose decreased the number of correct responses of the 
immediate word recall test and the subjective alertness. Although these 
effects might be an indication for limited cns depression, these were not 
consistent or dose-related. The study does not allow an interpretation 
whether this lack of consistent effects is due to insufficient brain 
penetration, low pharmacological activity, the absence of physiological 
changes during glycine reuptake inhibition in healthy humans or a 
methodological reason (i.e., we were not able to detect small cns-effects 
with our tests). 
The combination of r231857 with scopolamine caused a reduction 
of cmax and exposure of the GlyT1-reuptake inhibitor. This could be 
due to the anticholinergic action of scopolamine, which can lead to 
delayed gastric emptying and resorption of the highest dose of r231857. 
Scopolamine also changed the subtle pharmacodynamic effects of 
r231857, although these changes were small and inconsistent and could 
not be clearly attributed to either the doses of the GlyT1reuptake inhibitor 
or the small scopolamine-related reductions of plasma concentrations. 
velocity and smooth pursuit performance decreased after scopolamine 
compared with placebo administration. 
Powers of alpha (Fz-Cz and Pz-Oz) and beta Pz-Oz were statistically 
significantly lower after scopolamine than after placebo. Delta power 
(Fz-Cz and Pz-Oz) was statistically significantly higher after scopolamine 
than after placebo. Beta Fz-Cz and theta power (Fz-Cz and Pz-Oz) after 
scopolamine was not statistically significantly different from placebo. 
Scopolamine deteriorated all parameters of the vvlt (Table 1): delayed 
word recall (number correct), immediate word recall (number correct) 
and delayed word recognition (number correct). Similarly, the following 
parameters of the Stroop test were deteriorated compared with placebo: 
number correct in both basic and conflict situation and reaction time in 
conflict situation. The delayed word recognition (reaction time) and the 
Stroop parameter reaction time in basic situation after placebo were not 
statistically significantly different than after scopolamine. 
The vas alertness and vas mood were significantly lower after 
scopolamine than after placebo and the vas calmness was not changed 
by scopolamine. The vas internal perception, external perception, the 
vas feeling high and the vas colour perception were all higher after 
scopolamine than after placebo. 
All hormone levels increased after scopolamine compared with 
placebo. 
r231857	
r231857 80 mg marginally decreased adaptive tracking performance  
by 1.41% (95% ci -2.78, -0.05). The 160 mg dose marginally decreased the 
number correct of the immediate word recall test by 2.0 (95% ci -4.0, -0.1) 
and the vas alertness scale by 3.4 mm (95% ci -6.2, -0.6). 
r231857	and	scopolamine	
eeg beta power (Fz-Cz), which was not changed by scopolamine alone, 
was decreased after 160 mg r231857 by 6.7% (95% ci -12.7, -0.4%). 
The vas calmness scale, which was also not changed after scopolamine 
alone, was increased after 320 mg r231857 by 2.5 mm (95% ci 0.2, 4.8). 
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There were changes in eeg power and subjective calmness, subjective 
colour perception and hormones, which does not seem to point to 
alterations of any specific brain network or physiological system. Glycine 
reuptake inhibition would be expected to cause some glutamatergic 
effects in the cns, but also in this respect, we could not identify any trends 
in the results (such as cns stimulation). In healthy subjects, the literature 
has only reported one study on the effects of the glycine reuptake inhibitor 
D-cycloserine on scopolamine-induced memory impairment (Jones, et al, 
1991). The only other studies investigating D-cycloserine alone in healthy 
volunteers on cognitive function report contradictive results (Bailey, et al, 
2007; D’Souza, et al, 2000; Trevisan, et al, 2008). Therefore, it is difficult to 
make useful comparisons to previously published reports. 
The lack of clear and consistent r231857 effects on scopolamine-
induced cns-impairment could have several causes. These include 
non-optimal dosing of the glycine reuptake inhibitor, the unsuitability 
of the scopolamine model or a dose that was too high to detect effects 
of glycine reuptake inhibitors and the composition of the cns battery 
(which may have consisted of tests that were too insensitive to pick up 
effects). Because previous studies have shown some reversal of scopol-
amine effects with D-cycloserine, the most plausible explanation is that 
the doses of r231857 were too low. If so, the small and non-dose-related 
effects that were observed in this study could have been an indication of 
very early cns-effects, which and may have been too small and/or too vari-
able to consistently surpass the detection limit. In this case, higher doses 
will cause both larger and more consistent effects. A limited blood-brain-
barrier penetration of r231857 may also have increased the variability of 
its cns-effects in the low 80- 320 mg dose range. The doses used in this 
study were based on the in-vitro ic50 for the GlyT1-transporter. Based 
on pre-clinical experiments, this level was considered to be sufficient to 
cause pharmacologically relevant and functionally detectable effects in 
healthy volunteers, but it was actually based on practical limitations with 
the formulation of higher doses. In hindsight, and particularly if cns-
exposure was low, this exposure level may have been too small. 
In summary, the scopolamine challenge test proved to be accurate, 
reproducible and a safe model for cns-impairment. Most of the 
scopolamine-induced changes were in agreement with the findings of 
previous studies. Both alone and in combination with scopolamine, 
r231857 only showed marginal, inconsistent effects, which could not 
be readily attributed to any consistent functional or pharmacological 
modification. This absence of consistent effects seems most logically 
explained by r231857 concentrations in the cns that were too low to cause 
any reliable changes in healthy volunteers. To show pharmacological 
activity of this compound in healthy volunteers, studies with higher doses 
would be required. In addition, clinical trials are needed to investigate 
which level of glycine reuptake inhibition is needed to show efficacy in 
patients. 
185	 6-effects	of	glyt1	reuptake	inhibitor	on	cns	&	scopolamine-induced	impairments	in	healthy	men184	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia
Figure 1 Structural formula of r231857







Three subjects decided to stop participation in the study for
personal reasons. Subjects were on average 27.5 years old
(range: 18–55).
Clinical effects
Scopolamine induced the well-known anticholinergic effects
(characterised by increased pupil size, dry mouth, drowsiness
and impaired eye focusing) in 43 of the 44 subjects. Other
reported effects were dizziness in 4 and headache in 3 of the
44 subjects.
The most frequently reported adverse events for R231857
were headache (12 of 45), somnolence (10 of 45) and nausea
(5 of 45). The incidence of these events seemed slightly higher
following dosing with R231857 than with placebo. For head-
ache, this was 6 of 43 after all three doses of R231857 compared
with 4 of 44 for placebo, for somnolence 5 of 43 compared with
2 of 44 and for nausea 2 of 43 compared with 0 of 44. However,
these numbers are too small to draw any conclusions.
Pharmacokinetic results
The mean concentration-versus-time profile of R231857 is pre-
sented in Figure 2. After administration, R231857 was rapidly
absorbed with a time of maximum concentration 1 h or less
after dose administration and a maximum concentration of
370, 1200 and 2050 ng/mL for the three different doses. The ter-
minal elimination half-life was short, that is, less than 3 h (range:
1.6–2.8 h) and clearance ranged between 125 and 160 L/h. Phar-
macokinetics were dose-linear for the tested doses, with the
exception of slightly more than dose proportional pharmacoki-
netics between 80 and 160 mg. When combined with scopol-
amine, the pharmacokinetic profile of R231857 was slightly
altered for some parameters (see Figure 2). For all doses, but
mainly at the highest dose, the maximum concentration was
reduced. Consequently, exposure was also reduced when
320 mg R231857 was combined with scopolamine (from approx-
imately 2700 to 1900 ng.h/mL).
The average scopolamine concentration 0.5 h after the end
of dosing (with and without R231857) was 1335 pg/mL and the
terminal elimination half-life was 1.5 h. Clearance was 186 L/h.
Scopolamine was not affected by the addition of R231857.
Pharmacodynamic results
Scopolamine Scopolamine resulted in a considerable number
of CNS-effects and affected almost every parameter measured
in this study (Table 1). Scopolamine deteriorated adaptive
tracking, body sway and finger tapping rate performance com-
pared with placebo. Both saccadic peak velocity and smooth
pursuit performance decreased after scopolamine compared
with placebo administration.
Powers of alpha (Fz-Cz and Pz-Oz) and beta Pz-Oz were
statistically significantly lower after scopolamine than after
placebo. Delta power (Fz-Cz and Pz-Oz) was statistically
significantly higher after scopolamine than after placebo. Beta
Fz-Cz and theta power (Fz-Cz and Pz-Oz) after scopolamine
was not statistically significantly different from placebo.
Scopolamine deteriorated all parameters of the VVLT
(Table 1): delayed word recall (number correct), immediate
word recall (number correct) and delayed word recognition
(number correct). Similarly, the following parameters of the
Stroop test were deteriorated compared with placebo: number
correct in both basic and conflict situation and reaction time in
conflict situation. The delayed word recognition (reaction time)
and the Stroop parameter reaction time in basic situation after
placebo were not statistically significantly different than after
scopolamine.
The VAS alertness and VAS mood were significantly lower
after scopolamine than after placebo and the VAS calmness
was not changed by scopolamine. The VAS internal percep-
tion, external perception, the VAS feeling high and the VAS
colour perception were all higher after scopolamine than after
placebo.
All hormone levels increased after scopolamine compared
with placebo.
R231857 R231857 80 mg marginally decreased adaptive
tracking performance by 1.41% (95% CI −2.78, −0.05). The
160 mg dose marginally decreased the number correct of
the immediate word recall test by 2.0 (95% CI –4.0, −0.1) and
the VAS alertness scale by 3.4 mm (95% CI −6.2, −0.6).
R231857 and scopolamine EEG beta power (Fz-Cz), which
was not changed by scopolamine alone, was decreased after
160 mg R231857 by 6.7% (95% CI −12.7, −0.4%). The VAS
calmness scale, which was also not changed after scopolamine
alone, was increased after 320 mg R231857 by 2.5 mm (95% CI
0.2, 4.8). Scopolamine-induced increases in the VAS colour
perception scale were further increased after 320 mg R231857
by 1.2 mm (95% CI 0.4, 2.0) and scopolamine-induced
R231857, 80 mg R231857 p.o. 
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+ Placebo I.v.





0 2 4 6 8 10
Figure 2 Mean (+SD) plasma concentration profile of 80 mg.
4 Effects of a novel glycine reuptake inhibitor R231857
No inal time post administred ose, h
r231857, 80 mg r231857	p.o.  
+ 0,5 mg Scopoismine l.v. 
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Scopolamine, also known as hyoscine, is an antimuscarinic agent 
approved for use in the prevention of motion sickness. Scopolamine 
competitively antagonizes the effect of acetylcholine on the muscarinic 
receptors by occupying postsynaptic receptor sites [1]. Scopolamine has 
a high affinity for the muscarinic receptor family with little selectivity for 
any of the five receptor subtypes M1-M5 [2], and it has a negligible affinity 
for histaminergic and dopaminergic receptors [3]. The peripheral effects 
of scopolamine include typical anticholinergic effects like a dry mouth, 
skin and throat, decreased blood pressure, decreased heart rate, difficulty 
urinating, constipation, pupil dilatation and impaired eye focusing 
(mydriasis and cycloplegia). The cns effects consist of drowsiness, 
reduced attention and memory impairments, and a range of other  
cns-effects including changes in several eeg frequency bands [4-6].
At present, scopolamine is the most extensively studied and 
documented model for cognitive deficits [7-10]. The scopolamine model 
is frequently used in preclinical studies of cognitive impairment. Studies 
in animals showed that scopolamine induced memory impairments 
similar to those seen in humans [11-13]. Scopolamine has been used 
in humans for several different purposes, for example to study the role 
of cholinergic systems in memory processing [14]. Since cholinergic 
systems play an important role in memory processing, scopolamine has 
been applied as a disease model for dementia [10] and working memory 
impairment in schizophrenia [15]. The challenge test has been used to 
show the pharmacological activity of putative cognition enhancers by 
reversal of scopolamine-induced cognitive and other cns-deficits in 
healthy volunteers, including cholinergic drugs [16,17], oxiracetam [18] 
and D-cycloserine [19]. 
A methodological disadvantage of the model is the sedation induced 
by scopolamine. This is not a feature of dementia and may contribute to 
scopolamine-induced impairment of memory and cognition. However, 
in many scopolamine studies measures of sedation were unrelated 
to memory impairment effects [20-24]. Additionally, no cognitive 
Abstract
aim		Although scopolamine is a frequently used memory impairment 
model, the relationships between exposure and corresponding central 
nervous system (cns) effects are mostly unknown. The aim of our study 
was to characterize these using pharmacokinetic–pharmacodynamic  
(pk-pd) modelling. 
methods	 In two double-blind, placebo-controlled, four-way crossover 
studies, 0.5-mg scopolamine was administered i.v. to 90 healthy male 
subjects. pk and pd/safety measures were monitored pre-dose and up  
to 8.5 h after administration. pk-pd	relationships were modelled using 
non-linear mixed-effect modelling. 
results  Most pd responses following scopolamine administration in 
85 subjects differed significantly from placebo. As pd measures lagged 
behind the plasma pk profile, pk-pd relationships were modelled using 
an effect compartment and arbitrarily categorized according to their 
equilibration half-lives (t1/2keo; hysteresis measure). t1/2keo for  
heart rate was 17 min, saccadic eye movements and adaptive tracking 
1–1.5 h, body sway, smooth pursuit, visual analogue scales alertness  
and psychedelic 2.5–3.5 h, pupil size, finger tapping and visual analogue 
scales feeling high more than 8 h. 
conclusions  Scopolamine affected different cns functions in a concen-
tration-dependent manner, which based on their distinct pk-pd	charac-
teristics seemed to reflect multiple distinct functional pathways of the 
cholinergic system. All pd effects showed considerable albeit variable 
delays compared with plasma concentrations. The t1/2keo of the central 
effects was longer than of the peripheral effects on heart rate, which at 
least partly reflects the long cns retention of scopolamine, but possibly 
also the triggering of independent secondary mechanisms. pk-pd analysis 
can optimize scopolamine administration regimens for future research 





A total of 90 male subjects aged 18-55 years with a bmi of 18-28.5 kg/m2  
were recruited by the Centre of Human Drug Research (Leiden, The Neth-
erlands). After giving written informed consent, subjects were medically 
screened within 3 weeks prior to study participation. Exclusion criteria 
included the use of agents known to affect cns performance (including 
smoking and drug or alcohol abuse), consuming more than five cups of 
caffeine-containing drinks per day and evidence of relevant clinical abnor-
malities. The use of medication was not allowed during the entire study 
period. Also, subjects were not allowed to consume caffeine-containing 
drinks from 48 hours prior to dosing until the end of each treatment period. 
The Ethics Review Board of the Leiden University Medical Centre approved 
the study protocols.
Study design
Data for this analysis were obtained in two separate studies evaluating the 
effect of investigational glycinergic compounds on cognitive dysfunction 
in schizophrenia [35,36]. In these studies, scopolamine was used as a tran-
sient cognition impairment model. Both studies had equal double-blind, 
placebo-controlled, 4-period crossover ascending dose designs. This article 
is limited to the study visits on which scopolamine or placebo were adminis-
tered without the experimental glycinergic compounds. Study periods were 
separated by a washout period of at least 1 week. Scopolamine (0.5 mg) or 
placebo was administered as a short-term intravenous (i.v.) infusion over  
15 minutes starting at T = 0 hours. The sampling and measurement sched-
ules for the scopolamine challenges were identical for both studies. 
Clinical observations
Adverse events, electrocardiogram (ecg), body temperature, blood 
pressure and heart rate (after a supine position for minimally 5 minutes) 
impairment was produced by lorazepam at a dose which induced 
similar sedation as scopolamine [25]. Moreover, most stimulant drugs 
that were added to scopolamine in animals and humans were able 
to reverse the scopolamine-induced ‘fatigue’, but not the cognitive 
impairment [11,26,27], whereas cholinergic agents were [14]. 
Another source of debate is the dissimilarity between scopolamine 
effects and the features of memory failure associated with dementia 
in some studies [28,29]. For example, Alzheimer’s disease (ad) is also 
characterized by other neuropharmacological deficits that are not 
captured by a single cholinergic deficiency model. These differences 
are not a reason to completely invalidate the model per se, but they 
would essentially limit the application to cognitive deficits specifically 
associated with cholinergic dysfunction - of which loss of recent 
memory might be the most prominent example [11]. With these 
limitations and caveats, the scopolamine model seems to simulate 
essential elements of the deficits of ad, and can help studying the 
physiologic (particularly cholinergic) mechanisms involved in learning 
and memory [30].
A major part of the uncertainty about the value of the scopolamine 
challenge is related to the large variability in exposure (due to 
different administration routes, doses, study populations etc) and/
or corresponding effect(s). This limitation is inherent to many 
pharmacological challenge tests [31], and much of the variability 
can be better understood by linking exposure and effect(s) in a 
pharmacokinetic/pharmacodynamic (pk-pd) model [32-34]. Once 
identified and validated, these pk-pd models can be used to predict  
the concentration-effect relationship of various dosing regimens and 
their subsequent optimization.
At present, there is only one study correlating the plasma pk of 
scopolamine to its corresponding pd effects. However, this study was 
limited to eeg as a measure of central activity [6]. Therefore, the aim  
of our study was to evaluate and characterize the pk-pd relationships  
of scopolamine for a wide range of central nervous system functions  
in a large group of healthy volunteers using pk-pd modeling. 
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(within 1 hour before scopolamine administration) and approximately 
0.75, 1.0, 1.5, 2.0, 2.5, 3.5, 4.5, 6.5, and 8.5 hours post-dose. Tests were 
performed in the following order (relative time difference to the approxi-
mate time points): body sway (-10 min), saccadic eye movements (-8 
min), smooth pursuit measurement (-7 min), pupil/iris ratio (-5 min), 
pharmaco-eeg (-4 min), vas Bond&Lader (-3 min), vas Bowdle (-2 min), 
adaptive tracking (+2 min), finger tapping (+6 min), and Stroop test (+8 
min). A memory task (i.e. the Visual Verbal Learning Test) was performed 
once per study period. Blood for hormones (fsh, lh, and prolactin) was 
taken regularly from 4 minutes up to 24 hours after scopolamine admin-
istration. Average baseline values for each variable were obtained by cal-
culation of the mean of the two baseline assessments. Pharmacodynamic 
tests were performed in a quiet room with ambient illumination with only 
one subject in the same room per session. Subjects had a standardized 
breakfast one hour before scopolamine administration. All subjects were 
thoroughly trained and familiarized with the psychometric tests within 14 
days preceding study start to minimize learning effects during the study.
neurophysiological	
For body sway, the sum of all spontaneous anterior-posterior move- 
ments over two minutes (in millimeter) was used for statistical analysis 
[37]. Saccadic and smooth pursuit eye movements were performed as 
described before [38]. Average values of saccadic peak velocity (spv), 
latency (= reaction time) and inaccuracy were calculated for all artefact 
free saccades. The average percentage of smooth pursuit for all stimulus 
frequencies was used as response parameter for smooth pursuit eye 
movements. 
Pharmaco-eeg was measured as previously described [39]. Fast Fourier 
transform analysis was performed to obtain the sum of amplitudes in 
the delta- (0.5-3.5 Hz), theta (3.5-7.5 Hz), alpha- (7.5-11.5 Hz) and beta- 
(11.5-30 Hz) frequency ranges. The square root of the total power (in µV) 
was analyzed.
The diameter of the iris and the pupil of both eyes was determined as 
described previously [35,40].
were monitored throughout the study. ecgs were assessed using a 
Cardioperfect ecg recorder (Welch Allyn, Delft, The Netherlands).  
Blood pressure and heart rate were measured using an automated  
device (Nihon Kohden, Life Scope ec, Tokyo, Japan). 
Pharmacokinetics
Blood samples (4mL) were drawn at 0.5, 0.75, 1.0, 2.5, 6.5 h post 
dosing of scopolamine. Samples were protected from light at all times. 
Scopolamine concentrations were determined by using a validated, 
selective and sensitive liquid lc-ms/ms method (lloq = 10 pg/mL).  
The method consisted of a liquid-liquid extraction sample clean-up 
with 1-chlorobutane. After evaporation of the organic layer, the residue 
was reconstituted in a mixture of acetonitrile and 0.1% ammonia (24%) 
in water (10:90, v/v). 15 µl of this extract was injected onto an X-Bridge 
shield C18 column (50 x 2.1 mm, 3.5 µm; Waters Corporation,Milford, 
ma, usa) operated at 30°c. The mobile phase, a mixture of 0.1% ammonia 
(24%) in water as solvent A and acetonitrile as solvent B, was delivered 
at 0.4 mL/min. Quantitation was achieved by ms/ms detection in the 
positive ion mode, using a PE Sciex (Foster City, ca, usa) API 4000 mass 
spectrometer, equipped with a Turboionspray™ interface. The inter-
run precision (expressed as % cv) and accuracy (expressed as % bias) 
ranged from 1.9% to 5.6% and from -1.0% to 4.3% respectively (n=18). 
Scopolamine bioanalysis was performed by Pharma Bio-Research Group 
b.v., Zuidlaren, the Netherlands.
Pharmacodynamics
A battery of quantitative pd measurements was chosen for its repeatabil-
ity and sensitivity to many different cns-active drugs in healthy volunteers 
[35-39] and was incorporated to provide background information on 
general cns-performance and functional cns-domains (neurophysiolo-
gical, cognitive, neuroendocrine and autonomic changes). Eleven blocks 
of pharmacodynamic measurements were performed: twice pre-dose 
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subjective
The Bond and Lader Visual Analogue Scale was performed to measure 
subjective alertness, mood and calmness [38]. The Bowdle vas evaluates 
psychedelic effects. These could cluster into two distinct total sum scores 
(see [33] for further details): internal perception (reflects inner feelings 
that do not correspond with reality, including mistrustful feelings) and 
external perception (reflects a misperception of an external stimulus or a 
change in the awareness of the subject’s surroundings). The vas ‘feeling 
high’ and ‘colour intensity’ are subscales of the vas Bowdle. 
neuroendocrine
Blood samples (3mL) for lh, fsh and prolactin were kept at room 
temperature for at least 15 and maximally 60 minutes. The hormones 
were analyzed by the Central Clinical Chemistry Laboratory (Leiden 
University Medical Center, Leiden, The Netherlands) using an elec-
trochemoluminiscence-immunoassay (eclia) for prolactin, and a 
fluoro-immunoassay for lh and fsh. The assays have a lower limit 
of quantification (lloq) of 0.12 (lh), 0.05 (fsh) U/L and 0.047 µg/L 
(prolactin). Intra-assay precision (expressed as coefficient of variation) 
was 3.8 - 5.1% (lh), 3.0 - 14.8% (fsh), and 1.81 - 1.90% (prolactin).  
Inter-assay precision was 5.5 - 6.8% (lh), 3.8 - 5.3% (fsh), and  
2.39 - 2.64% (prolactin). 
Statistical analysis
pharmacodynamics	(pd)
pd parameters were analyzed by mixed model analyses of variance  
using sas®proc	mixed (sas Institute, Inc., Cary, nc, usa). with 
treatment, period, time and treatment by time as fixed effects, with 
subject, subject by time and subject by treatment as random effects, 
and with the baseline value as covariate, where baseline is defined 
as the average of the available values obtained prior to dosing. Body 
sway, eeg and neuroendocrine parameters were analyzed after log-
transformation and back-transformed after analysis (results may be 
The adaptive tracking test, as originally described by Borland and 
Nicholson [41], was performed as previously explained [42]. The  
average performance and the standard deviation of scores over a 
3.5-minute period were used for analysis. 
The finger tapping test (adapted from the Halstead Reitan Test 
Battery [43]) was performed as previously described [35] and evaluates 
motor activation and fluency. Speed of finger tapping was measured 
for the index finger of the dominant hand and a session contained five 
performances of ten seconds. The mean tapping rate and the standard 
deviations were used for statistical analysis. 
cognitive
The Stroop colour-word conflict test is helpful in understanding atten tion, 
perception, and reading as well as the cognitive and neural mechanism 
of mental inhibition, interference and controlled versus automatic 
processing [44] and was performed as previously described [36]. 
Outcome parameters are the number of correct answers and the  
reaction time in basic and conflict situation.
The Visual Verbal Learning Test (vvlt) addresses different components 
of learning behaviour, such as acquisition, consolidation, storage and 
retrieval. The vvlt contains three different subtests that cover immediate 
and delayed word recall and a delayed word recognition [44]. The imme-
diate word recall test was administered 2 hours and 8 minutes after the 
start of the scopolamine infusion. For the delayed word recall test this was 
2 hours and 38 minutes and for the delayed word recognition test 2 hours 
and 43 minutes. The 30-word learning test avoids ceiling effects in healthy 
students, and has shown cns effects for example for benzodiazepines 
[32,38,46], cannabinoids [33] and antipsychotics [47]. For each study 
period a different 30-word learning list was used to avoid learning effects 
over time. All versions of the 30-word learning are validated for differences 
in complexity. Main parameters for the immediate and delayed word 
recall were the average and the maximum number of correct responses. 
For the delayed word recognition, the number of correct items and mean 




Eighty-five of the included 90 subjects completed the study. Four subjects 
withdrew for reasons unrelated to the study. One subject withdrew after 
what was considered to be a second moderate vasodepressive episode 
following dosing with scopolamine. The scopolamine treatment was 
well tolerated by all other subjects. Ninety-eight percent of the subjects 
reported at least one adverse event. The most commonly reported mild 
adverse events following dosing with scopolamine were anticholinergic 
symptoms (97%), nausea (8%), dizziness (7%), and palpitations (6%). 
The anticholinergic symptoms consisted of variable combinations of 
drowsiness, dizziness, dry mouth, concentration problems and blurred 
vision. 
Two to 6.5 hours after dosing with scopolamine the mean supine 
systolic and diastolic blood pressure was lower than with placebo.  
A similar effect was seen on pulse rate. There was a decrease in mean 
heart rate (approximately 23%, from 66.8 to 51.2 beats per minute) 
and consequently a transient increase in mean uncorrected qt interval 
(approximately 9%, from 381 to 415 milliseconds) without qtc-changes. 
There were no other clear consistent changes in vital signs, ecg or 
laboratory safety parameters. 
Pharmacodynamics
neurophysiological
Except for three eeg parameters (beta Fz-Cz, theta Fz-Cz and Pz-Oz), the 
changes in the other neurophysiological measures were highly statisti-
cally significant after scopolamine compared to placebo treatment (table 
1, figure 1). While alpha and beta power increased, delta power decreased. 
Furthermore, scopolamine decreased saccadic peak velocity (by 22.7 o/
sec), adaptive tracking performance (by 9.6%), finger tapping rate (by 3.4 
taps/10 seconds) and smooth pursuit (by 6.1%). Body sway and average 
pupil/iris ratio were both increased by 57.4% and 0.057 respectively. 
interpreted as percentage change). The analysis resulted in Least Square 
Means (lsm) estimates that indicate the change from baseline where 
baseline in the graph is set at 0 for t = 0 hours. Treatment effects were 
reported as the contrasts between placebo and scopolamine, where the 
average of the measurements up to and including 8.5 hours (22 hours 
for neuroendocrine parameters) were calculated within the statistical 
model. Contrasts were reported along with 95% confidence intervals and 
analyses were two-sided with a significance level of 0.05. 
pharmacokinetics	(pk)	and	pk-pd	analysis
pk and pk-pd modeling and simulations were performed using non-
linear mixed effect modeling as implemented in the nonmem program 
[45]. Non-linear mixed effect modeling allows the description of a 
population of individuals using a common structural model while 
allowing the individuals to vary. Estimates of location and spread 
between individuals are estimated for the model parameters. Using 
the population values, individual specific empirical Bayes estimates 
can be determined that allow description of individual time profiles. 
Competing models can be compared using the likelihood ratio test, 
which compares the difference between log-likelihoods for the models 
(or minimum value of then objective function: mvof) to a Chi-square 
distribution with degrees of freedom corresponding to the difference in 
number of parameters between the two models. First order conditional 
estimation (foce) was used throughout, with additive (on log-scale for 
concentrations) residual error models. 
When analyzing the data, it could be shown that there was no 
significant placebo response (flat dose-response curve) for most of  
the parameters. Therefore, it was decided to include a separate placebo 
model in the analysis for those parameters were a placebo response was 
observed (tracking performance and smooth pursuit performance), 
while this was not done for those pd measures where a flat dose-




When plotting scopolamine plasma concentrations against correspond-
ing effects, pd responses clearly lagged behind the plasma pk profile and 
showed a much more gradual increase and decline (see figures 3A for spv 
and 4A for vas alertness). In order to overcome this temporal disconnect, 
data were modeled using an effect compartment, and the relationship 
between effect compartment concentration and response was assumed to 
be linear (see figures 3B and 4B). Exploration of the mean predicted and 
observed time profile for these models did not indicate sufficient model-
misspecification to warrant more complex models. With this model aver-
age graphs of predicted and observed time-effect curve were made (figure 
3C and 4C). In table 3 the pk-pd-parameters intercept, slope, equilibra-
tion half-life (T1/2keo) and residual error are presented. T1/2keo is a 
measure of hysteresis and is the time in which the effect-compartment 
concentration reaches half the concentration of the central compartment. 
In this study, we were not able to measure a maximal effect (Emax) for any 
of these outcome parameters. These parameters were categorized accord-
ing to their equilibration half-lives in four arbitrarily divided groups, i.e. 
shorter than 0.5 hours, 1-1.5 hours, 2.5-3.5 hours and longer than 8 hours. 
No simple pk-pd model could be fitted adequately for blood pressure, 
hormones (lh, fsh, prolactin), eeg, pupil/iris ratio, Stroop test, vvlt and 
vas scales for calmness, mood and colour (reasons for this are given in the 
discussion). 
Discussion
In this study the pk, pd and pk-pd relationships following the i.v. 
administration of 0.5 mg scopolamine were assessed using an extensive 
cns test battery, frequent measurements and a sizeable study population. 
The scopolamine challenge proved to be an accurate, reproducible, and 
safe model for cognitive impairment. 
 
cognitive
Of the cognitive function tests, the reaction time of the Stroop colour-
word conflict test increased after scopolamine with 110.5 msec compared 
to placebo, while the number of correct responses of this test decreased 
by 0.6 (table 1). Memory performance deteriorated after scopolamine, 
since compared to placebo the number of correct responses decreased 
by 5.8 items for the third immediate recall trial, and by 5.1 items during 
delayed recall. The average reaction time of the delayed word recognition 
test (for correct responses) was 48.4 msec longer after scopolamine 
compared to placebo. The number of correct responses for this same test 
decreased by 2.3. 
subjective	measurements
Except for the vas mood and vas calmness, all subjective measures  
were statistically significantly affected by scopolamine (table 1, figure 
1). The Bond & Lader vas alertness scale decreased 9.0 mm compared 
to placebo. For the Bowdle vas, an increase in vas internal perception, 
external perception, feeling high, and colour perception was seen.
neuroendocrine	measurements
All hormones were increased after scopolamine compared to placebo:  
fsh by 5.6%, lh by 20.2%, and prolactin by 15.3% (table 1). 
Pharmacokinetics 
Scopolamine pharmacokinetics were described using a two-compartment 
model. Individual empirical Bayes estimates were determined that were 
used to describe the concentration profiles in subsequent pk-pd analyses 
(see figure 2 for average concentration-time profile with the average 
nonmem predicted profile superimposed). 
After 30 minutes scopolamine showed a mean maximum concentration 
of 1287 pg/mL. Plasma concentrations declined rapidly with a mean 
terminal half-life of 1.5 (range 1.2-2.49) hours (table 2). The auc0-∞ was 
2752 (range 1737-4604) pg.h/mL. 
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The increases in vas of internal perception, external perception, and 
feeling high confirms that scopolamine has some psychomimetic 
properties [2]. When comparing the increase in vas feeling high with that 
of tetrahydrocannabinol (thc, the psychoactive component of cannabis), 
the effects of thc (2, 4, 6 mg intrapulmonary [39]) are twice as large 
as those of scopolamine. The effects of zolpidem (10 mg orally) on vas 
feeling high are close to the values observed with scopolamine [52]. 
In the pk-pd-analysis of our study, all the effects showed hysteresis 
and Emax could not be estimated for any of the effects using a single dose 
of 0.5 mg. This delay was modeled by assuming a direct relationship 
between the concentrations in the effect compartment (estimated from 
the pharmacodynamic effect) and those in the central compartment. 
Variations in T1/2keo can be caused by strong retention of the drug within 
a certain compartment (like for lipophilic compounds in the cns) or 
subsequent pharmacological and physiological processes that can lead 
to a delay or prolongation of a pharmacodynamic effect [34]. It should be 
kept in mind that the descriptive approach of our model is a limitation of 
the analysis. As we are evaluating a large variety of effects that certainly 
can not be characterized by a single mechanism-based model we decided 
to keep it reasonably simple and consistent for all outcome parameters. 
We arbitrarily divided the equilibration half-lives in four groups, namely 
shorter than 0.5 hour, 1-1.5 hours, 2.5-3.5 hours and longer than 8 
hours. Although these differences seem large enough to be related to 
meaningful functional distinctions, a physiological explanation is not 
immediately apparent and may in fact differ among pharmacodynamic 
effects even within the same group. 
Heart rate showed a short T1/2keo of 17 minutes. The fact that an 
effect compartment with a significant equilibration half-life was needed 
suggests that both central and peripheral effects are involved. In case of 
purely peripheral effects, we would have expected a more direct link the 
plasma pk to the corresponding pd effect. However, the physiological 
situation is more complex. An apparently long equilibration half-
life can also ensue from a high affinity of the drug for cardiac tissue 
leading to prolongation of the (peripheral) effects of scopolamine on 
With regard to autonomic changes, the paradoxical reduction in heart 
rate of 15.6 bpm on average was larger than is typically observed with 
scopolamine doses of 0.4-0.6 mg, but probably still because of blockade  
of m1-receptors on postganglionic parasympathetic neurons, as 
suggested previously [46]. 
Scopolamine affected most of the measured pd parameters of this 
study. Most effects were reasonably consistent with the effects described in 
the literature [5,18,23,26,27,47,48] and disappeared within eight hours. 
Some of the more noticable pd results will be briefly discussed below. 
The very long duration of pupil dilation, in line with the prolonged 
cycloplegic effects of anticholinergic ocular mydriatics [49], could 
possibly be explained by an element of retention of the drug in the  
anterior chamber of the eye and/or a high sensitivity of the iris to 
cholinergic inhibition. This could not be examined any further, because 
the effect lasted much longer than the observation period of this study, 
which refuted pk-pd-analyses.
All tested components of memory showed a significant impairment 
compared to placebo. In our study, this was particularly due to a reduction 
of the capacity to immediately actively reproduce memorized words, 
from 53% (16/30) after placebo to 34% (10.2/30) with scopolamine. This 
difference was comparable when these words were reproduced 30 minutes 
later (41% versus 24%). Memory storage (assessed using the delayed word 
recognition test) was also affected, but to a smaller extent: 75% (22.6/30) 
of the presented words was still recognized three hours after scopolamine 
treatment, compared to 83% (24.9/30) with placebo. 
Performance of the Stroop test was also significantly impaired, similar 
to the results of Mintzer and Griffiths [50]. A central mechanism seems 
the most logical cause for these changes in Stroop performance as the 
effects were larger in the conflict than in the basic situation, where the 
colours were the same. Reduced attention could have contributed, since 
Mintzer [50] also found a strong difference between conflict and basic 
situation of the Stroop test after benzodiazepine administration.  
The observed changes in vas colour intensity could have been  
influenced by pupil dilation or cholinergic retinal impairment [51]. 
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functional mechanisms may have refuted an adequate pk-pd-analysis, 
which was not possible for all endpoints. This was the case for blood 
pressure, possibly because of homeostatic mechanisms interfering 
between the direct relation between scopolamine concentration and 
blood pressure. Once lh and fsh are activated (by scopolamine), these 
hormones have their own complicated and poorly described system 
dynamics. For eeg parameters, the complex profiles during placebo 
treatment (which probably not only reflect diurnal rhythms but also 
unspecified variability) made pk-pd modelling too complicated. The 
excessive duration of the effects on the pupil/iris ratio and the absence 
of measurements in this late phase refuted an adequate description 
of the pk-pd relationships. For many cognitive processes (e.g. Stroop 
and memory tasks), it is hard - if not impossible - to include enough 
measurements in a study to have reliable pk-pd, since repeated 
assessments are complicated by learning effects, different versions and 
long test durations. pk-pd relationships could also not be described for 
three other vas scales (calmness, mood, and colour), mainly because the 
effects were too small and/or inconsistent. 
The results of this study can be used for the design of new studies of 
the cholinergic system. One example would be when stable cns-effects 
(e.g. a certain level of objective alertness) of scopolamine are required 
for a functional imaging study of longer duration. The dosing regimen 
predicted to result in reasonably stable reductions of saccadic peak 
velocity (spv - an objective measure of sedation) of 50˚/sec and of vas 
alertness of 10 mm for approximately seven hours (figure 3D and 4D), 
would result in a 0.45 mg continuous infusion for 15 minutes and 0.15 mg 
infusions for 15 minutes at t=150, t=250 and t=350 minutes. 
The models can also be used for individual dose optimization in patient 
studies when large inter-individual differences are anticipated, and to 
study the integrity of the cholinergic system in different individuals, 
populations or disorders (i.e. disease progression or effects of treatment 
on the cholinergic system in dementia). However, as this study was done 
in healthy young men, it is not yet known whether the results are also 
applicable to older (or demented) men. 
the heart. Moreover, heart rate is determined by complex peripheral 
cardiovascular regulatory systems, and changes in one part of the system 
(like muscarinic blockade) will usually cause compensatory changes in 
the components. Similar T1/2keo values are found for cannabis-induced 
tachycardia [34].
Adaptive tracking and saccadic peak velocity (spv) were both 
characterized by longer equilibration half-lives of about one hour (see 
table 3). spv is one of the most sensitive parameters for alertness [53-55]. 
Adaptive tracking performance is a visuomotor task that is influenced by 
attention and vigilance. These measurements usually show fairly direct 
concentration-effect relationships with other cns-active drugs [56-59] 
indicating that an underlying prolonged physiological mechanism is 
unlikely to be the cause for an extended effect duration. It is more likely 
that an effect prolongation is mainly due to retention of scopolamine in 
a certain part of the central nervous system, and not solely to induction 
of independent physiological processes. This is confirmed by a pet-study 
performed by Frey et al [60], who showed that 11C-scopolamine was 
retained in different brain regions for many hours. The compound was 
most rapidly removed from the cerebellum, where receptor binding still 
had a half-life of several hours. Functionally, this region is most relevant 
for body sway, which also had an effect half-life of approximately two-
and-a-half hours. The tracer showed even longer retention times in other 
brain regions (pons, thalamus, occipital cortex and caudate nucleus), 
which cannot be easily related to functional parameters in our study. 
It is possible therefore that some very long lasting effects like on some 
of the vas-scales and finger tapping (see table 3) are still related to the 
active presence of scopolamine in relevant brain regions. Obviously, it 
cannot be excluded that functional adaptations play a role in the final 
effect duration and the length of its equilibration half-life. Although all 
effects seem closely related to the activity (i.e. inhibition) of cholinergic 
systems in the brain, the features of these relationships vary considerably. 
This indicates that different mechanisms could be involved in the effects 
of scopolamine, and that they are not caused by a single underlying 
anticholinergic effect like for instance ‘cns-depression’. More complex 
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In conclusion, the results of our pk-pd-analyses show that scopolamine 
causes a range of different effects, which are regulated by systems that 
are functionally and pharmacologically at least partly distinct. The rather 
extensive data set obtained in this study allowed for accurate analyses of 
the effects of scopolamine and their concentration-effect relationships 
across a wide range of different cns-domains, and provides a useful set of 
normal reference values for the design optimization of future studies. 
Table 1 Pharmacodynamic differences in Least Square Means (lsms) relative to placebo for all measurements 
Variable Least Square Means Difference 95%CI p-value
Placebo Scopolamine
Neurophysiological
Body sway (mm) 268 422 57.4% 48.3 67.1 <0.0001
Saccadic peak velocity (˚/sec) 471.0 448.3 -22.7 -28.5 -16.8 <0.0001
Saccadic latency (sec) 0.200 0.217 0.017 0.013 0.022 <0.0001
Saccadic inaccuracy (%) 5.73 8.14 2.41 2.14 2.68 <0.0001
Smooth pursuit eye movements (%) 48.37 42.32 -6.05 -8.10 -3.99 <0.0001
eeg alpha Fz-Cz (µV) 2.889 2.064 -28.6% -32.8 -24.1 <0.0001
eeg alpha Pz-Oz (µV) 5.472 3.133 -42.7% -46.9 -38.3 <0.0001
eeg beta Fz-Cz (µV) 1.998 1.982 -0.8% -4.3 2.8 0.6492
eeg beta Pz-Oz (µV) 2.508 2.010 -19.8% -23.1 -16.4 <0.0001
eeg delta Fz-Cz (µV) 1.801 2.064 14.6% 9.6 19.9 <0.0001
eeg delta Pz-Oz (µV) 1.779 1.983 11.5% 6.4 16.8 <0.0001
eeg theta Fz-Cz (µV) 2.112 2.134 1.1% -3.3 5.6 0.6332
eeg theta Pz-Oz (µV) 2.293 2.310 0.7% -4.8 6.6 0.8011
Average pupil/iris ratio 0.532 0.590 0.057 0.042 0.072 <0.0001
Adaptive tracking performance (%) 21.70 12.07 -9.62 -10.29 -8.95 <0.0001
Finger tapping rate (taps/10sec) 65.4 62.0 -3.4 -4.4 -2.4 <0.0001
Cognitive
Stroop test RT conflict situation (msec) a 657.0 767.4 110.5 82.2 138.8 <0.0001
Stroop test # correct conflict situation b 19.5 18.9 -0.6 -0.9 -0.3 <0.0001
Immediate word recall # correct 3rd trial b 16.0 10.2 -5.8 -6.7 -5.0 <0.0001
Delayed word recall # correct b 12.4 7.3 -5.1 -6.0 -4.3 <0.0001
Delayed word recognition average rt 
correct a answers (msec)
903.1 951.4 48.4 17.4 79.3 0.0025
Delayed word recognition # correct b 24.9 22.6 -2.3 -3.3 -1.4 <0.0001
Subjective
vas alertness (mm) 54.7 45.7 -9.0 -10.9 -7.2 <0.0001
vas mood (mm) 57.2 56.6 -0.6 -1.9 0.6 0.3243
vas calmness (mm) 57.5 58.7 1.2 -0.5 2.9 0.1567
vas internal perception (log mm) 0.35 0.43 0.08 0.04 0.11 <0.0001
vas external perception (log mm) 0.34 0.50 0.15 0.11 0.19 <0.0001
vas feeling high (log mm) 0.36 0.68 0.32 0.24 0.40 <0.0001
vas colour perception (log mm) 0.35 0.42 0.08 0.04 0.11 <0.0001
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Neuroendocrine
fsh (U/L) 3.70 3.90 5.6% 3.7 7.6 <0.0001
lh (U/L) 4.39 5.28 20.2% 13.6 27.1 <0.0001
Prolactin (U/L) 7.91 9.12 15.3% 10.5 20.3 <0.0001
a rt = reaction time; b # = number
Table 2 Population pk parameters of scopolamine 
Mean a sem	b iiv ar c
Clearance (L/min) 2.53 0.0791 15.4%
Central volume (L) 66.3 8.37 36.6%
Intercompartmental Clearance (L/min) 4.78 0.309 8.9%
Steady State Vd (L) 250 12.6 7.2%
Residual error (sd/Mean) 0.102 0.00736
a. Mean: population average; b. sem: Standard error population mean; c. iiv ar: Inter-individual variability.
 
 
Table 3 Population parameters of pk-pd	analysis sorted by equilibration half-life; depicted as population 
mean (semd - iicvf) 
Outcome parameter mean 
(iicv)











Saccadic peak velocity  
(˚/sec) a
485	(nae	-	55.05) -0.0737 (nae - 45.3%) 65.1	(nae	-	0.0%) 28.4	(nae)
Adaptive tracking (%) 0.0479	(0.457	-	4.336) -0.0217 (0.000931 - 22.6%) 86.6	(4.14	-	28.4%) 2.98	(0.155)
2.5 - 3.5 hours
vas external perception 
(log mm) a
0.34	(0.00931	-	28.6%) 0.000633	(0.000109	-	107%) 161	(25.5	-	86.5%) 0.0935	
(0.0062)
Body Sway (log mm) a 2.4	(0.0219	-	8.2%) 0.00147	(0.000105	-	32.4%) 181	(12	-	30.6%) 0.102	
(0.0053)
vas alertness (mm) a 53.6	(nae	-	14.8%) -0.0622 (nae - 62.9%) 199	(nae	-	53.8%) 4.05	(nae)
vas internal perception 
(log mm) a
0.336	(nae	-	28.1%) 0.000331	(nae	-	130%) 200	(nae	-	1.6%) 0.083	(nae)
Smooth pursuit (%) a 3.1	(0.951	-	12.25) -0.0264 (0.0029 - 44.4%) 221	(31.5	-	97.8%) 6.28	(0.238)
> 8 hours
vas feeling high 
(log mm) a
0.328	(nae	-	21.0%) 0.00313	(nae	-	93.9%) 483	(nae	-	207%) 0.216	(nae)
Finger tapping 
(taps/10 sec) a,b
63.4	(0.895	-	12.6%) -0.0797 (0.0571 - 25.3%) 649	(472	-	62.9%) 3.09	(0.217)
a.	Placebo results not subtracted; b. Finger tapping has a time slope of 19.3 (9.187) number/day; c.	Unit of the slope = unit of 
the outcome parameter/pg/mL.dose (mg) of r231857 inducing a change in scopolamine; d.	sem	= Standard Error of the Mean; 
e.	na = not available due to aborted covariance step; for the residual error only the sem is depicted; f.	iicv = inter-individual 
variability coefficient of variation; g. effect is parameterized: a decrease from baseline is depicted as a positive value.
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Figure 1  Time–effect profiles for all pharmacodynamic measurements which resulted in a successful 
pharmacokinetic–pharmacodynamic analysis. 
Figure 2 Average observed (with sd error bars) and predicted (two-compartment model) scopolamine plasma 
concentrations
Figure 3 Saccadic peak velocity (spv)  
a.	clockwise hysteresis loop formed by the plasma concentration-effect curve; b.	effect compartment concen-
tration-effect curve; c.	predicted (dark line) and observed (closed circles) time-effect curve with 95% CI error 
bars; d.	mean predicted dosing regimen (0.45 mg i.v. infusion 15 minutes at t=0 and 0.15 mg i.v. infusion over 
15 minutes at t=150, t=250 and t=350 minutes) to attain a spv reduction of 50˚/sec 
0 500 1000 1500 2000 2500 3000 3500









































0 10 20 30 40 50 60 70 80 90 100














































































































































































Time (min) Time (min) Time (min)




























































































































































































Time–effect profiles for all pharmacodynamic measurements which resulted in a successful pharmacokinetic–pharmacodynamic analysis.  placebo, 
scopolamine 0.5 mg i.v. VAS, visual analogue scale
PK, PD and PK–PD of scopolamine





















Figure 4 For vas alertness  
a.	clockwise hysteresis loop formed by the plasma concentration-effect curve; b.	effect compartment concen-
tration-effect curve; c.	predicted (dark line) and observed (closed circles) time-effect curve with 95% CI error 
bars; d.	mean predicted dose regimen (0.45 mg i.v. infusion over 15 minutes at t=0 and 0.15 mg i.v. infusion 
over 15 minutes at t=150, t=250 and t=350 minutes) to attain a vas alertness reduction of 10 mm
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In this study, the hypothesis that haloperidol would lead to an ameliora-
tion of ∆9-tetrahydrocannabinol (thc)-induced ‘psychotomimetic’ effects 
was investigated. In a double-blind, placebo-controlled, partial three-
way crossover ascending dose study the effects of thc, haloperidol and 
their combination were investigated in 35 healthy, male mild cannabis 
users, measuring Positive and Negative Syndrome Scale, Visual Analogue 
Scales for alertness, mood, calmness and psychedelic effects, saccadic 
and smooth pursuit eye measurements, electroencephalography, Body 
Sway, Stroop test, Visual and Verbal Learning Task, hormone levels 
and pharmacokinetics. Compared with placebo, thc significantly 
decreased smooth pursuit, Visual Analogue Scales alertness, Stroop 
test performance, immediate and delayed word recall and prolactin 
concentrations, and significantly increased positive and general Positive 
and Negative Syndrome Scale score, Visual Analogue Scales feeling high, 
Body Sway and electroencephalography alpha. Haloperidol reversed the 
thc-induced positive Positive and Negative Syndrome Scale increase 
to levels observed with haloperidol alone, but not thc-induced ‘high’ 
feelings. Compared with placebo, haloperidol significantly decreased 
saccadic peak velocity, smooth pursuit, Visual Analogue Scales mood 
and immediate and delayed word recall and significantly increased Body 
Sway, electroencephalography theta and prolactin levels. thc-induced 
increases in positive Positive and Negative Syndrome Scale but not in 
Visual Analogue Scales feeling high were reversed by haloperidol. This 
indicates that psychotic-like effects induced by thc are mediated by 
dopaminergic systems, but that other systems are involved in ‘feeling 
high’. Additionally, the clear reductions of psychotic-like symptoms by 
a clinically relevant dose of haloperidol suggest that thc administration 
may be a useful pharmacological cannabinoid model for psychotic effects 
in healthy volunteers. 
Introduction 
The underlying mechanisms of the contribution of cannabinoid systems 
in the pathophysiology of the psychotic symptoms of schizophrenia 
are still unclear. There is increasing evidence for pharmacological 
relationships between cannabinoid and dopamine systems (Gardner, 
2005; Laviolette and Grace, 2006). Both animal and human studies 
show contradictive results. Preclinical evidence was recently 
summarized (D’Souza et al, 2008). In general, animal models are 
reasonably predictive of several characteristics of schizophrenia, such as 
disorganized behaviour, psychomotor agitation and social withdrawal, 
but do not adequately represent typical positive features like delusions, 
hallucinations and disorganized speech. These positive phenomena 
are reminiscent of the e¬ects of cannabis in humans, and although 
there is an ongoing debate about the link between cannabis use and 
the development of schizophrenia (Phillips and Johnson, 2001), there 
is little doubt that cannabis can lead to clinical psychosis, particularly 
in susceptible individuals and/or after heavy use (Henquet et al, 2005, 
2006). Since psychotic symptoms have consistently been related to 
increased dopamine function in the striatum (Angrist and Van Kammen, 
1984; Seeman and Lee, 1975), elevated striatal dopamine release 
after ∆9-tetrahydrocannabinol (thc) use may explain how cannabis 
contributes to the development and pathophysiology of schizophrenia 
(Bossong et al, 2009). Dopamine release from the ventral tegmental area 
into the nucleus accumbens is also a consistent feature of drugs that 
a¬ect the brain reward system. It is possible therefore that the typical 
pleasurable ‘high feelings’ of cannabis are also mediated by this reward 
system (Lupica et al, 2004). 
The Centre for Human Drug Research (chdr) has recently developed 
an intrapulmonary thc-challenge model (Zuurman et al, 2008) and 
demonstrated clear e¬ects on most of the psychedelic Visual Analogue 
Scales (vas). This vas was previously used by Bowdle et al (1998) to 
quantify psychotomimetic e¬ects of ketamine, which is suggested  
to induce some schizophrenia-like symptoms in healthy volunteers  
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(Adler et al, 1999). Di¬erent vas subscales and various other central 
nervous system (cns) e¬ects showed clear but distinct concentration-
e¬ect relationships with thc, suggesting that di¬erent pathways mediate 
the various e¬ects of thc (Strougo et al, 2008; Zuurman et al, 2008). 
thc-induced psychotomimetic e¬ects could be used as a pharmaco-
logical challenge test to study the involvement of cannabinoid systems  
in psychosis, or even as a practical ‘psychosis’ model to assess therapeutic 
e¬ects of antipsychotic agents. As haloperidol is a well-known classic 
antipsychotic that is particularly e¬ective against the positive symptoms 
of schizophrenia, our hypothesis was that haloperidol would lead to 
an amelioration of the psychotic-like e¬ects of the thc challenge. 
At the same time, it was expected that the antidopaminergic e¬ects 
of haloperidol in the reward system would cause a reduction of the 
pleasurable subjective e¬ects of thc. These issues were recently also 
addressed by D’Souza et al (2008), who were unable to demonstrate 
unequivocally that haloperidol reverses psychotic-like symptoms 
induced by cannabis. In the current study, which started before D’Souza 
et al’s results were published, a novel mode of intrapulmonary thc-
administration was employed. 
Methods 
Subjects 
Healthy male subjects aged between 18 and 45 years with a body mass 
index (bmi) of 18-28.5 kg/m2 were recruited by the chdr. The subjects had 
to be cannabis users, but not use more than once a week in the last year. 
After signing informed consent, subjects were medically screened within 
three weeks prior to study participation and excluded when relevant 
clinical abnormalities were found. The use of medication and agents 
known to a¬ect cns performance (including nicotine, xanthines, drugs or 
alcohol) were not allowed and were screened during screening and prior 
to each study day (i.e. the 24-h period at chdr). The Ethics Review Board 
of the Leiden University Medical Center approved the study protocol.
Study design 
This was a randomized, double-blind, placebo-controlled, partial 
three-way crossover interaction study with washout periods of at least 
two weeks. All 24 subjects received the treatment combinations ‘thc 
+ placebo’ and ‘thc + haloperidol’, but half of the subjects received 
‘haloperidol + placebo’ and the other half ‘placebo + placebo’. 
In order to estimate the sample size for a study that has 80% power  
of detecting half of the thc e¬ect on the vas Bowdle ‘external perception’ 
subscale (i.e. 50% of 0.437) as observed in a previous thc study, a sample 
size of 26 was calculated (two-sided test, alpha = 0.05) and rounded to 24 
for randomization using Williams Squares. 
Drugs 
Each study day started with a dose of 3 mg haloperidol (or its matching 
placebo) orally. After 3 h, three consecutive doses of thc 2, 4 and 6 mg  
(or matching placebo) were given intrapulmonary (described in more  
detail elsewhere (Zuurman et al, 2009b)) around the expected maximum  
of plasma concentrations and pharmacodynamic e¬ects of haloperidol,  
at t = 180, t = 270, and t = 360 min (Chakraborty et al, 1989). Subjects 
remained in the unit for a 24-h observation period (see Table 1). 
The dose of haloperidol in healthy volunteers was based on recommen- 
dations by King (1997) and was previously used at chdr (Liem-Moolenaar  
et al, 2008) showing clear e¬ects with only limited, usually mild, and some  
moderate adverse events. thc doses were based on previous chdr studies  
using similar dosages, showing clear e¬ects and concentration-e¬ect rela- 
tionships on a range of di¬erent cns e¬ects, including vas Bowdle subsca- 
les feeling high and postural instability (Zuurman et al, 2008, 2009b, 2010).  
Safety 
Adverse events, electrocardiography, blood pressure, heart rate, and  
routine haematology and biochemistry measurements were performed 
throughout the study (see Table 1). 
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Pharmacodynamics 
The extensive cns battery was incorporated to provide background 
information on general cns performance and functional cns domains, 
which could have had a secondary impact on the primary endpoints of the 
study (e.g. changes in alertness or vigilance), with each drug alone or in 
combination. 
Pharmacodynamic measurements were performed pre-dose (twice 
before haloperidol administration) and frequently after thc dosing. Phar-
macodynamic tests were performed in a quiet room with ambient illumi-
nation with only one subject in the room per session. All subjects were 
trained within three weeks preceding study start to minimize learning 
e¬ects during the study. The tests were performed as described below. 
positive	and	negative	syndrome	scale
The Positive And Negative Syndrome Scale (panss) includes 30 items 
on three subscales: seven items covering positive symptoms (e.g. 
hallucinations and delusions), seven covering negative symptoms (e.g. 
blunted a¬ect), and 16 covering general psychopathology (e.g. guilt, 
uncooperativeness). Each item is scored on a seven-point Likert scale 
ranging from 1 to 7, resulting in a range from 7 to 49 for the positive and 
negative and 16 to 112 for the general psychopathology scale. Reliability 
and validity have been shown to be high (Kay and Opler, 1987). For the 
current study, several panss raters were trained to perform the interview, 
to observe changes in attitude, and inter-rater correlation was assessed. 
During the study, two interviewers both made their own assessment, and 
the final score was determined by consensus. panss assessments were 
videotaped during the interview to permit review at a later time point. 
visual	analogue	scales	(vas)
The vas Bond and Lader, originally described by Norris (1971) and applied 
to drug e¬ect by Bond and Lader (1974), was performed to measure 
subjective alertness, mood (or contentedness) and calmness, and the 
vas Bowdle (Bowdle et al, 1998) to measure psychedelic e¬ects, and were 
performed as previously described (De Haas et al, 2008). The vas feeling 
high is a subscale of the vas Bowdle. After thc administration, the 
Bowdle sub-scales clustered in two distinct groups, following stepwise 
discriminant, cluster and factor analysis. The first group could be 
described as ‘internal perception’ of changes in the way that the subject 
perceived his inner self (e.g. body composition, paranoid ideas), and  
the second group as ‘external perception’ of changes in the environment 
(e.g. time, colours) (Zuurman et al, 2008). 
saccadic	and	smooth	pursuit	eye	movements
Saccadic and smooth pursuit eye movements have shown dose-and 
concentration-related e¬ects of many di¬erent cns active drugs, 
including gaba-ergic (De Haas et al, 2008; De Visser et al, 2003), 
serotonergic (Gijsman et al, 2002) and noradrenergic compounds 
(Kemme et al, 2003; Van der Post et al, 2004b), and to a limited extent 
dopaminergic drugs (Liem-Moolenaar et al, 2008). Eye movements were 
recorded as described previously (Van Steveninck et al, 1999). Saccadic 
eye movements are used to measure alertness and smooth pursuit 
eye movements to measure motor coordination. Average values of 
saccadic peak velocity (spv) for all artefact-free saccades and the average 
percentage of smooth pursuit for all stimulus frequencies were measured. 
pharmaco-electroencephalography	(-eeg)
Pharmaco-eeg was performed as a general measure of cns activity (Cohen 
et al, 1985) and was performed as previously described (De Haas et al, 
2008). The literature suggests that antipsychotics show distinct profiles 
of eeg changes (De Visser et al, 2001). Fast Fourier transform analysis was 
performed to obtain the sum of amplitudes in the delta-(0.5-3.5 Hz), 
theta-(3.5-7.5 Hz), alpha-(7.5-11.5 Hz) and beta(11.5-30 Hz) frequency 
ranges. The square root of the total power (in microvolts) was analysed. 
body	sway
The Body Sway meter records body movements in a single plane, 
providing a measure of postural stability. 
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Changes in Body Sway have been seen for many di¬erent cns active drugs, 
including gaba-ergic drugs (De Haas et al, 2008; De Visser et al, 2003) and 
thc (Zuurman et al, 2008) and was performed as described previously 
(Liem-Moolenaar et al, 2008). 
stroop	test
The Stroop e¬ect is helpful in understanding attention, perception 
and reading as well as the cognitive and neural mechanism of mental 
inhibition, interference and controlled versus automatic processing 
(Laeng et al, 2005). Individual di¬erences in Stroop interference are 
considered to be among the most reliable or stable measures (Laeng 
et al, 2005). The test battery is a¬ected by many di¬erent cns-active 
compounds (Bohnen et al, 2005; Gri~ths et al, 1986; Rose and Duka, 
2007). In the first part of the test (E-prime, http://www.pstnet.com/e-
prime/support/samples), 20 coloured items (green, red and blue) are 
randomly presented (basic situation). In the second part, 20 colour 
and word pairs are randomly presented, forming either congruent or 
incongruent matches (conflict situation). Subjects are asked to respond 
as quickly and accurately as possible by pressing the keys 1, 2 or 3 on the 
number pad with the index, middle and ring finger of the dominant hand. 
Outcome parameters are the number of correct answers and the reaction 
time in basic and conflict situation. 
visual	and	verbal	learning	task	(vvlt)
The vvlt test has shown cns e¬ects of various compounds such as 
benzodiazepines (De Visser et al, 2008), antidopaminergic (Liem-
Moolenaar et al, 2008), and cannabinoid drugs (Zuurman et al, 2008) and 
was performed as described previously (Liem-Moolenaar et al, 2008). The 
primary outcome parameters for the immediate and delayed word recall 
tasks were the numbers of correct responses, and for the delayed word 
recognition the number of correct items and mean response time for 
correct responses. Learning was assessed from the change in reproduced 
words with three consecutive memorization trials, decay from the change 
in reproduced words after a time delay (delayed word recall versus last 
trial of immediate word recall), and retrieval from the di¬erence between 
delayed word recognition and delayed word recall.  
hormones
Prolactin levels were measured as a biomarker for dopaminergic activity 
(De Visser et al, 2001; Liem-Moolenaar et al, 2008). Blood samples for 
luteinizing hormone (lh), follicle-stimulating hormone (fsh), prolactin 
and cortisol were collected pre-dose, frequently and up to 24 h after 
haloperidol administration (for frequency see Table 1) and kept at room 
temperature for between 30 and 45 minutes. Serum was separated by 
centrifugation (2000g at 4°c for 10 min) within 1 h of collection. The 
hormones were analysed by the Central Clinical Chemistry Laboratory 
(Leiden University Medical Center) using an electrochemoluminiscence-
immunoassay for prolactin and cortisol, and a fluoro-immunoassay for  
lh and fsh (Bieglmayer et al, 2004).  
Pharmacokinetics 
thc			
Blood samples for plasma concentrations of thc were drawn frequently 
up to 24 h after haloperidol administration (for frequency see Table 1). 
Samples were protected from light at all times to prevent degradation of 
the compound, centrifuged (2000g at 4°c for 10 min) within 1 h and stored 
at a temperature of at least -20°c. 
Pharmacokinetic analysis was performed by the Analytisch 
Biochemisch Laboratorium bv (abl), Assen, The Netherlands (http://
www.abl.nl/), using a validated Good Laboratory Practices assay The 
analysis was performed by protein precipitation followed by online solid 
phase extraction on a Symbiosis Pharma System using an Agilent hplc 
Column followed by an api 4000 liquid chromatography/ tandem mass 
spectrometry (lc-ms/ms). One of the two most prominent metabolites of 
thc, 11-nor-9-cooh-thc, has been reported to have no psychotropic or 
cardiologic e¬ects (Barnett et al, 1982; Grotenhermen, 2003). The other 
metabolite, 11-oh-thc, was shown to be equipotent (Grotenhermen, 
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2003) to twice as potent (Howlett et al, 2004; Perez-Reyes et al, 1972) as 
thc, but the contribution to overall activity was assumed insignificant 
since 11-oh-thc concentrations were approximately 25 times lower 
than thc concentrations (Zuurman et al, 2008). Therefore, only thc 
concentrations are reported. The assay was linear from 1.00-500 ng/
mL, the limit of quantitation (loq) 1.0 ng/mL, recovery 99.99% and the 
variation coe~cient (cv) ranged between 3.5 and 5.7%. 
haloperidol		
Blood samples for haloperidol were collected pre-dose and frequently, up 
to 24 h after haloperidol administration (for frequency see Table 1). After 
collection, tubes were kept at room temperature for between 30 and 60 
minutes, and serum was separated by refrigerated centrifugation (2000g 
at 4°c for 10 min) and stored at approximately -20°c. Pharmacokinetic 
analysis was performed by the laboratory of the ‘Apotheek Haagse 
Ziekenhuizen’, Den Haag, The Netherlands (www.ahz.nl), using a 
validated high-performance lc/ms/ms assay. The assay was linear from 
0.05-2.0 µ/L, the loq 0.0517 µ/L, the recovery 101.8% and the cv ranged 
between 2.4 and 4.6%. 
Statistical analysis 
pharmacodynamics		
The pharmacodynamic endpoints were analysed by mixed-model analyses 
of variance (using sas	proc	mixed) with sub ject, subject by treatment 
and subject by time as random e¬ects, with treatment, study day, time 
and treatment by time as fixed e¬ects, and the average baseline value as 
covariate. Contrasts were estimated within the overall treatment e¬ect 
and contrasts between treatments and between treatments over 360 and 
420 min were calculated. Body Sway, eeg and neuroendocrine parameters 
were analysed after log-transformation and back-transformed after 
analysis (results may be interpreted as percentage change). 
In patient studies using the panss, a comparison of panss scores and 
an expert assessment was performed to ensure inter-rater reliability.  
As there is no ‘gold standard’ for panss scores in healthy volunteers 
using thc, the comparison to this standard was not possible. Instead,  
we determined the inter-rater variability of panss scores by performing  
a Pearson’s correlation after showing all eight raters four panss inter-
views on video. Based on the correlations and means, one rater showed 
a low correlation (<0.8) and one rater showed a good correlation but 
with a substantially higher mean value for the negative panss subscale. 
Therefore the negative subscales for these two raters were re-rated from 
video recordings by two independent raters, and these new values were 
used for the analysis. To take rater e¬ects into account, this was added as 
a random factor to the mixed model for the analysis of the panss scores. 
Results are presented as di¬erences with 95% confidence intervals (ci). 
pharmacokinetics	
thc		Pharmacokinetic modelling was performed using non-linear mixed 
e¬ect modelling as implemented in the nonmem software package (Ver-
sion VI, nonmem Project Group, University of California, San Francis co, 
ca). Previous assessment of thc pharmacokinetics indicated the require-
ment of a two-compartment model with a bolus administration in the  
central compartment (Strougo et al, 2008). 
The first-order conditional estimation method with interaction was 
used. Individual empirical Bayesian estimates were generated in a post 
hoc step and used to plot predicted concentration profiles. To account 
for variability between di¬erent thc administrations within a subject,  
a relative bioavailability parameter was used. 
The terminal half life and area under curve (auc) were obtained using 
a non-compartmental analysis which was performed using the software 
package WinNonLin (version 5.0, Pharsight Corp., Mountain View, ca). 
haloperidol		Individual pharmacokinetic parameters of haloperidol  
were calculated by a non-compartmental analysis using WinNonLin 
software (version 5, Pharsight Corp., Mountain View, ca, usa). Terminal 
half life was estimated by log-linear regression of the terminal part of the 
concentration time curve. auc0-∞ was calculated using the log-down trap-
ezoidal method in plasma concentration-time curves. Terminal half life, 




A total of 35 subjects aged 18-38 years with a bmi of 18.8- 28.4 kg/m2 were 
included in 2007 and 2008. Thirteen subjects (37%) stopped the study 
after participation in at least one study day: six due to non-compliance 
(three were excluded by the investigator and three stopped for personal 
reasons) and seven due to adverse events (after thc alone or after the 
combination with haloperidol). Three subjects considered their subjective 
high e¬ects too intense, and the study physician decided to not continue 
dosing of thc. Five other participants dropped out due to physical adverse 
e¬ects (nausea, drowsiness, dizziness). The resulting loss of power was 
considered to be adequately compensated by the incorporation of all 
completed occasions of the 13 dropouts in the final analyses. 
Clinical effects 
Following thc dosing the most frequently reported adverse events were 
sleepiness, ‘feeling high’, dizziness and headache. After haloperidol 
administration sleepiness was most frequently reported. All adverse 
events were transient and mild (discomfort, but no reduced normal daily 
activity) to moderate (normal daily activity reduced) in severity. After 
the combination of haloperidol and thc, sleepiness (24 versus 18) and 
headache (9 versus 5) were reported more frequently and dizziness was 
reported less frequently (4 versus 7) than after thc alone.  
Pharmacodynamic results 
panss	and	vas	scales	(table	2)
Compared with placebo, the positive and general panss scale, the vas 
external and internal perception and vas feeling high were increased 
after thc administration, while the vas alertness was decreased. thc 
caused a significant increase of 2.5 points in positive panss, which was 
significantly reduced by 1.1 points after pre-treatment with haloperidol 
(Figure 1), comparable to those with haloperidol alone (baseline values 
were 7.4 after placebo, 7.8 after thc, 8.2 after haloperidol and 7.7 after 
the combination). In contrast, the significant and strong increase in vas 
feeling high after thc was not a¬ected by haloperidol (Figure 2). Com-
pared with placebo, haloperidol caused a small reduction of vas mood. 
A visual inspection of the distributions of the panss data provided no 
clear indications for excessive skewness. Therefore, this distribution was 
considered not to refute further parametric analyses, also because non-
parametric methods would not account for the complexity of the study 
design and the data set. However, since the data were not completely 
normally distributed and could not be fully normalized using log-
transformation, a non-parametric check of the main outcome of the study 
was performed. The panss scores after the second thc inhalation (at t = 
306 min) were analysed with a Wilcoxon signed rank test, to compare the 
thc and thc + haloperidol treatments. The result was highly significant 
(p = 0.0091). 
neurophysiological	parameters	(table	3)
thc administration decreased smooth pursuit eye movements, while 
Body Sway and eeg alpha Fz-Cz power were increased. Body Sway and 
eeg theta Fz-Cz power were increased after haloperidol administration, 
but spv and smooth pursuit eye movements were decreased. Further 
reductions in these last two parameters were found after the combination 
of haloperidol and thc compared with thc alone. 
cognition	(table	4)
thc administration deteriorated the number of correct responses on 
the Stroop test (conflict situation). Both thc and haloperidol caused 
an impairment of immediate and delayed word recall tasks. The 
deterioration in correct responses of immediate word recall by thc  
alone (on average 10.7/30 words compared with 16.2/30 words with 
placebo) was statistically significantly reversed by haloperidol by 2.2 
words, to levels observed with the antipsychotic alone (12.5-12.9/30 
words). Delayed word recognition was not a¬ected by any treatment. 
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hormones	(table	5)
Compared with placebo, prolactin concentrations were slightly decreased 
after thc administration (baseline values were 9.7 after placebo, 10.8 
after thc, 11.4 after haloperidol and 9.7 after the combination). This 
e¬ect was completely reversed by the strong increase after haloperidol 
administration. Cortisol levels were increased after thc compared 
with placebo, but haloperidol had no e¬ects on cortisol. Neither thc 
nor haloperidol alone had an e¬ect on lh and fsh concentrations, but 
the combination caused (near) significant reductions of both these 
gonadotrophic hormones. 
Pharmacokinetic results 
Analysis of concentration-time profiles of thc revealed a biphasic 
clearance from the plasma, confirmed by the successful implementation 
of a two-compartment model (Figure 3). The nonmem pharmacokinetic 
population parameter estimates were very comparable with a previously 
published pk- pd model of thc (Strougo et al, 2008). Haloperidol clearly 
did not influence thc pharmacokinetics (determined by a paired t-test). 
Haloperidol pharmacokinetics were described using a non-
compartmental analysis. Haloperidol showed a relatively long absorption 
phase (tmax after almost 5 h) and terminal half life (more than 19 h), 
a maximum concentration around 1 mg/L and clearance/f of 2.9 L/
min (Figure 4). Haloperidol administration alone resulted in a higher 
maximum concentration for haloperidol than after the combination with 
thc (on average (sd) 1.07 (0.53) versus 0.79 (0.38) mg/L, p < 0.05 using a 
paired t-test, see Figure 4). 
Discussion 
The main objective of this study was to examine the e¬ects of haloperidol 
on behavioural e¬ects of thc assessed with panss scores and vas Bowdle 
scales. The increase in positive panss with thc alone was reduced after 
pre-treatment with haloperidol to a level that was similar to the e¬ects 
of haloperidol alone. This is consistent with the reported associations 
between cannabinoid and dopamine systems in the brain (Bossong 
et al, 2009; Gardner, 2005). thc had another dopaminergic e¬ect, 
consisting of a small decrease in prolactin. This completely disappeared 
in combination with haloperidol, which produced an overwhelming 
prolactin increase. This thc-induced decrease in prolactin concentrations 
was probably mediated by (indirect) cannabinoid 1 receptor activation of 
tuberoinfundibular dopaminergic neurons (Rodriguez et al, 1992).  
This decrease was comparable to levels observed with the dopamine 
agonist lisuride (Van der Post et al, 2004a). It is much harder to show a 
statistically significant decrease in prolactin due to a ‘floor e¬ect’ (i.e. it is 
more di~cult to find a decrease of low prolactin levels than an increase). 
Although the reduction in prolactin after thc seems small, this finding 
should not be neglected, since these findings provide functional support 
for the stimulation of dopaminergic systems by thc. The only other 
ameliorating e¬ect of haloperidol was a partial reversal of thc-induced 
working memory impairment (immediate recall). Dopaminergic systems 
have been implicated in working memory (Mehta and Riedel, 2006), but 
their role in memory and cognition is complex (Kulisevsky, 2000). Many 
studies have shown that cannabis causes deteriorations of immediate 
recall and working memory (Ranganathan and D’Souza, 2006; Zuurman 
et al, 2009a), although the dose- response relationships are complex 
(Zuurman et al, 2009a). 
Haloperidol did not interact with other thc-induced cns e¬ects, 
such as the general panss, vas ‘internal’, ‘external’ perception, and 
alertness, Body Sway, eeg alpha reductions, number of correct answers 
of delayed word recall and Stroop test and cortisol concentrations. In 
most cases, the e¬ects of the combination were similar to those of the 
individual compound with the largest impact. Since haloperidol is a 
potent d2 antagonist, it would seem that the unmodified e¬ects of thc 
are mediated by other than dopaminergic mechanisms. This also appears 
to be the case for the ‘high feelings’ induced by thc, which remained very 
clear after co-treatment with haloperidol. This was unexpected, since 
the literature contains many links between striatal dopamine release 
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and mood improvement for drugs such as amphetamine (Drevets et al, 
2001), cocaine (Schlaepfer et al, 1997), alcohol (Yoder et al, 2007) and 
nicotine (Brody et al, 2009; Drevets et al, 2001; Yoder et al, 2007). Although 
the reward system has also been implicated in the typical ‘high feelings’ 
caused by cannabis (Lupica et al, 2004), this was until recently not as 
clearly demonstrated in humans. However, in line with earlier animal 
studies (Gardner and Lowinson, 1991; Tanda and Goldberg, 2003), 
Bossong et al showed a 3% decrease in [11C]-raclopride binding after thc 
in humans, as a measure of dopamine release in the ventral striatum. 
Bossong et al used the same mode of thc administration as in the current 
study, which caused comparable levels of ‘feeling high’ (Bossong et 
al, 2009). The amount of dopamine release following cannabinoids, 
however, seems to be considerably smaller (or even absent after oral 
dronabinol (Stokes et al, 2009)) than with typical addictive drugs such 
as ethanol (15% (Boileau et al, 2003)), nicotine (8.4-37% (Brody et al, 
2004, 2009)), alfentanil (7.4% (Hagelberg et al, 2002)), amphetamine 
(12-16% (Drevets et al, 2001; Martinez et al, 2003, 2007)) or cocaine 
(12% (Schlaepfer et al, 1997)). In several studies, statistically significant 
correlations were found between the level of striatal dopamine release 
and the intensity of subjective intoxication or mood changes (Brody et al, 
2009; Drevets et al, 2001; Yoder et al, 2007), which was not the case for thc 
(Bossong et al, 2009). Thus, the absence of this correlation with thc and 
the limited striatal dopamine release reported suggest that stimulation of 
the reward system after thc administration is not mediated (exclusively) 
by dopamine (Wise, 1988, 2004). Most addictive drugs cause rewarding 
e¬ects by activation of dopamine release from the ventral tegmentum into 
the nucleus accumbens, but some drugs, including cannabinoids, are 
also thought to produce reward partly through direct stimulation of the 
accumbens (Hyman et al, 2006). 
The relationships between dopamine release and thc-induced 
psychosis have not been directly studied with positron emission 
tomography (pet,) but are likely to involve brain areas other than the 
striatum and the reward system. Low-a~nity dopamine receptors 
in the cerebral cortex, for instance, are not captured accurately with 
[11C]-raclopride pet, but require other ligands such as [11C]-fallypride 
or [11C]-flb 457. Such experiments have not been performed with thc, 
but several pet studies using [11C]-flb 457 (Narendran et al, 2009) 
or [11C]-fallypride (Cropley et al, 2008; Riccardi et al, 2006a,b) have 
shown cortical dopamine release after amphetamine administration. 
Haloperidol is not region specific, and shows comparable binding to 
both cortical and striatal d2 receptors (Kessler et al, 2005). 
The literature about the relationships between antipsychotics and 
cannabis-induced psychotic symptoms is not conclusive. In clinically 
stable and medication-responsive schizophrenia patients, antipsychotic 
treatment did not prevent all thc-induced panss-increases (D’Souza 
et al, 2005). The study did not compare the results with unmedicated 
patients, so it cannot be excluded that the positive symptoms were 
actually blunted. Recently, another study of D’Souza et al in healthy 
volunteers was published after the start of our experiment. This study 
was reminiscent of ours, and panss e¬ects of thc either alone or 
combined with haloperidol were studied (D’Souza et al, 2008). panss 
e¬ects were similar to those observed in the current study. Haloperidol 
appeared to reduce the positive panss and perceptual alterations 
induced by thc, but this was not statistically significant. Also, D’Souza 
et al found a worsening of cognitive function after the combination 
of haloperidol and thc compared with thc alone, while we found 
improvement. The di¬erences in findings could have been caused 
by di¬erent factors. First, the doses of thc and haloperidol and the 
administration routes of thc di¬ered. D’Souza et al used doses of active 
oral haloperidol (0.057 mg/kg) or placebo in random order followed 
90 and 215 min later by a fixed-order intravenous administration 
over 20 min of placebo and active (0.0286 mg/kg) thc, respectively. 
Haloperidol doses are generally lower in our study and those of thc 
substantially higher. It is hard to exactly compare these as no blood 
concentrations were measured in D’Souza et al’s study. When comparing 
pharmacokinetics to an earlier study by D’Souza et al (2004), which 
used slightly higher doses than in the thc-haloperidol interaction 
study (D’Souza et al, 2008), the observed maximum concentrations 
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seemed at least 10 times higher in our study. Another reason for the 
di¬erences in results could have been the rate of increase of thc brain 
levels, which would have been higher in our study due to the inhalation 
method for thc. Stokes et al (2009) also hypothesized that this could 
have contributed to a lack of dopamine release in their study with oral 
dronabinol, as opposed to Bossong et al’s (2009) study that used our 
method. Also, di¬erent relative timing of administration of thc and 
haloperidol and assessment methods could have caused di¬erences.  
In our study the thc administration and measurements were performed 
later than in D’Souza et al’s trial, aiming for the tmax of haloperidol and 
continuing for longer. In this way, we tried to achieve the maximum 
e¬ects of thc when d2 occupancy by haloperidol was also maximal. 
In the current study, thc mainly a¬ected the individual positive  
panss items ‘delusions’, ‘conceptual disorganization’ and ‘hallucinatory 
behaviour’. ‘Excitement’, ‘grandiosity’, ‘suspiciousness/persecution’ and 
‘hostility’ did not change significantly. Haloperidol completely reversed 
thc-induced increases in ‘delusions’ and ‘conceptual disorganization’ 
and almost halved the increase in ‘hallucinatory behaviour’. Although 
not statistically significant, haloperidol seemed to increase the items 
‘conceptual disorganization’, ‘suspiciousness/persecution’ and 
‘hostility’ compared with placebo. This may in part correspond to the 
reduced contentedness (as shown by the vas mood), and is reflected by 
the somewhat higher average positive panss values after haloperidol 
treatment shown in Figure 1. 
A limitation of this study is the drop-out rate. Thirty-five subjects 
started the study, but only 22 completed all three study days according 
to protocol. It is hard to determine an exact reason for this, but the 
intensiveness of the study could have been a contributing factor. As 
subjects who withdrew from the study did not di¬er clearly from the ones 
who stayed in and all the e¬ects of thc were similar to those of previous 
studies, drop-out does not seem to have introduced a bias. Also, all 
completed study days were included, even if subjects withdrew after one 
or two occasions. 
In this group of mild cannabis users without a personal or family history 
of psychosis or other relevant psychiatric disorders, the thc e¬ects were 
small compared with a clinical psychotic episode in schizophrenia. The 
panss has not been designed for short time intervals such as in this study 
(i.e. four times per study day). Therefore, some modifications were made 
in conjunction with psychiatric experts in this field, mainly consisting 
of adaptations in the time periods and the situations addressed in the 
interview. In addition, all raters were trained by an expert using standard 
interview samples, and the inter-rater variability was assessed and found 
to be low. Nonetheless, the e¬ects were very robust; they seemed to 
cover many aspects of positive psychotic symptoms, and the percentage 
changes in positive panss reduction with haloperidol pre-treatment were 
similar to clinically relevant reductions. Clearly, this does not validate the 
thc challenge as a psychosis model. However, the results provide support 
for a role of cannabinoid systems in some aspects of schizophrenia, 
and could suggest applications of the thc challenge model in further 
pathophysiological research in this area. 
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Table 1 Overview of study day procedures 
Time (hours) Procedures study day
-1.5h00m – 0h00m Arrival, breakfast, vital signs, ecg, safety lab, drug screen, alcohol breath test, ae assessment, 
pharmacodynamic measurements (twice)
0h00m Haloperidol administration
1h00m Blood sampling hormones, haloperidol
2h00m Blood sampling hormones, haloperidol
2h55m Blood sampling hormones, haloperidol, thc
3h00m 1st thc administration
3h00m - 4h10m Pharmacodynamic blocka, blood sampling hormones & thc (3h05m, 3h20m), haloperidol 
(4h00m), vital signs, ecg, ae assessment (twice), lunch
3h35m – 3h50m Positive And Negative Syndrome Scale (panss)
4h25m Blood sampling hormones, thc
4h30m 2nd thc administration
4h30m – 5h35m Pharmacodynamic blocka, blood sampling hormones & thc (4h35m, 4h50m), haloperidol 
(5h00m, 6h00m), vital signs, ecg, ae assessment (twice), snack
4h35m – 4h50m wlt (Visual and Verbal Learning Task) word learning and immediate recall 
5h05m – 5h20m panss
5h20m – 5h30m wlt delayed word recall & delayed word recognition
5h55m Blood sampling hormones, thc
6h00m 3rd thc administration
6h00m – 7h10m Pharmacodynamic blocka, blood sampling hormones & thc (6h05m, 6h20m), vital signs, ecg, 
ae assessment (twice), snack
6h35m – 6h50m panss
7h25m Blood sampling hormones & thc
8h00m Blood sampling hormones, thc & haloperidol
8h45m – 9h20m Pharmacodynamic blocka, ae assessment, dinner
12h00m – 13h00m Blood sampling hormones & haloperidol, ae assessment, vital signs, bed
24h00m – 24h30m Blood sampling hormones & haloperidol, ae assessment, ecg, breakfast, home
a.	Pharmacodynamic block consists of Body sway, vas (B&L, Bowdle), eye movements, eeg, vas (B&L, Bowdle), Stroop test,  
vas (B&L, Bowdle), Body Sway respectively (panss and vvlt is indicated separately)
Table 2: Least square means, estimates of differences and confidence intervals of panss (Positive and 
Negative Syndrome Scale) and vas (Visual Analogue Scale) effects of thc, haloperidol and the combination 
Parameterd Least square means Estimate of difference (95% CIc) P-value
plaa thc halb thc + 
halb
thc vs plaa halb vs plaa thc + halb vs thc
Positive panss 7.4 9.8 8.4 8.7 2.5  
(1.2 / 3.7)
0.0002 1.0  
(-0.5 / 2.6) 
0.18 -1.1  
(-2.1 / -0.1) 
0.03
Negative panss 9.2 10.2 11.4 11.2 1.0  
(-0.9 / 3.0) 
0.29 2.2  
(-0.1 / 4.4) 
0.06 0.9	
(-0.7 / 2.6) 
0.26
General panss 18.5 22.5 19.7 21.8 4.0  
(2.0 / 6.0) 
0.0002 1.3  
(-1.1 / 3.7) 
0.30 -0.7  





0.32 0.52 0.33 0.48 0.20  
(0.11 / 0.29) 
<0.0001 0.01  
(-0.10 / 0.13) 
0.84 -0.04  





0.31 0.39 0.34 0.37 0.08  
(0.02 / 0.14) 
0.01 0.03  
(-0.05 / 0.11) 
0.46 -0.01  
(-0.06 / 0.04) 
0.60
vas feeling high log 
(mm)
0.34 1.08 0.37 0.92 0.74  
(0.50 / 0.98) 
<0.0001 0.03  
(-0.28 / 0.33) 
0.87 -0.17  
(-0.36 / 0.03) 
0.09
vas Alertness (mm) 52.0 44.9 49.5 44.7 -7.1  
(-11.4 / -2.7) 
0.002 -2.5  
(-7.6 / 2.6) 
0.34 -0.2  
(-3.8 / 3.4) 
0.89
vas Calmness (mm) 52.8 55.1 51.0 54.6 2.3  
(-0.9 / 5.5)
0.15 -1.8  
(-5.5 / 1.9) 
0.34 -0.5  
(-3.2 / 2.1) 
0.69
vas Mood (mm) 54.6 54.5 51.5 52.7 -0.1  
(-2.7 / 2.5)
0.94 -3.1  
(-6.2 / -0.1) 
0.05 -1.8  
(-4.0 / 0.3) 
0.09
a.	pla = placebo; b.	hal = haloperidol; c.	95% CI = 95% confidence interval; d.	statistically significant differences (i.e. p<0.05) 
are indicated in bold
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Table 4 Least square means, estimates of differences and confidence intervals of cognition effects of thc, 
haloperidol and the combination 
Parameterd,e Least square means Estimate of difference (95% CIc) P-values
plaa thc halb thc + 
halb
thc vs plaa halb vs plaa thc + halb	vs 
thc
Learning (immediate 
word recall #3 – #1)e
6.8 4.7 4.8 6.1 -2.1  
(-4.3 / 0.0) 
0.05 -2.0  
(-4.6 / 0.6) 
0.12 1.4  
(-0.3 / 3.1) 
0.10
Immediate word recall 
number correct (# 3)e
16.2 10.7 12.5 12.9 -5.5  
(-7.8 / -3.2) 
<0.0001 -3.6  
(-6.5 / -0.8) 
0.01 2.2  
(0.4 / 3.9) 
0.02
Decay (immediate word 
recall #3 – delayed recall)
3.0 2.0 3.6 3.7 -0.9  
(-2.6 / 0.7) 
0.26 0.6  
(-1.3 / 2.5) 
0.51 1.7  
(0.3 / 3.1) 
0.02
Delayed word recall 
number correct
12.9 9.2 9.1 9.3 -3.7  
(-6.1 / -1.3) 
0.003 -3.8  
(-6.8 / -0.9) 
0.01 0.1  
(-1.9 / 2.0) 
0.95
Retrieval (delayed word 
recognition – delayed 
recall)
9.3 10.2 11.6 11.0 0.9  
(-4.2 / 5.9) 
0.73 2.3  
(-3.0 / 7.6) 
0.38 0.8  
(-3.6 / 5.2) 
0.72
Delayed word recognition 
number correct
23.1 20.2 19.9 20.7 -2.9 (-7.7 / 
1.9) 
0.23 -3.2 (-8.3 / 
1.9) 





19.5 19.2 19.5 19.1 -0.3 (-0.7 / 
-0.0) 
0.04 -0.0 (-0.4 / 
0.4) 





658 663 666 697 5 (-39 / 48) 0.82 8 (-44 / 59) 0.76 34 (-1 / 70) 0.06
a.	pla = placebo; b.	hal = haloperidol; c. 95% CI = 95% confidence interval; d. statistically significant differences (i.e. p<0.05) 
are indicated in bold; e. # = trial number; f	rt = reaction time; g. stroop data for the basic situation are not statistically 
significant and are not shown
Table 5 Least square means, estimates of differences and confidence intervals of hormone effects of thc, 
haloperidol and the combination 
Parameterd Least square means Estimate of difference (95% CIc) P-values
plaa thc halb thc + 
halb
thc vs plaa halb vs plaa thc + halb	 vs thc
Prolactin 
(ng/mL)
8.71 7.26 20.11 19.53 -16.6%  
(-28.3 / -3.0%) 
0.02 130.9%  
(91.0 / 179.1%) 
<0.0001 168.9%  




0.27 0.32 0.26 0.29 18.4%  
(4.0 / 34.8%) 
0.01 -0.7%  
(-15.6 / 16.7%) 
0.93 -8.0%  
(-16.9 / 1.8%) 
0.11
fsh (U/L)e 3.0 2.9 3.1 2.9 -2.5%  
(-5.7 / 0.9%) 
0.15 2.5%  
(-1.7 / 6.9%) 
0.24 -0.6%  
(-3.3 / 2.1%) 
0.64
lh (U/L)f 4.21 3.71 4.45 3.64 -12.0%  
(-23.4 / 1.1%) 
0.07 5.7%  
(-11.4 / 26.3%) 
0.53 -1.7%  
(-12.0 / 9.9%) 
0.76
a.	pla = placebo; b.	hal = haloperidol; c. 95% CI = 95% confidence interval; d. statistically significant differences (i.e. p<0.05) 
are indicated in bold; e.	fsh = Follicle-Stimulating Hormone; f. lh = Luteinizing Hormone
Table 3 Least square means, estimates of differences and confidence intervals of neurophysiological effects 
of thc, haloperidol and the combination 
Parameterd Least square means Estimate of difference (95% CIc) p-value
plaa thc halb thc + 
halb
thc vs plaa halb vs plaa thc + halb vs thc
Body sway (mm) 274 395 318 405 44.1%  
(29.3 / 60.5%)
<0.0001 16.0%  
(1.5 / 32.5%)
0.03 2.5%  




490.6 489.3 465.1 474.6 -1.3
(-15.8	/	13.3) 
0.86 -25.5  
(-42.8 / -8.3)





52.2 48.9 46.0 45.7 -3.3 
(-6.3 / -0.3) 
0.03 -6.2  
(-9.9 / -2.6) 
0.001 -3.2  
(-5.6 / -0.7)
0.01
eeg alpha Fz-Cz 
(power)
2.77 3.49 3.03 3.37 26.0%  
(4.4 / 52.2%)
0.02 9.3% (-12.4 
/ 36.5%) 
0.43 -3.5%  
(-17.5 / 12.8%) 
0.65
eeg theta Fz-Cz 
(power)
2.03 2.19 2.38 2.30 7.8%	
(-5.2	/	22.5%)	
0.25 17.0%  
(1.1 / 35.4%) 
0.04 4.9%  
(-5.8 / 16.9%) 
0.38
a.	pla = placebo; b.	hal = haloperidol; c.	95% CI = 95% confidence interval; d.	statistically significant differences (i.e. p<0.05) 
are indicated in bold e. eeg parameters for which there are no significant (i.e. p<0.05) estimates of differences are not included 
in the table
241	 8	–	cns	effects	of	haloperidol	on	thc	in	healthy	male	volunteers240	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia
Figure 1 Graph of Least Square Means Positive panss change from baseline with 95% CI error bars for thc 
(up) and placebo (down) and drug administration (vertical lines) at T=0 (haloperidol), T=180, 270, 360 (thc)


































































Figure 2 Graph of Least Square Means vas feeling high (subscale of vas Bowdle) change from 
baseline with 95% CI error bars	thc (up) and placebo (down) and drug administration (vertical lines) 
at T=0 (haloperidol), T=180, 270, 360 (thc)
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Figure 3 Average graph of predicted (solid black line) and observed concentration-time profiles of thc (open 
circles) and thc + haloperidol (closed circle) with sd error bars for thc (down) and thc + haloperidol (up) and 
drug administration (vertical lines) at T=0 (haloperidol), T=180, 270, 360 (thc)
Figure 4 Average concentration-time profile of haloperidol (open circle) and haloperidol + thc (closed circle) 
with sd error bars for haloperidol + thc (down) and haloperidol (up) and drug administration (vertical lines) at 











































Adler CM, Malhotra AK, Elman I, et al (1999) Com-
parison of ketamine-induced thought disorder 
in healthy volunteers and thought disorder in 
schizophrenia. Am J Psychiatry 156: 1646-1649. 
Angrist B, Van Kammen DP (1984) cns stimulants 
as tools in the study of schizophrenia. Trends 
Neurosci 7: 388-390. 
Barnett G, Chiang CW, Perez-Reyes M, Owens SM 
(1982) Kinetic study of smoking marijuana. J 
Pharmacokinet Biopharm 10: 495-506. 
Bieglmayer C, Chan DW, Sokoll L, et al (2004) 
Multicentre performance evaluation of the E170 
module for modular analytics. Clin Chem Lab 
Med 42: 1186-1202. 
Bohnen NI, Kaufer DI, Hendrickson R, et al 
(2005) Degree of inhibition of cortical 
acetylcholinesterase activity and cognitive 
effects by donepezil treatment in Alzheimer’s 
disease. J Neurol Neurosurg Psychiatry 76: 
315-319. 
Boileau I, Assaad JM, Pihl RO, et al (2003) Alcohol 
promotes dopa-mine release in the human 
nucleus accumbens. Synapse 49: 226-231. 
Bond A, Lader M (1974) The use of analogue scales in 
rating subjective feelings. Br J Med Psychol 47: 
211-218. 
Bossong MG, van Berckel BN, Boellaard R, et al 
(2009) Delta 9-tetrahydrocannabinol induces 
dopamine release in the human striatum. 
Neuropsychopharmacology: 34: 759-766. 
Bowdle TA, Radant ad, Cowley DS, Kharasch 
D, Strassman RJ, Roy-Byrne PP (1998) 
Psychedelic effects of ketamine in healthy 
volunteers: relationship to steady-state plasma 
concentrations. Anesthesiology 88: 82-88. 
Brody AL, Mandelkern MA, Olmstead RE, et al (2009) 
Ventral striatal dopamine release in response to 
smoking a regular vs a denicotinized cigarette. 
Neuropsychopharmacology 34: 282-289. 
Brody AL, Olmstead RE, London ED, et al (2004) 
Smoking-induced ventral striatum dopamine 
release. Am J Psychiatry 161: 1211-1218. 
Chakraborty BS, Hubbard JW, Hawes EM, et al (1989) 
Interconversion between haloperidol and 
reduced haloperidol in healthy volunteers. Eur J 
Clin Pharmacol 37: 45-48. 
Cohen AF, Ashby L, Crowley D, Land G, Peck AW, 
Miller AA (1985) Lamotrigine (BW430C), a 
potential anticonvulsant. Effects on the central 
nervous system in comparison with phenytoin 
and diazepam. Br J Clin Pharmacol 20: 619-629. 
Cropley VL, Innis RB, Nathan PJ, et al (2008) Small 
effect of dopa-mine release and no effect of 
dopamine depletion on [18F]fallypride binding 
in healthy humans. Synapse 62: 399-408. 
D’Souza DC, Abi-Saab WM, Madonick S, et al (2005) 
Delta-9-tetrahydrocannabinol effects in schizo-
phrenia: implications for cognition, psychosis, 
and addiction. Biol Psychiatry 57: 594-608. 
D’Souza DC, Braley G, Blaise R, et al (2008) Effects 
of haloperidol on the behavioral, subjective, 
cognitive, motor, and neuroendocrine effects of 
delta-9-tetrahydrocannabinol in humans. Psy-
chopharmacology (Berl) 198: 587-603. 
D’Souza DC, Perry E, MacDougall L, et al (2004) The 
psychotomimetic effects of intravenous delta-
9-tetrahydrocannabinol in healthy individuals: 
implications for psychosis. Neuropsychophar-
macology 29: 1558-1572. 
De Haas SL, De Visser SJ, Van der Post JP, et al (2008) 
Pharmacodynamic and pharmacokinetic 
effects of MK-0343, a gaba(a) alpha2,3 subtype 
selective agonist, compared to lorazepam and 
placebo in healthy male volunteers. J Psycho-
pharmacol 22: 24-32. 
De Visser SJ, Van der Post JP, De Waal PP, Cornet F, 
Cohen AF, Van Gerven JM (2003) Biomarkers for 
the effects of benzodiazepines in healthy volun-
teers. Br J Clin Pharmacol 55: 39-50. 
De Visser SJ, Van der Post J, Pieters MS, Cohen AF, Van 
Gerven JM (2001) Biomarkers for the effects of 
antipsychotic drugs in healthy volunteers. Br J 
Clin Pharmacol 51: 119-132. 
Drevets WC, Gautier C, Price JC, et al (2001) Amphet-
amine-induced dopamine release in human 
ventral striatum correlates with euphoria. Biol 
Psychiatry 49: 81-96. 
Gardner EL (2005) Endocannabinoid signaling sys-
tem and brain reward: emphasis on dopamine. 
Pharmacol Biochem Behav 81: 263-284. 
Gardner EL, Lowinson JH (1991) Marijuana’s interac-
tion with brain reward systems: update 1991. 
Pharmacol Biochem Behav 40: 571-580. 
Gijsman HJ, Van Gerven JM, Verkes RJ, et al (2002) 
Saccadic peak velocity and eeg as end-points for 
a serotonergic challenge test. Hum Psychophar-
macol 17: 83-89. 
Griffiths AN, Jones DM, Richens A (1986) Zopiclone 
produces effects on human performance similar 
to flurazepam, lormetazepam and triazolam. Br 
J Clin Pharmacol 21: 647-653. 
Grotenhermen F (2003) Pharmacokinetics and 
pharmacodynamics of cannabinoids. Clin 
Pharmacokinet 42: 327-360. 
245	 8	–	cns	effects	of	haloperidol	on	thc	in	healthy	male	volunteers244	 human	pharmacology	of	current	and	new	treatments	for	schizophrenia
Hagelberg N, Kajander JK, Nagren K, Hinkka S, 
Hietala J, Scheinin H (2002) Mu-receptor 
agonism with alfentanil increases striatal 
dopamine d2 receptor binding in man. Synapse 
45: 25-30. 
Henquet C, Krabbendam L, Spauwen J, et al (2005) 
Prospective cohort study of cannabis use, 
predisposition for psychosis, and psychotic 
symptoms in young people. Br Med J 330: 11. 
Henquet C, Rosa A, Krabbendam L, et al (2006) 
An experimental study of catechol-o-
methyltransferase Val158Met moderation 
of delta-9-tetrahydrocannabinol-induced 
effects on psychosis and cognition. 
Neuropsychopharmacology 31: 2748-2757. 
Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, 
Hampson RE, Porrino LJ (2004) Cannabinoid 
physiology and pharmacology: 30 years of 
progress. Neuropharmacology 47(Suppl 1): 
345-358. 
Hyman SE, Malenka RC, Nestler EJ (2006) Neural 
mechanisms of addiction: the role of reward-
related learning and memory. Annu Rev 
Neurosci 29: 565-598. 
Kay SR, Opler LA (1987) The positive-negative 
dimension in schizophrenia: its validity and 
significance. Psychiatr Dev 5: 79-103. 
Kemme MJ, Van der Post JP, Schoemaker RC, 
Straub M, Cohen AF, Van Gerven JM (2003) 
Central nervous system effects of moxonidine 
experimental sustained release formulation 
in patients with mild to moderate essential 
hypertension. Br J Clin Pharmacol 55: 518-525. 
Kessler RM, Ansari MS, Riccardi P, et al (2005) 
Occupancy of striatal and extrastriatal 
dopamine d2/D3 receptors by olanzapine and 
haloperidol. Neuropsychopharmacology 30: 
2283-2289. 
King DJ (1997) Guidelines for the use of antipsychotic 
drug studies in healthy volunteers. The BAP 
Consensus Group. J Psychopharmacol 11: 
201-209. 
Kulisevsky J (2000) Role of dopamine in learning 
and memory: implications for the treatment 
of cognitive dysfunction in patients with 
Parkinson’s disease. Drugs Aging 16: 365-379. 
Laeng B, Lag T, Brennen T (2005) Reduced Stroop 
interference for opponent colors may be due 
to input factors: evidence from individual 
differences and a neural network simulation. J 
Exp Psychol Hum Percept Perform 31: 438-452. 
Laviolette SR, Grace AA (2006) Cannabinoids 
potentiate emotional learning plasticity in 
neurons of the medial prefrontal cortex through 
basolateral amygdala inputs. J Neurosci 26: 
6458-6468. 
Liem-Moolenaar M, Gray F, de V S, et al (2008) 
Psychomotor and cognitive effects of a 
single oral dose of talnetant (sb223412) in 
healthy volunteers compared with placebo or 
haloperidol. J Psychopharmacol (Epub ahead 
of print). 
Lupica CR, Riegel AC, Hoffman AF (2004) Marijuana 
and cannabinoid regulation of brain reward 
circuits. Br J Pharmacol 143: 227-234. 
Martinez D, Narendran R, Foltin RW, et al (2007) 
Amphetamine-induced dopamine release: 
markedly blunted in cocaine dependence and 
predictive of the choice to self-administer 
cocaine. Am J Psychiatry 164: 622-629. 
Martinez D, Slifstein M, Broft A, et al (2003) Imaging 
human mesolimbic dopamine transmission 
with positron emission tomography. Part ii: 
amphetamine-induced dopamine release in the 
functional subdivisions of the striatum. J Cereb 
Blood Flow Metab 23: 285-300. 
Mehta MA, Riedel WJ (2006) Dopaminergic 
enhancement of cognitive function. Curr Pharm 
Des 12: 2487-2500. 
Narendran R, Frankle WG, Mason NS, et al (2009) 
Positron emission tomography imaging of 
amphetamine-induced dopamine release in 
the human cortex: a comparative evaluation of 
the high affinity dopamine d2/3 radiotracers 
[11C]flb 457 and [11C]fallypride. Synapse 63: 
447-461. 
Norris H (1971) The action of sedatives on 
brain stem oculomotor systems in man. 
Neuropharmacology 10: 181-191. 
Perez-Reyes M, Timmons MC, Lipton MA, Davis 
KH, Wall ME (1972) Intravenous injection in 
man of 9-tetrahydrocannabinol and 11-oh-9 
-tetrahydrocannabinol. Science 177: 633-635. 
Phillips P, Johnson S (2001) How does drug and 
alcohol misuse develop among people with 
psychotic illness? A literature review. Soc 
Psychiatry Psychiatr Epidemiol 36: 269-276. 
Ranganathan M, D’Souza DC (2006) The acute 
effects of cannabinoids on memory in humans: 
a review. Psychopharmacology (Berl) 188: 
425-444. 
Riccardi P, Li R, Ansari MS, et al (2006a) 
Amphetamine-induced displacement of [18F] 
fallypride in striatum and extrastriatal regions 
in humans. Neuropsychopharmacology 31: 
1016-1026. 
Riccardi P, Zald D, Li R, et al (2006b) Sex differences in 
amphetamine-induced displacement of [(18)F]
fallypride in striatal and extrastriatal regions: a 
pet study. Am J Psychiatry 163: 1639-1641. 
Rodriguez DF, Fernandez-Ruiz JJ, Murphy 
LL, et al (1992) Acute effects of delta-9-
tetrahydrocannabinol on dopaminergic activity 
in several rat brain areas. Pharmacol Biochem 
Behav 42: 269-275. 
Rose AK, Duka T (2007) The influence of alcohol 
on basic motoric and cognitive disinhibition. 
Alcohol Alcohol 42: 544-551. 
Schlaepfer TE, Pearlson GD, Wong DF, Marenco S, 
Dannals RF (1997) pet study of competition 
between intravenous cocaine and [11C]
raclopride at dopamine receptors in human 
subjects. Am J Psychiatry 154: 1209-1213. 
Seeman P, Lee T (1975) Antipsychotic drugs: direct 
correlation between clinical potency and 
presynaptic action on dopamine neurons. 
Science 188: 1217-1219. 
Stokes PR, Mehta MA, Curran HV, Breen G, Grasby 
PM (2009) Can recreational doses of thc 
produce significant dopamine release in the 
human striatum? Neuroimage 48: 186-190. 
Strougo A, Zuurman L, Roy C, et al (2008) Modelling 
of the concentration-effect relationship of thc 
on central nervous system parameters and heart 
rate - insight into its mechanisms of action and 
a tool for clinical research and development of 
cannabinoids. J Psychopharmacol 22: 717-726. 
Tanda G, Goldberg SR (2003) Cannabinoids: reward, 
dependence, and underlying neurochemical 
mechanisms - a review of recent preclinical 
data. Psychopharmacology (Berl) 169: 115-134. 
Van der Post J, De Waal PP, De Kam ML, Cohen 
AF, Van Gerven JM (2004a) No evidence 
of the usefulness of eye blinking as a 
marker for central dopaminergic activity. J 
Psychopharmacol 18: 109-114. 
Van der Post JP, De Visser SJ, Schoemaker RC, Cohen 
AF, Van Gerven JM (2004b) Pharmacokinetic/
pharmacodynamic assessment of tolerance 
to central nervous system effects of a 3 mg 
sustained release tablet of rilmenidine in 
hypertensive patients. J Psychopharmacol 18: 
221-227. 
Van Steveninck AL, Van Berckel BN, Schoemaker RC, 
Breimer DD, Van Gerven JM, Cohen AF (1999) 
The sensitivity of pharmacodynamic tests for the 
central nervous system effects of drugs on the 
effects of sleep deprivation. J Psychopharmacol 
13: 10-17. 
Wise RA (1988) The neurobiology of craving: 
implications for the understanding and 
treatment of addiction. J Abnorm Psychol 97: 
118-132. 
Wise RA (2004) Dopamine, learning and motivation. 
Nat Rev Neurosci 5: 483-494. 
Yoder KK, Constantinescu CC, Kareken da, et al 
(2007) Heterogeneous effects of alcohol on 
dopamine release in the striatum: a pet study. 
Alcohol Clin Exp Res 31: 965-973. 
Zuurman L, Roy C, Schoemaker R, et al (2010) 
Inhibition of thc-induced effects on the 
central nervous system and heart rate by a 
novel cb1 receptor antagonist AVE1625. J 
Psychopharmacol 24: 374-382. 
Zuurman L, Ippel ae, Moin E, Van Gerven JM (2009a) 
Biomarkers for the effects of cannabis and thc 
in healthy volunteers. Br J Clin Pharmacol 67: 
5-21. 
Zuurman L, Passier PC, de K M, Kleijn HJ, Cohen AF, 
van Gerven JM (2009b) Pharmacodynamic and 
pharmacokinetic effects of the intravenously 
administered cb1 receptor agonist Org 28611 
in healthy male volunteers. J Psychopharmacol 
23: 633-644. 
Zuurman L, Roy C, Schoemaker RC, et al (2008) 
Effect of intrapulmonary tetrahydrocannabinol 






In the introduction (chapter 1) of this thesis we discussed the pharma-
cology of the currently existing treatments for schizophrenia, the lack of 
concrete treatment options with new pharmacological mechanisms of 
action, and the relatively unsuccessful drug development for schizophre-
nia compared to other disease areas in the last 50 years. At this moment, 
however, there are several new compounds in development involving new 
pharmacological mechanisms of action. Most if not all of these drugs are 
aimed at treating one or more symptoms of schizophrenia, more than 
its underlying processes. Despite their limited therapeutic scope, these 
drugs could still be used to improve the patient’s quality of life, particu-
larly in individually targeted polytherapeutic strategies, if the symptom-
atic benefits outweigh the adverse effects. It is important to determine the 
potential added value of a new schizophrenia therapy and its therapeutic 
position as well as to identify the potential (dis)advantages of new com-
pounds as early as possible during development. There are several ways 
to predict the clinical effects of a drug, since these largely depend on the 
compound’s pharmacological properties. In some cases, it is possible to 
examine the functional effects of a new drug, and to obtain an impression 
of the potentially beneficial and less desirable effects of a drug in patients. 
In this thesis we have also described different ways to characterize the 
human pharmacology of drugs in development for the various symptom-
atic domains of schizophrenia. To this end, we have used a range of dif-
ferent functional and pharmacological tests that were combined in a cns 
test battery, the NeuroCart. 
The central nervous system (cns) can be divided into different func-
tional domains, for example in neurophysiological, neuropsychologi-
cal and neuroendocrine functions. Drugs acting on the cns will usually 
influence more than one of these functions, which offers the possibility 
to frequently measure drug-induced changes across a range of different 
cns-activities. For the studies in this thesis, the NeuroCart test battery 
was used in healthy volunteers, with the aim of covering a broad range of 
cns-functional domains that could be responsive to drug effects. Healthy 
volunteers function optimally and are therefore quite sensitive to drug 
effects that interfere with normal cns activity. However, in most cases, 
it is impossible to measure therapeutic effects of a new schizophrenia 
drug in healthy volunteers, because they do not suffer from the disease. 
The main aim of early human studies with such drugs is to characterize 
the (new) compound, using a range of different tests. Integration of this 
information can help to provide support for the compound’s distinctive 
pharmacological properties, to predict interactions or adverse events in 
an early stage of development, and to identify dosing regimens with an 
optimal balance between potentially beneficial and undesirable phar- 
macological effects. Many of the tests that are described in this thesis 
provide direct or indirect indications for drug-related adverse effects.  
The broad composition of the NeuroCart test battery provides some  
protection against unnoticed adverse drug effects. This thesis has used a 
large number of ‘drug biomarkers’, and developed and validated several 
others, which provide different types of information about the effects  
of a new drug. These so called drug biomarkers can be divided in func-
tional biomarkers, pharmacological biomarkers and other biomarkers. 
For each functional domain of the central nervous system, several 
different tests or measurement instruments were employed in this  
thesis (see table 1). 
Psychotic-like effects were determined with the Positive and Negative 
Syndrome Scale (panss) and the Bowdle visual analogue scales for psy-
chomimetic effects. Cognitive impairment was evaluated using memory 
tests (visual and verbal immediate & delayed recall and recognition), the 
Tower of London (tol), the Stroop Test, the Simple Reaction Time Test,  
the Left/Right Distraction Task, the Digit Vigilance Choice Reaction Test, 
the Spatial Working Memory Task and the Numeric Working Memory 
Task. Depression and anxiety were assessed with the Visual Analogue 
Scales assessing mood and calmness. Extrapyramidal adverse effects were 
indirectly measured with tests of motor function (Body Sway) or eye-hand-
coordination (Adaptive Tracking, Reaction Time Tests). Metabolic and 
autonomic adverse effects were determined by measurement of several 
hormones (cortisol, lh, fsh, testosterone and prolactin). In most studies, 
several of these tests were combined to generate functional effect profiles 
that provide important information about the new drug’s expected side 
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effects -or anticipated lack thereof. This information is quite useful during 
early drug development, but it is restricted to functional outcomes and 
may miss more subtle cns-effects that can be used to answer several spe-
cific questions about the drug’s pharmacological characteristics in more 
detail. To this end, pharmacological biomarkers can be used. 
Some tests are validated reasonably well for a certain specific 
pharmacological process. Prolactin release for instance is closely 
regulated by d2-receptor activity and hence strongly induced by 
drugs that directly or indirectly affect dopaminergic activity, such as 
neuroleptics. Cortisol release is under serotonergic 5-ht2-control, and 
stimulated by many serotonergic compounds. Subjective ‘high feelings’ 
are strongly increased after activation of the cannabinoid system. 
Anticholinergic activity causes pupil dilation, which is a nonspecific 
effect of many psychopharmacological compounds. In this way, specific 
physiological or even subjective effects can be interpreted as biomarkers 
for a particular pharmacological activity of a new cns-active drug. 
Most tests however are neither validated as surrogate parameters for 
clinical endpoints, nor as primarily receptor-mediated pharmacological 
biomarkers. This holds true for the majority of tests used in early drug 
development. In principle, tests that do not allow a clear functional or 
pharmacological interpretation are less useful in drug development, but 
such tests cannot always be avoided in exploratory studies of compounds 
with novel mechanisms of action. In such cases, the interpretation of 
the test results can be strongly facilitated by the design or the analysis of 
the study. This thesis explored several ways of providing indications for 
a drug’s pharmacological characteristics, using biomarkers that were 
not unequivocally validated for proof-of-pharmacological activity. In 
chapters 2 and 3, the effect profiles of a novel compound were compared 
with a carefully selected positive control. Chapter 4 used the demonstration 
of dose- effect relationships to provide support for the pharmacological 
activity of a new drug. The last four chapters of this thesis employed a 
pharmacological challenge test to study new drugs, which by themselves were 
expected to have limited direct effects in healthy volunteers. A challenge 
test consists of stimulation of a central neurotransmitter system by 
a single dose of a relevant drug, which leads to known quantitative 
effects in healthy volunteers or patients [5]. Although a challenge test 
in healthy volunteers is not an attempt to imitate a disease, it can often 
lead to a better understanding of both the pharmacological and the 
functional aspects of a treatment. A scopolamine challenge test was 
used in chapters 5 and 6 as a cognitive impairment model and a model 
of cholinergic activity. The scopolamine model was explored further 
in chapter 7, where pharmacokinetic-pharmacodynamic (pk-pd) modelling 
was employed as a sophisticated technique to examine the drug’s 
pharmacological characteristics in greater detail. Chapter 8 used delta-
9-tetrahydrocannabinol (thc) to produce functional signs and symptoms 
in healthy volunteers that are reminiscent of psychosis. The model 
was used to examine whether it is possible to demonstrate the acute 
antipsychotic effects of haloperidol (and hence possibly also of other 
antipsychotics). At the same time, the clear demonstration of psychotic-
like phenomena in healthy volunteers during the thc challenge 
supported the involvement of endocannabinoid systems in psychosis. 
Most of these tests would not be immediately considered as validated 
pharmacological biomarkers, because they are not unequivocally 
linked to the pathophysiology of schizophrenia. Nonetheless, 
many of the tests provided indirect but important support for the 
pharmacological activity of novel compounds that are in development 
for aspects of schizophrenia and related conditions or other disorders. 
In chapter 2, a basic pharmacology interaction effects study was 
performed between the 5-ht6 receptor antagonist sb742457 and 
risperidone. Several lines of evidence suggest a possible role of 5-ht6 
receptor antagonists in cognitive dysfunction of schizophrenia. 
Risperidone, commonly used to control agitation and psychotic features 
in schizophrenia, is a d2/5-ht2a antagonist with low affinity for 5-ht6 
receptors. As the combination of risperidone and sb742457 may 
constitute a reasonable combination in cognitively impaired patients, 
pharmacologic interaction effects were investigated in this study in 
healthy volunteers. The chance of showing improvement in cognitive 
dysfunction is low in healthy volunteers. However risperidone causes 
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significant cns-depression in healthy subjects, and it is also a significant 
side effect in psychiatric patients, albeit less than with many older 
neuroleptics. This notion was used to investigate the effects of sb742457 
alone and in combination with risperidone. 
As expected, risperidone caused mild depression of many cns tests, 
and we did not detect clear effects of sb742457 by itself in this group 
of optimally functioning healthy young males. However, sb742457 did 
cause a small increase of eeg alpha and beta bands in combination with 
risperidone. This suggests a mild arousing activity of sb742457 on the 
cns-depressant effects of risperidone, and provides indications for a 
pharmacological effect of this compound in the cns. It cannot be certified 
that this isolated finding represents a true pharmacological reversal of 
risperidone-induced cns-depression. Also there is no indication on the 
potential clinical relevance for patients. 
In chapter 3, the dopamine receptor antagonist haloperidol was used  
as a positive control for the new neurokinin 3 (nk3) antagonist talnetant. 
By adding a positive control the effects of a new compound can be 
compared to the effects of a currently used treatment. While haloperidol 
effects were predominantly cns-depressant (affecting almost all 
pharmacodynamic measures in the study), those of talnetant seemed 
slightly stimulatory (decreased eeg alpha power, improved visuo-motor 
control, and reduced calmness on visual analogue scales). As an nk3 
antagonist is thought to decrease dopamine by indirect modulation 
of dopamine release rather than by dopamine receptor inhibition, a 
lower effect on prolactin was expected than following haloperidol. There 
appeared to be no prolactin release after the nk3 antagonist compared 
to the anticipated high release after haloperidol. The results suggest 
that talnetant penetrates the blood-brain-barrier, but it remains to be 
established whether this dose and the effect is sufficient in patients, and 
whether the observed effect profile is class-specific for nk3 antagonists. 
In chapter 4 three studies of the development of the new glycine 
reuptake inhibitor sch 900435, given to healthy males were described. 
In the first study, a single ascending dose study, this compound was 
unexpectedly found to induce dose-related visual disturbance (increases 
in pupil/iris ratio, changes in vas colour perception and spontaneous 
reports of short-lasting visual disturbance). Dose-related effects were 
also seen in the neuroendocrine system (decreases in fsh and lh). As 
dose escalation was based on frequent interim analyses, this resulted in 
a far smaller dose range (0.5-30mg) than predicted before the study (0.5-
135mg). Instead of discontinuing drug development for this compound 
or expose subjects or patients unnecessarily to the visual effects, a side 
step was taken by further examining the compound in dedicated visual 
effects studies in animals and humans. These studies demonstrated that 
the visual effects were transient without underlying electrophysiological 
changes. This provided enough safety information for starting a multiple 
ascending dose study, which showed rapid development of tolerance for 
visual effects without detrimental long-term consequences. 
The development strategy that was chosen allowed for careful stepwise 
assessment of the pharmacological and clinical characteristics of the 
drug. The visual adverse effects were not foreseen, but preclinical and 
biological data about a new drug can be used to predict the anticipated 
effects of this new drug, even if it has a new mechanism of action. As 
extensively discussed in the introduction of this thesis, many such new 
compounds are currently in development. Frequent measurement of 
multiple pharmacodynamics can also provide indications for cns-
penetration and dose-related pharmacological activity, especially since 
the early studies in healthy volunteers cover a large dose range. This is 
clearly demonstrated by the consistency of almost all effects that were 
observed during the first study, which may have seemed spurious at first. 
Many of the biomarkers showed dose-related effects. The changes in 
visual vas scales, pupil dilation, and reported visual symptoms are most 
compatible with a direct retinal effect, although central causes cannot 
be excluded. The neuroendocrine and cns measurements following 
doses of 8 mg and higher provide indications for cns penetration and 
pharmacological activity of sch 900435. The antipsychotic activity 
still needs to be investigated in a patient study. It also remains to be 
established whether the observed effects are pharmacological effects  
of this drug class, or specific for this compound. 
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In chapter 5 and 6 the effects of two other glycine reuptake inhibitors 
r213129 and r231857 on cns function were investigated in healthy 
males. In these cases, the drugs were not administered to humans for 
the first time, and the dose range was limited by systemic adverse effects 
that had been observed earlier. This refuted the use of dose response 
relationships to demonstrate pharmacological activity, and required 
an alternative approach. Based on preclinical experiments, it was 
decided to use a pharmacological challenge test to show that the glycine 
reuptake inhibitors penetrated into the brain, and indirectly affected 
the cholinergic system. Scopolamine produces robust and consistent 
effects in psychomotor and cognitive function in healthy volunteers and 
is used both as a cholinergic pharmacological model, and as a cognitive 
dysfunction model because of the importance of acetylcholine in memory 
function. r231857 alone showed some pharmacodynamic changes 
compared with placebo, whereas r213129 did not. Both r213129 and 
r231857 had some small effects on scopolamine-induced central nervous 
system impairments, which were not clearly related to the limited dose 
range. There were no visual effects, like had been observed with high 
doses of sch 900435. Although these effects might be an indication that 
these glycine reuptake inhibitors penetrated the cns to some extent, 
it seemed likely that the cns concentrations were too low to cause 
reproducible cns-effects or to affect the scopolamine challenge in healthy 
volunteers. It is also possible that the tests were not sensitive enough to 
detect the pharmacological actions of the two compounds. It cannot be 
excluded that other techniques (like pet-imaging or cerebrospinal fluid 
sampling) or higher doses in healthy volunteers would have been able 
to demonstrate effects. At any rate, clinical trials are needed to provide 
feedback on the predictive value of the pharmacological biomarkers that 
we used in our studies, for therapeutic effects in patients. 
In chapter 7 a pharmacokinetic-pharmacodynamic (pk-pd) analysis of 
scopolamine was performed to improve the scopolamine challenge test. 
The cholinergic system is important for different central nervous system 
functions, including memory, learning and attention. Scopolamine is 
a centrally active muscarinic antagonist, which is frequently used as a 
memory impairment model. Nevertheless, the relationships between 
exposure and corresponding central nervous system (cns) effects are 
mostly unknown. We determined the pk-pd relationships of scopola- 
mine using a multidimensional cns test battery in a large group of 
healthy volunteers. The results suggested there are various functional 
cholinergic systems with different pharmacological characteristics, which 
can be used to study the effects of drugs that directly or indirectly modify 
cholinergic systems. The design of such studies should take the different 
concentration-effect relationships into account. Other reasons to perform 
pk-pd modelling are the use of the model for individual dose optimization 
in studies when large inter-individual differences are anticipated, or to 
give insight into the physiology and pharmacology of human cholinergic 
systems and to find proof-of-pharmacological-activity. 
In chapter 8 a human cannabinoid model was used in healthy volun-
teers, by administration of tetrahydrocannabinol (thc), the most active 
ingredient of cannabis. Animal models for schizophrenia or psychosis 
typically do not capture the complex and unravelled pathophysiology of 
this disease. In general, preclinical models are reasonably predictive of 
several characteristics of schizophrenia, such as disorganized behaviour, 
psychomotor agitation and social withdrawal, but do not adequately rep-
resent typical positive features like delusions, hallucinations and disorga-
nized speech. Therefore, human models for (the symptoms) of the disease 
could be useful. 
The hypothesis that haloperidol would lead to an amelioration of thc-
induced ‘psychotomimetic’ effects was investigated in healthy volunteers. 
thc-induced increases in positive Positive and Negative Syndrome Scale 
(panss) but not in Visual Analogue Scales feeling high were reversed 
by haloperidol. This indicates that psychotic-like effects induced by 
thc are mediated by dopaminergic systems, but that other systems are 
primarily involved in ‘feeling high’. The clear reductions of psychotic-
like symptoms by a clinically relevant dose of haloperidol suggest that 
thc administration seems a useful pharmacological cannabinoid model 
for psychotic effects in healthy volunteers. This could be of value for the 
assessment of therapeutic effects of antipsychotic agents. 
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abnormalities that also occur in other neuropsychiatric diseases, not 
being one disease but a spectrum of symptoms that partly overlap. 
Consequently, the pharmacological results and especially the way of 
investigating the human pharmacology and the models can be applied 
to other related cns disorders, such as for Alzheimer’s disease (5-ht6 
antagonist) or other related psychiatric disorders (schizoaffective 
disorder, psychotic disorder). In fact many of the novel compounds 
described in this thesis are also considered for other indications than 
schizophrenia. This tendency is quite prevalent in drug development, 
where compounds are designed to have specific pharmacological 
characteristics, rather than to correct a certain pathophysiological deficit 
(which in case of neuropsychiatric disorders is often unknown). 
There are many reasons why frequent and multiple human 
pharmacology measurements in an early stage of drug development 
can be helpful. One of the reasons is the possibility to create a 
pharmacological fingerprint of a new compound in a much earlier stage. 
This makes it possible to earlier predict effects and to select doses (or 
compounds) that avoid side-effects in study subjects and subsequently 
in patients. Consequently, vulnerable patients are not unnecessarily 
burdened and development costs can be reduced. Careful stepwise 
flexible decisions can be taken based on actual findings. In addition, a 
human pharmacological model as a practical ‘psychosis’ model could be 
an alternative to assess therapeutic effects of new antipsychotic agents as 
there are no suitable animal models for psychosis. 
Summarizing, the studies in this thesis together show different ways 
of studying human pharmacology, give an impression of the current 
drug development in schizophrenia, and provide examples how human 
pharmacology can be applied in an early stage of drug development. 
Short summary and conclusions 
All studies in this thesis make use of pharmacological monitoring in an 
early stage of drug development in healthy volunteers. An intensive cns 
test battery consisting of multiple tests was used to measure effects in 
different functional domains of the brain. In this way we have tried to 
create a pharmacological fingerprint of the investigated compounds. 
Besides this test battery, we have made use of additional methods and 
‘tools’ (such as positive controls, dose escalation, pk-pd modelling and 
challenge tests) to improve the reliability of tests, which each on its own 
has a limited functional of pharmacological validation. 
We have studied the effects of the currently used antipsychotics risperi-
done (chapter 2) and haloperidol (chapter 3 and 8) and of compounds in 
development for schizophrenia: the 5-ht6 antagonist sb742457 (chapter 
2), the nk3 antagonist talnetant (chapter 3) and the three glycine reup-
take inhibitors sch 900435, r213129 and r231857 (chapters 4-6). We have 
used two functional models by administration of scopolamine (chapter 
5-7) and thc (chapter 8). These compounds give a good impression of the 
trends in drug development for schizophrenia. They affect a range of neu-
rotransmitters (or systems) such as dopamine, serotonin, glutamate, ace-
tylcholine and the cannabinoid system, and are often targeted at negative 
rather than (or in addition to) positive symptoms of schizophrenia. 
Table 2 gives a summary of the main neurotransmitters that are 
currently thought to be involved in the pathophysiology of schizophrenia. 
Additionally, the table shows several functional relationships between 
neurotransmitters and symptoms, and where these are addressed in this 
thesis. 
We investigated both pure agonists and antagonists, but also drugs 
that rather modulate or indirectly influence neurotransmitters. Newer 
compounds are increasingly being developed to treat different symptoms 
of schizophrenia (other than psychotic symptoms), rather than for the 
cause of the disease. 
The framework of this thesis is drugs in development for schizophrenia. 
However, this disorder is characterized by a range of different functional 
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Table 1: Organization of all tests used in this thesis, into their corresponding clusters, domains (in grey) 
according to Zoethout et al [1] and reference to the chapter(s) of this thesis 
Language
Cluster Test Chapter(s)
Semantics Verbal Learning Test* 2, 3, 5-8
Attention
Cluster Test Chapter(s)
Divided attention Left/Right Distraction Task
Digit Vigilance Choice Reaction*
3
4
Reaction time Stroop Test*
Simple Reaction Time Task




‘dsst-like’ Digit Vigilance Choice Reaction* 4
Time/distance estimation Digit Vigilance Choice Reaction* 4
Working memory Digit Vigilance Choice Reaction* 4
Executive
Cluster Test Chapter(s)
Inhibition Stroop Test* 5-8
Planning Tower of London 3
Working memory Spatial Working Memory Task







Immediate Word Recall (vvlt)* 2-8
Visual/spatial
memory: immediate recall
Immediate Word Recall (vvlt)* 2-8
Learning Verbal Memory Task (vvlt)* 2-8
Auditory/verbal
memory: delayed recognition
Delayed Word Recognition (vvlt)* 2-8
Visual/spatial
memory: delayed recognition
Delayed Word Recognition (vvlt)* 2-8
Visual/spatial
memory: delayed recall
Delayed Word Recall (vvlt)* 2-8
Auditory/verbal
memory: delayed recall
Delayed Word Recall (vvlt)* 2-8
Motor
Cluster Test Chapter(s)
Motor control Finger Tapping Task 2,3, 5-7
Postural stability Body Sway 2-8
Visuo-motor control Adaptive Tracking Test 2-7
Neurophysiologic
Cluster Test Chapter(s)
eeg – frequency spectrum Pharmaco-eeg 2-8
Eye movements - pursuit Smooth Pursuit Eye Movements Task 2-8
Eye movements - saccadic Saccadic Eye Movements Task 2-8
Pupil-iris ratio Pupillometry 4-7
Perception
Cluster Test Chapter(s)
Scale perception vas colour perception (Bowdle) 4
Subjective experience
Cluster Test Chapter(s)
Scale alertness Visual Analogue Scale (vas) alertness[2] 




Scale mood Visual Analogue Scale (vas) mood[2] 2-8
Scale calmness Visual Analogue Scale (vas) 
calmness[2]
2-8
Scale psychomimetic Visual Analogue Scale (vas) 
psychomimetic[4] – high – external 
perception – internal perception






Cortisol Cortisol determination 3, 8
fsh fsh determination 4-8
lh lh determination 4, 5, 6, 7, 8
Prolactin Prolactin determination 2, 3, 4, 5, 6, 7, 8
Testosterone Testosterone determination 4
Whenever tests provided different parameters with information on more than one functional domain, de tests were marked (*); 
vvtl = Visual and Verbal Learning Task (consists of immediate & delayed word recall and delayed word recognition)
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Table 2: Summary of neurotransmitters which are thought to be involved in the pathophysiology of 
schizophrenia with expected symptoms after activation (↑) or inhibition (↓) of the neurotransmitter and 










effects (e.g. hyper- 
prolactinaemia)
Dopamine D2 ↓8 ↑2,3 ↑ ↑2,3,8
Serotonin 5-ht6 ↑/↓ ↓2
Glutamate nmda/ampa ↑ ↑ ↑4-6













effecten en mogelijke bijwerkingen in een zo vroeg mogelijk stadium  
van de ontwikkeling van een geneesmiddel worden herkend. 
In dit proefschrift beschrijven we een verzameling van onderzoeken, 
waarin in een vroege fase van onderzoek bij gezonde vrijwilligers wordt 
gekeken naar effecten van nieuwe middelen. Aangezien de klinische 
effecten van een geneesmiddel voor een groot deel afhangen van de  
farmacologische eigenschappen van een geneesmiddel, hebben wij  
farmacologische testen uitgevoerd met bestaande en nieuwe middelen. 
Deze testen werden uitgevoerd met behulp van een testbatterij voor het 
centraal zenuwstelsel (genaamd de NeuroCart), waarmee verschillende 
testen kunnen worden afgenomen, die leiden tot veranderingen in zo- 
genaamde ‘biomarkers’ (parameters die gebruikt kunnen worden om  
het beloop van een aandoening of het effect van een behandeling te 
meten). Daarnaast werd de concentratie van alle geneesmiddelen 
regelmatig in het bloed bepaald. Door het frequent meten van zeer veel 
verschillende ‘biomarkers’ hebben we geprobeerd een farmacologisch 
profiel te verkrijgen van alle middelen in dit proefschrift. Gezonde vrijwil-
ligers zijn over het algemeen gevoelig voor geneesmiddeleffecten die het 
centraal zenuwstelsel beïnvloeden. Het is echter vaak niet mogelijk om  
bij gezonde vrijwilligers therapeutische effecten te meten, omdat de 
ziekte niet aanwezig is. Daarom hebben we gebruik gemaakt van farma-
cologische modellen om dit toch mogelijk te maken (bijvoorbeeld door 






In dit hoofdstuk wordt een nieuw middel, bedoeld voor het verbeteren van 
de cognitieve disfunctie bij schizofrenie, onderzocht bij gezonde vrijwil-
ligers. Het gaat om het middel sb742457, een 5-ht6 (hydroxytryptamine 
6) antagonist. Dit middel zou effectief zijn bij cognitieve verslechtering, 
In dit proefschrift wordt de humane farmacologie (de wisselwerking 
tussen een geneesmiddel en de mens) van bestaande en nieuwe genees-
middelen voor schizofrenie besproken. Schizofrenie is een van de meest 
slopende psychiatrische aandoeningen en komt bij 1-1,5% van de wereld-
bevolking voor. Het ontstaat meestal bij jong volwassenen en blijft  
gedurende het hele leven aanwezig. Bij de diagnose van schizofrenie 
wordt gekeken naar bepaalde karakteristieke symptomen, die kunnen 
worden onderverdeeld in zogenaamde positieve symptomen (hallucina-
ties, wanen, incoherente gedachten), negatieve symptomen (apathie, 
gebrek aan emotie, matig sociaal functioneren) en cognitief disfunctio-
neren (geheugen- en concentratieproblemen, ongeorganiseerd gedrag). 
Er is nog weinig bekend over hoe schizofrenie ontstaat en welke ‘afwijkin-
gen’ in de hersenen precies bijdragen aan het ontstaan van deze aandoe-
ning. Dit heeft te maken met de ondoorgrondelijkheid van de hersenen 
en de variabiliteit in de klinische verschijningsvormen van schizofrenie. 
Er zijn al zeer veel hypothesen geopperd voor de oorsprong van schizofre-
nie. Ditzelfde geldt voor de geneesmiddelen die deze aandoening zouden 
moeten tegengaan. Deze onbekendheid met de aandoening heeft zijn 
weerslag gehad en heeft nog steeds effect op de ontwikkeling van nieuwe 
geneesmiddelen voor schizofrenie. 
 
hoofdstuk	1:	introduction	
In de introductie wordt de farmacologie van de huidige behandelingen en 
de relatief trage geneesmiddelenontwikkeling voor schizofrenie bespro-
ken. Ook het gebrek aan behandelingsmogelijkheden komt aan het licht. 
Op dit moment is er een aantal middelen in ontwikkeling die nieuwe far-
macologische werkingsmechanismen hebben. Het is opvallend dat een 
groot deel van de nieuwe middelen zich meer richt op bepaalde sympto-
men van schizofrenie dan op de onderliggende oorzaak van de aandoe-
ning. Deze middelen kunnen worden gebruikt om de kwaliteit van leven 
van een pati‘nt te verbeteren, maar dan moeten de voordelen wel opwegen 
tegen de bijwerkingen. Om dit te bepalen is het daarom belangrijk dat 
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van dopamine tegen. Daarentegen is talnetant een middel dat de dopa-
mine meer moduleert dan tegengaat. De verwachting van dit onderzoek  
was daarom dat de bijwerkingen van talnetant veel milder zullen zijn dan 
die van haloperidol. 
Zoals verwacht, had haloperidol een ‘dempend’ effect op bijna alle  
testen van het centraal zenuwstelsel, terwijl de effecten van talnetant  
(op verschillende testen) juist wat stimulerend leken. Een bekend resul-
taat van het antagoneren van dopamine is prolactinestijging in het bloed. 
Bij haloperidol was er de verwachte prolactinestijging, terwijl dit voor  
talnetant niet het geval was. 
De resultaten lijken aan te geven dat talnetant in de gegeven dosering 
veilig is bij gezonde vrijwilligers en dat het door de bloed-hersen-barrière 
heen lijkt te gaan. Wat echter de effecten zijn voor patiënten moet nog 






Dit hoofdstuk beschrijft de drie eerste onderzoeken van de glycine her-
opnameremmer sch 900435, in ontwikkeling voor schizofrenie. Glycine 
heropname-remmers zouden een nieuwe effectieve behandeling voor 
schizofrenie kunnen zijn. De ervaring met dit type middelen is schaars, 
maar dieronderzoeken en beperkt onderzoek bij patiënten laten zien dat 
het mogelijk effectief zou zijn. De theoretische verklaring van de werking 
is dat het een indirecte manier is om het glutamaterge-systeem in het 
lichaam te stimuleren. En dit systeem zou nu bij schizofreniepatiënten 
net verlaagd zijn. 
sch 900435 laat in het eerste onderzoek (enkelvoudige, oplopende 
doseringen) veel sterkere effecten zien dan vooraf te verwachten was op 
basis van onderzoeken bij dieren. Daarnaast werden onverwachte effecten 
waargenomen, bijvoorbeeld veranderingen in een aantal hormonen en op 
zoals is aangetoond in dieronderzoeken en in kleinschalige onderzoeken 
bij patiënten met de ziekte van Alzheimer. Aangezien gezonde vrijwil-
ligers geen cognitieve verslechtering hebben, is het therapeutisch effect 
moeilijk aan te tonen. Het gaat er in dit onderzoek dan ook vooral om te 
kijken of het middel veilig lijkt voor mensen en of het veilig te combine-
ren is met een ander bestaand geneesmiddel voor schizofrenie, namelijk 
risperidon. Dit middel, dat veel wordt gebruikt, lijkt niet in staat de cog-
nitieve problemen van schizofrenie patiënten (voldoende) tegen te gaan 
en het antagoneert de 5-ht6 receptor vrijwel niet. De combinatie van 
deze middelen lijkt logisch en we hebben daarom onderzocht of er een 
interactie optreedt tussen deze twee middelen. Dit wordt gedaan door bij 
gezonde vrijwilligers op frequente basis verschillende testen af te nemen. 
Zoals verwacht, werd er bij gezonde vrijwilligers geen cognitieve ver-
betering waargenomen na toediening van sb742457. Ook liet sb742457 
geen andere effecten zien. Risperidon daarentegen liet op de meeste  
testen wel een duidelijke depressie van het centraal zenuwstelsel zien.  
De combinatie (t.o.v. risperidon alleen) vertoont in bepaalde frequen-
ties een kleine stijging van het elektro-encefalogram (eeg), wat een mild 
opwekkend effect van sb742457 zou kunnen betekenen. Aangezien het 
slechts een alleenstaand effect is, dient dit nog verder onderzocht te wor-







In dit onderzoek werd het nieuwe middel talnetant (een neurokinine 
3 antagonist) vergeleken met het bestaande middel haloperidol. 
Haloperidol werd in dit onderzoek gebruikt als positieve controle.  
We weten goed wat voor effecten er optreden bij haloperidol en die 
effecten kunnen we vergelijken met de onbekende effecten van talnetant. 
Haloperidol is een dopamine2 antagonist en deze gaat dus de werking 
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positieve effecten op cognitie bij gezonde vrijwilligers lastig zijn aan te 
tonen, werd in deze onderzoeken gebruik gemaakt van het farmacolo-
gisch model scopolamine. In diermodellen waren effecten waargenomen 
na combinatie met de glycineheropname-remmer t.o.v. scopolamine 
alleen. Scopolamine is het meest gebruikte model voor het onderzoeken 
van de cognitieve disfunctie bij dieren en mensen. Het laat immers 
robuuste en consistente verslechtering zien van de psychomotorische en 
de cognitieve functie. 
Na toediening van r231857 waren een aantal effecten te zien (vergele-
ken met placebo), terwijl dit voor r213129 niet het geval was. Er werden 
geen visuele effecten waargenomen zoals bij sch 900435 (hoofdstuk 4).  
Zowel r213129 als r231857 leken in staat om kleine veranderingen in 
scopolamine-geinduceerde effecten te bewerkstelligen. Het zou een 
indicatie kunnen zijn dat deze glycineheropname-remmers de bloed-
hersen-barrière passeren. Deze effecten waren echter niet gerelateerd aan 
de dosis. De reden hiervoor zou kunnen zijn dat de concentraties in het 
centraal zenuwstelsel te laag zijn of de effecten van de scopolamine-test 
te groot voor deze nieuwe middelen om hierin een duidelijke verandering 
te brengen. Ook zou het kunnen zijn dat de testen niet gevoelig genoeg 
waren om de farmacologische effecten te detecteren. Helaas konden we 
door omstandigheden de doseringen niet meer verder verhogen om de 
effecten hiervan te onderzoeken. Daarom zullen de effecten in klinische 





In hoofdstuk 7 wordt een farmacokinetische-farmacodynamische (pk-pd) 
analyse van scopolamine uitgevoerd om het scopolamine model te opti-
maliseren. Farmacokinetiek (pk) kan worden omschreven als de invloed 
van het lichaam op het geneesmiddel en farmacodynamiek (pd) als de 
invloed van een geneesmiddel op het lichaam. Farmacokinetiek kan 
het eerste gezicht verontrustende visuele verstoringen (o.a. het zien van 
vlekken, veranderde kleurperceptie). Ophoging van de dosis werd gedaan 
op basis van een frequente interim-analyse, die resulteerde in een dosis 
range van 0.5-30mg (waarbij steeds kleine stappen werden genomen) 
i.p.v. 0.5-135mg. In plaats van staken van het middel, werd er een speci-
alistisch oog-onderzoek bij dieren en bij gezonde vrijwilligers uitgevoerd 
(tweede onderzoek dat in dit hoofdstuk wordt beschreven). Deze onder-
zoeken toonden aan dat de visuele effecten van voorbijgaande aard leken 
zonder elektrofysiologische veranderingen. Hierdoor kon het nieuwe 
middel veilig aan gezonde vrijwilligers worden gegeven (in meervoudige 
dosering, derde onderzoek). Dit onderzoek liet zien dat er tolerantie leek 
op te treden voor de visuele effecten. 
Op basis van deze onderzoeken is aangetoond dat de door ons geko-
zen onderzoeksstrategie een veilige introductie van middelen met een 
nieuw werkingsmechanisme mogelijk maakt, ondanks het optreden 
van onverwachte effecten. Dit werd gedaan door het frequent uitvoeren 
van verschillende farmacologische metingen. Deze metingen toonden 
bovendien aan dat een middel door de bloed-hersen-barrière heen gaat 
en dat er een dosis-gerelateerde farmacologische activiteit is. Dit was in 
dit onderzoek bijvoorbeeld het geval voor de resultaten van de hormonen, 
omdat zij een duidelijke dosis-effect relatie lieten zien. Of de effecten spe-
cifiek zijn voor deze groep middelen en of de antipsychotische activiteit 







In de hoofdstukken 5 en 6 worden de effecten van twee verschillende  
glycineheropname-remmers, r213129 en r231857, op het centraal  





In hoofdstuk 8 is gebruik gemaakt van een cannabinoid model in 
gezonde vrijwilligers door het toedienen van ∆9-tetrahydrocannabinol 
(thc), het meest actieve ingrediënt van cannabis. Het is bekend dat er 
een relatie is tussen thc en het ontstaan van psychosen en schizofrenie, 
maar wat de onderliggende mechanismen zijn van het cannabinoid 
systeem (geactiveerd door thc), waardoor psychotische symptomen 
en schizofrenie ontstaan, is nog steeds onduidelijk. Er is meer en meer 
bewijs voor een farmacologische relatie tussen het cannabinoid en het 
dopaminerge systeem. 
Diermodellen voor schizofrenie of psychose zijn redelijk goed voor-
spellend voor bepaalde symptomen van schizofrenie, zoals desorgani-
satie in gedrag, psychomotorische opwinding en sociale teruggetrok-
kenheid, maar ze zijn helaas geen goede voorspeller voor de typische 
positieve symptomen, zoals waanvoorstellingen, hallucinaties en 
spraakverwarring. Daarom zouden humane modellen voor deze symp-
tomen van de aandoening nuttig kunnen zijn. 
In dit onderzoek hebben we de hypothese onderzocht dat haloperidol 
thc-geïnduceerde ‘psychomimetische’ effecten zou verminderen bij 
gezonde vrijwilligers. Haloperidol is een geregistreerd antipsychoticum 
dat dopamine antagoneert (zie ook hoofdstuk 3). Psychomimetische 
effecten werden gemeten met behulp van de Positive and Negative  
Syndrome Scale (panss), een internationaal geaccepteerd, gestan d - 
 aar diseerd en semi-gestructureerd interview bij schizofrenie. 
We zagen in dit onderzoek dat de toename in positieve symptomen  
na thc weer werd teruggedrongen door toevoegen van haloperidol.  
Dit was niet het geval voor de ‘feeling high’, gemeten met de Visual 
Analogue Scales. Dit geeft aan dat de ‘psychomimetische’ effecten,  
die worden opgewekt door thc, waarschijnlijk worden gemedieerd door 
dopaminerge systemen, maar dat andere systemen betrokken zijn bij het 
ontstaan van ‘feeling high’. De resultaten van dit onderzoek wijzen er op 
bepaald worden door bloedspiegels van het geneesmiddel in het lichaam 
te meten. Hoe deze concentraties veranderen in het lichaam is voor ieder 
geneesmiddel weer anders. Farmacodynamiek kan bepaald worden door 
bepaalde functies van het lichaam te meten en de verandering hierin door 
een geneesmiddel, bijvoorbeeld hartslagfrequentie, vergroting van de 
pupil, cognitieve prestaties, reactiesnelheid, etcetera. De resultante van 
de farmacokinetische en farmacodynamische processen, die zich uiter-
aard gelijktijdig in het lichaam afspelen, bepalen uiteindelijk het farma-
cologisch profiel van een middel. 
Zoals in de hoofdstukken 5 en 6 is besproken, is scopolamine het meest 
gebruikte model voor het onderzoeken van cognitief disfunctioneren. 
Het antagoneert het cholinerge systeem (d.w.z. het antagoneert de neu-
rotransmitter acetylcholine). Dit systeem is belangrijk voor verschillende 
functies van het centraal zenuwstelsel zoals bijvoorbeeld geheugen, leren 
en aandacht. De exacte relaties tussen de pk van scopolamine en pd zijn 
nog vrijwel onbekend. Daarom hebben we in dit onderzoek de pk bepaald 
door bloedspiegels te meten (wat doet het lichaam met het geneesmid-
del) en de pd door het afnemen van diverse testen van het centraal zenuw-
stelsel (wat doet het geneesmiddel met het lichaam). Vervolgens hebben 
wij in dit onderzoek de pk-pd relaties bepaald in een grote groep gezonde 
vrijwilligers. 
Het onderzoek liet zien dat veel farmacologische systemen werden 
beïnvloed door scopolamine. De verandering in deze systemen kan wor-
den gebruikt om de effecten van (genees)middelen, die het cholinerge 
systeem (direct of indirect) beïnvloeden, te onderzoeken. Bij het ont-
werpen van nieuwe onderzoeken met scopolamine kan gebruik worden 
gemaakt van de pk-pd relatie die beschreven in dit hoofdstuk is. Dit is een 
van de redenen voor het bepalen van pk-pd relatie. Andere redenen zijn de 
toepassing van deze relaties voor individuele dosis optimalisatie wanneer 
grote inter-individuele verschillen worden voorzien, het vergroten van 
inzicht in de fysiologie en farmacologie van humane cholinerge systemen 
en het bewijzen van de farmacologische activiteit van een stof.  
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Alle geneesmiddelen in dit proefschrift werden ontwikkeld voor schizo-
frenie. Deze aandoening wordt gekarakteriseerd door een aantal afwij-
kingen, die ook bij andere neuropsychiatrische aandoeningen optreden. 
Daarom kunnen de farmacologische resultaten, de methode van onder-
zoek van deze humane farmacologie en het gebruik van modellen worden 
toegepast op andere aandoeningen van het centraal zenuwstelsel, zoals 
bijvoorbeeld de ziekte van Alzheimer (5-ht6	antagonist) of andere gere-
lateerde psychiatrische aandoeningen (bijvoorbeeld schizo-affectieve 
aandoening). De middelen die werden onderzocht in dit proefschrift,  
werden daarom ook vaak - behalve voor de toepassing schizofrenie -  
voor andere indicaties ontwikkeld. 
Er zijn vele redenen waarom frequent meten d.m.v. veel verschillende 
testen in een vroeg stadium van de geneesmiddelenontwikkeling nuttig 
kan zijn. Een van de redenen is de mogelijkheid om een farmacologisch 
profiel van een nieuw middel te verkrijgen in een vroeger stadium dan 
dat nu meestal het geval is. Dit maakt het mogelijk om eerder effecten 
en bijwerkingen te voorspellen, doseringen te selecteren en aldus deze 
gewilde en ongewilde effecten in volgende onderzoeken te voorkomen. 
Hierdoor worden kwetsbare patiënten niet onnodig belast en kunnen ont-
wikkelingskosten worden teruggedrongen. Aangezien er geen geschikte 
diermodellen zijn voor psychose, kan een humaan farmacologisch model 
als praktisch model voor psychose of cognitief disfunctioneren worden 
gebruikt om therapeutische effecten van nieuwe antipsychotische midde-
len te onderzoeken. 
Heel kort samengevat bevatten de onderzoeken in dit proefschrift de 
volgende onderwerpen: er wordt getoond op welke verschillende manie-
ren humane farmacologie van bestaande en nieuwe middelen bij schi-
zofrenie kan worden onderzocht, ze geven een indruk van de huidige 
ontwikkeling van middelen tegen schizofrenie en ze laten voorbeelden 
zien van hoe humane farmacologie van nut is en kan worden toegepast in 
vroege stadia van geneesmiddelenontwikkeling. 
dat de toediening van thc een nuttig farmacologisch cannabinoid model 
voor ‘psychomimetische effecten’ lijkt in gezonde vrijwilligers. Mogelijk 
kan dit model voor de bepaling van therapeutische effecten van nieuwe 
antipsychotica van nut zijn.  
 
hoofdstuk	9:	discussion	and	conclusions
Alle onderzoeken in dit proefschrift maken gebruik van farmacolo gische 
monitoring in een vroege fase van geneesmiddelenontwikkeling bij 
gezonde vrijwilligers. Er werd gebruik gemaakt van een testbatterij voor 
het centraal zenuwstelsel die uit diverse testen bestond. Op deze manier 
hebben we geprobeerd om een farmacologisch profiel van de onderzochte 
middelen te bepalen. Dat dit in een zo vroeg stadium van de geneesmid-
delenontwikkeling gebeurt, is momenteel nog vrij ongewoon. 
Daarnaast hebben we gebruik gemaakt van andere methoden om 
de betrouwbaarheid van de testen te verbeteren, bijvoorbeeld van een 
positieve controle, van pk-pd modelling (het bepalen van pk-pd relaties) 
en van farmacologische modellen. We hebben effecten bestudeerd van 
geneesmiddelen die al lang op de markt zijn, zoals de antipsychotica 
risperidon (hoofdstuk 2) en haloperidol (hoofdstukken 3 en 8) en van 
nieuwe middelen in ontwikkeling voor schizofrenie, zoals de 5-ht6 
antagonist sb742457 (hoofdstuk 2), de nk3 antagonist talnetant 
(hoofdstuk 3) en drie glycine heropname-remmers sch 900435, 
r213129 en r231857 (hoofdstukken 4-6). Deze nieuwe middelen 
geven een goede indruk van de huidige trends op het gebied van 
geneesmiddelenontwikkeling voor schizofrenie. Ze beïnvloeden een 
aantal neurotransmitters (of systemen) zoals dopamine, serotonine, 
glutamaat, acetylcholine en het cannabinoid systeem, en ze zijn 
vaak meer (of met name) gericht op de negatieve dan op de positieve 
symptomen van schizofrenie. We hebben gebruik gemaakt van twee 
farmacologische modellen door het toedienen van scopolamine 
(hoofdstukken 5-7) en thc (hoofdstuk 8). We onderzochten zowel pure 
agonisten en antagonisten als middelen die neurotransmitters meer 
moduleren of indirect beïnvloeden (een trend van de laatste jaren). 
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